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ABSTRACT 
Drug-induced nephrotoxicity is a dose limiting factor and a common side effect of many 
drugs such as antibiotics, cancer chemotherapeutics or diagnostic agents and represents 20 
– 25% of all cases of acute kidney injury (AKI). Due to a lack of representative animal 
models and metabolically competent renal cell lines, only 10.5% of the drug-induced 
nephrotoxicity cases can be predicted in preclinical studies. Furthermore, it has been 
recently accepted that mitochondria represent an important target for a broad spectrum of 
renal toxins. However, the supraphysiological glucose concentrations used in many culture 
conditions favour an energetic metabolic change known as the Crabtree effect, based on 
using glycolysis as the main route for ATP production and hence producing cell lines highly 
resistant to mitochondrial impairment. Therefore, there is a need for better physiologically-
based renal in vitro models that can better assess drug-induced nephrotoxicity. 
 
Conditionally immortalised proximal tubule epithelial cells (ciPTECs) had been previously 
postulated as a novel renal model with good transporter expression that could produce 
reliable nephrotoxicity data for pharmacological studies. In order to confirm the 
applicability of the received ciPTECs for further drug transporter and toxicity studies, the 
transporter expression was assessed and compared with other cell lines such as HEK 293 
cells as well as isolated cells from a proximal tubule (PT) fraction. The functionality of some 
transporters that are crucial in drug-induced nephrotoxicity such as megalin, MRP2, MRP4 
and P-gp were assessed via CMFDA accumulation. Data revealed a very close mRNA 
expression of ciPTECs compared to the PT fraction and better transporter functionality than 
HEK 293 cells. Therefore, it was confirmed that ciPTECs hold the necessary transporter 
functionality to be a valuable nephrotoxicity model.  
 
The Crabtree effect had been previously circumvented in other cell lines by replacing 
glucose for galactose in the medium for 8 weeks. As a result, cells became highly aerobically 
dependant and more susceptible to mitotoxins. A recently developed strategy with only a 4 
h pre-incubation period in galactose conditions was implemented in ciPTECs. As 
hypothesised, ciPTECs cultured in galactose medium displayed a significant upregulation of 
mitochondrial OXPHOS compared to glucose-grown cells, which caused a higher 
susceptibility in front of mitotoxins (rotenone EC50ATPglu / EC50ATPgal > 3125, p < 0.001 
and antimycin A EC50ATPglu / EC50ATPgal > 14925, p < 0.001). Furthermore, when exposed 
to adefovir, a postulated mitotoxin in the clinic, galactose-cultured ciPTECs showed a 
significantly lower EC50 (EC50ATPglu / EC50 ATPgal > 6.12, p = 0.0049, 3 days). Tenofovir 
(TFV), a lower toxic analogue of adefovir, was also submitted to the glucose vs. galactose 
model ATP depletion did not reach 50%. 
 
Causes of mitochondrial dysfunction are variable but they all eventually trigger a 
perturbation of the respiratory parameters. Hence, to further explore the molecular 
mechanisms behind adefovir and TFV mitochondrial toxicity, ciPTECs bioenergetics were 
interrogated. After a 24 h adefovir exposure, a decrease in oxygen consumption linked to 
ATP production was detected as well as a 40% reduction of the coupling efficiency at 100 
μM. Electron transport chain (ETC) complexes were also quantified and results revealed a 
depletion of complex I (45%) and complex IV (20%). These are the only two complexes with 
an important mtDNA encoded core. Furthermore, reactive oxygen species (ROS) levels 
increased 2 fold after adefovir exposure (48 h). In conclusion, these data evidenced that 
adefovir targets either mitochondrial RNA or protein synthesis, impeding a correct protein 
assembling of ETC complexes and therefore hampering cell respiration. However, other 
factors such as ROS might also play an important role. No decrease in oxygen consumption 
 v 
 
was detected after ciPTECs were exposed to TFV for 15 days. In contrast, a dose-dependent 
increase in extracellular acidification rate (ECAR) was observed, which could be an initial 
sign of mitochondrial dysfunction. 
 
Although ciPTECs exhibit most of the necessary features to investigate nephrotoxicity such 
as good transporter expression, they cannot take into account different people’s 
pharmacokinetics or transporter polymorphisms that alter drug-induced toxicity. In 
contrast, urine-derived progenitor cells (UPCs) represent a non-invasive and limitless source 
of kidney cells that could be differentiated into PT cells. Even though the PT-differentiation 
was not fully achieved, we successfully isolated three colonies of UPCs that reached 
passaged 10 with similar clonogenicity values to cancer cell lines (31%) at the exponential 
growth phase. Therefore, if the differentiation process could be optimised, urine-derived 
cells could have the potential to be used as a patient-specific nephrotoxicity model as well 
as being applied in personalised medicine and regenerative studies.  
 
In summary, the data presented in this thesis demonstrate that drug-induced mitochondrial 
dysfunction responsible for nephrotoxic events can be detected using the ciPTECs glucose 
vs. galactose in vitro model. Furthermore, in addition of screening for mitotoxic 
compounds, it has been shown that the model can also be used as a tool to investigate the 
molecular events preceding adefovir toxicity as well as other undisclosed mitotoxicities. 
Finally, the work undertaken has also demonstrated that UPCs and PT-differentiated UPCs 
hold promising answers to tackle and prevent drug-induced nephrotoxicity.   
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1.1 THE KIDNEY 
1.1.1 Structure and function  
The mammalian urinary apparatus is composed of two kidneys, which are connected to the 
ureters, bladder and urethra. A  single mammalian kidney  is  a  bean-shaped  organ  with  a  
concave  renal  hilum, where blood vessels connect and the ureter exits (Deshmukh 2009). 
The kidney has distinct zones forming a cone shaped renal lobe comprising the cortex at the 
top widest region, adjoined to the medulla and followed by the papilla at the inner tip 
(Hebert 2008). The kidney has important homeostatic functions which are essential to 
maintain the acid-base balance and an adequate blood pressure (Witzgall 2008). 
Specifically, the kidney receives 20 – 25% of the cardiac output and processes 
approximately 100 litres of filtrate per day. This filtrate contains high concentrations of 
metabolites which will ultimately be reabsorbed, leaving only 2 litres of filtrate to be 
excreted via the urethra as urine daily (Nagai and Takano 2010, Rahmoune et al. 2005). 
The  basic structural and functional  unit  of  the  kidney is  the  nephron, a tubular-like 
structure spanning  from the cortex  to the medulla (Frank 2012).  The physiological 
function  of  the  nephron  is  to  regulate  blood  entering  the  kidney  by adjusting its 
water and salt content, volume and pH and the removal of toxins and unwanted substances 
(Hebert 2008).  Remarkably, it is estimated that each human possesses more than 1 million 
nephrons (Witzgall 2008). A  nephron  is  composed  of  several  structures, each  with a 
specific function including the glomerulus and Bowman’s capsule, the proximal tubule (PT), 
the loop of Henle and the distal tubule which adjoins the collecting duct (Deshmukh 2009), 
see Figure 1.1 . 
The renal corpuscle is the initial section of the nephron, formed by the glomerulus and the 
Bowman’s capsule, filters the blood supply from the renal circulation. The glomerulus is a 
tuft of capillaries located in the cortex that receives and filters blood from the afferent 
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arteriole. The fenestrated capillary walls facilitate the passage of molecules of up to 70 kDa 
(Deshmukh 2009) and  pressure  is  created  by  the  difference  in  diameter  between  the 
afferent arteriole and the narrower efferent arteriole, which can also be hormonally 
regulated. Collectively, the glomerulus, the basement membrane and the podocytes from 
Bowman’s capsule  selectively  filter  small  molecules  such  as  water,  ions,  low  molecular  
weight proteins, glucose and amino acids whilst excluding blood cells and platelets as well 
as high molecular weight and anionic proteins (Hebert 2008), producing an ultrafiltrate. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
The ultrafiltrate is further processed to produce urine  upon entering the PT in the cortex, 
which  has  resorptive  (glucose,  salt,  water,  proteins)  and  secretive  (creatinine)  
functions (Deshmukh 2009). The loop of Henle extends into the medulla from the PT and 
facilitates water and salt exchange.  The  remaining  filtrate  enters  the  distal  tubule  
which  mediates  the  uptake  of calcium,  phosphate,  sodium  and  potassium  from  the  
filtrate (Deshmukh 2009) before  it reaches the collecting duct, draining towards the ureter. 
Figure 1.1 Nephron: the basic functional and structural unit of the kidney. 
Each nephron is composed of an initial filtering section (formed by the glomerulus and the 
Bowman’s capsule) and a tubule specialized section in reabsorption and secretion of 
metabolites. The renal tubule is attached to the Bowman’s capsule and starts with the PT, 
followed by the loop of Henle, the distal tubule and finally the collecting duct.  
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1.1.2 Drug-induced nephrotoxicity 
Drug-induced  nephrotoxicity  is  a  type  of  kidney  injury  where  functional  or  structural 
damage  to  the  organ,  pre-renal,  intrinsic  or  post-renal,  is  caused  by  exposure  to  one  
or several  therapeutic  agents.  It  is  a  common  clinical  adverse  event  and,  although  
the  true incidence  is  difficult  to  determine,  US  hospital  data  suggests  that  drug-
induced  kidney injury accounts for 18-27% of all acute kidney injury (AKI) cases in the US 
(Taber and Pasko 2008). This number can rise to 66% in older adults (Nagai and Takano 
2010). Some examples of pathogenic mechanisms caused by drugs range from altered 
intraglomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy and 
rhabdomyolysis (Naughton 2008).     
As drug-induced kidney toxicity is a common side effect amongst many drugs, it is 
considered an important attrition factor during drug development. Nephrotoxicity accounts 
for 2% of drug failures in preclinical studies (Jang et al. 2013), however, on moving into 
clinical trials, this rises to 19%. Such a high fraction of drug-induced renal toxicity in human 
studies generates concern, and lays the need to improve nephrotoxicity models to better 
predict the incidence of toxicity at a preclinical stage. A more accurate prediction would 
decrease AKI prevalence and could reduce hospital interventions (Vaidya et al. 2010) as 
well as provide a reduction of costs for compounds which trigger nephrotoxicity levels that 
are considered too high to allow the drug onto the market. 
 
1.1.3 In vivo vs. in vitro nephrotoxicity models 
Pre-clinical studies are performed in both in vivo models, involving animals, and in vitro 
models, which include well-established cell lines. Although variable, animal studies have 
shown to be a valuable model to predict certain human toxicities produced by 
pharmaceutical agents. Nevertheless, they have a poor prediction of renal toxicity due to 
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producing 30% false negatives (Olson et al. 2000). In addition, the animal of choice and the 
compliance with the 3Rs are crucial detecting truly human hazard. In vivo studies are also 
time consuming, expensive and not suitable for performing mechanistic studies at a 
molecular level (Table 1.1).  
Table 1.1 In vivo vs. in vitro models: advantages and disadvantages. 
 
ADVANTAGES DISADVANTAGES 
In vivo 
models 
3D models 
Definite methodology     
Highly reliable to predict some 
toxicities:  
  - Haematological 
  - Gastrointestinal  
  - Cardiovascular  
Poor nephrotoxicity prediction 
(30% false negatives) 
Ethical regulations (3Rs) 
Expensive and time consuming 
Not useful for mechanistic 
studies at a molecular level 
In vitro 
models 
No ethical problems 
Cheaper and quicker than 
animal models 
High-throughput analysis 
Potentially useful for 
mechanistic studies at a 
molecular level 
3D cultures in development 
Experiments can only be 
conducted using one cell type 
(mainly) 
Lack expression of key 
functions/transporters 
Spheroids and chip devices are 
still far from mimicking kidney 
processes 
 
In in vitro models, it is critical to choose the adequate cell line to study the mechanism of 
interest. As any other organ, the kidney is assembled with different cell types that execute 
different functions and express different transporters. Altogether, it influences the drug 
uptake and consequently the toxicity. In particular, the clearance and reabsorption of drugs 
is primarily conducted in the PT, thus this structure can be subjected to high concentrations 
of toxic compounds (Naughton 2008, Bonventre et al. 2010). As a result, PT cells are the 
most affected cells by drug-induced injuries and thus, the cell line of choice to monitor 
renal drug toxicity (Bonventre et al. 2010). In vitro models also offer the opportunity to 
Chapter One 
 
7 
 
perform high through-put drug screening that produce large amounts of data at a 
molecular level, and are generally cheaper and quicker than carrying out animal studies 
(see Table 1.1). PT cells are usually seeded in 96 well plates and drug screening is 
performed. After exposure to the compound, OMICs, kinetic and functional data can be 
collected and integrated in a cell model to elucidate different nephrotoxicity pathways 
(Wilmes et al. 2013, Jennings et al. 2012).  
In vitro cultures in 2D lack the organ architecture and complexity of the mammalian kidney. 
Hence, spheroids (Heuser et al. 2003, Buzhor et al. 2011) and renal chip devices (Jang et al. 
2013) represent a bridge between the two strategies. In particular due to the fluidic flow 
the cells are exposed to, chip devices are able to mimic key PT functions (Jang et al. 2013). 
Despite the expense and bio-complexity of development, they have the potential to recover 
more sensitive information and provide the ability to study drug-induced nephrotoxicity in 
preclinical studies. Nevertheless, there is an inverse relationship between through-put 
analysis and the level of complexity. 
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1.2 THE PROXIMAL TUBULE 
1.2.1 Structure and function 
The PT is the region of the nephron between the Bowman’s capsule and the loop of Henle. 
Initially, the PT forms several coils known as pars convoluta which are followed by a straight 
segment known as pars recta that descends towards the medulla (Levy et al. 2006). 
Regarding ultrastructure, three sequential segments can be differentiated named S1, S2 
and S3, each of which is characterised by a unique cell type. The pars convoluta includes S1 
and most of S2. A sudden transition takes place in the upper section of the pars recta to S3. 
Each segment has distinct cellular characteristics such as a longer brush border microvilli in 
S3 and S1. Moreover, mitochondria in S1 are long and perpendicularly stacked to the 
cellular axis, and get progressively shorter and more randomly distributed in S2 and S3 
(Venkatachalam et al. 1978). 
Generally, cells of the PT are characterised by their dense microvilli on the apical surface 
known as brush border, which increases their surface area to facilitate reabsorption and 
sense the flow within the lumen (Wang 2006). 
The PT reabsorbs approximately 67% of the filtered water, Na+, Cl-, K+ and other solutes 
(Levy et al. 2006). In addition, the PT is responsible for reabsorbing glucose (Wright 2001), 
low molecular weight proteins (Maack 1975) and other molecules to restore the plasma 
balance  of these compounds. Essentially, the Na+/K+-ATPase located in the basolateral 
membrane is key in the reabsorption process, as any form of reabsorption, including water, 
is linked to the operation of this pump (Levy et al. 2006).  
Another important function of the PT is the secretion of organic cations and anions. Many 
of these are secreted as end products of metabolism that circulate in the plasma. Other 
exogenous organic compounds are also secreted including penicillin and other toxic 
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chemicals. Many of them are bound to plasma proteins and hence not readily filtered 
through the glomerulus. Therefore, the PT contains powerful transport systems to remove 
the organic anions and cations from the plasma to the tubular fluid (Levy et al. 2006). 
 
1.2.2 Transporters of the PT 
The PT is the main contributor to endogenous and exogenous xenobiotic elimination due to 
its large selection of transporter proteins that hold diverse substrate specificities. It is worth 
noting that whilst transporters of the PT, as well as transporters in general, might possess a 
broad and overlapping substrate specificity, they may also display different affinities and 
turnover properties for specific compounds (Lee and Kim 2004). These renal transporters 
are categorised into families based on their selectivity and molecular properties: organic 
anion transporters (OATs), organic cation transporters (OCTs) and ATP-binding cassette 
(ABC) superfamily (Gallegos et al. 2012). Some PT transporters that play a crucial role in 
 
 
 
 
 
 
 
 
 
 
Apical Basolateral 
 
OAT1 
OAT3 
OCT2 
OATP4C1 
MRP4 
MRP2 
BCRP 
P-gp 
Figure 1.2 Localisation of some PT transporters involved in xenobiotic elimination. 
OATs and OCTs are located on the basolateral side and in contact with the blood flow. 
Due to the intracellular negative potential, OATs can only uptake the negatively 
charged anions through an energy-dependent active transport (Lee and Kim 2004). 
In contrast, ABC superfamily transporters are found on the apical side and secrete 
xenobiotic compounds to the tubular lumen. 
OATP4C1 ? 
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drug clearance and toxicity are specifically outlined in the next section (see Figure 1.2).  
A summary of some important PT transporters can be seen in Table 1.2. 
Table 1.2 A selection of transporters of the PT 
Transporter  
(Superfamily) 
Site of 
expression  
Substrates  Function References 
MRP2 
(ABC) 
Apical 
membrane 
Endogenous and 
xenobiotic organic 
anion compounds.  
e.g. Tenofovir 
(TFV), adefovir, 
glutathione 
- Efflux pump key to 
cellular protection 
against drug 
accumulation  
- Regulation of drug 
pharmacokinetics 
(International 
Transporter et al. 
2010, Jedlitschky et 
al. 2006, Russel et 
al. 2008) 
MRP4 
(ABC) 
Apical 
membrane 
Endogenous and 
xenobiotic organic 
anion compounds. 
e.g. TFV, adefovir, 
glutathione 
- Efflux pump key to 
cellular protection 
against drug 
accumulation  
- Regulation of drug 
pharmacokinetics 
(International 
Transporter et al. 
2010, Jedlitschky et 
al. 2006, Russel et 
al. 2008) 
P-gp  
(ABC) 
Apical 
membrane 
Endogenous and 
xenobiotic organic 
cation 
compounds. 
e.g. Digoxin, 
doxorubicin, 
steroids, lipids  
- Efflux pump key to 
cellular protection 
against drug 
accumulation  
- Exerts great 
influence in drug 
pharmacokinetics 
(Thiebaut et al. 
1987, Schinkel and 
Jonker 2003, 
International 
Transporter et al. 
2010) 
BCRP  
(ABC) 
Apical 
membrane 
Endogenous and 
xenobiotic organic 
compounds. 
e.g. Statins, 
sulphate 
conjugates, 
methotrexate 
- Efflux pump key to 
cellular protection 
against drug 
accumulation  
- Exerts great 
influence in drug 
pharmacokinetics  
(International 
Transporter et al. 
2010, Vlaming et al. 
2009) 
OAT1  
(Solute 
carrier 
(SLC)) 
Basolateral 
membrane 
Organic anions 
including many 
drugs and 
potential 
nephrotoxic 
endogenous 
compounds. 
e.g. TFV, adefovir, 
cidofovir 
- Rate-limiting step to 
clear organic anion 
drugs and other 
metabolites from 
blood 
- Involved in drug-
drug interactions 
(International 
Transporter et al. 
2010, Gallegos et 
al. 2012, Eraly et al. 
2006, Sweet et al. 
2002) 
OAT3  
(SLC) 
Basolateral 
membrane 
Organic anions 
including many 
drugs and 
potential 
nephrotoxic 
endogenous 
compounds. 
e.g. TFV, adefovir 
 
- Rate-limiting step to 
clear organic anion 
drugs and other 
metabolites from 
blood 
- Involved in drug-
drug interactions 
(International 
Transporter et al. 
2010, Gallegos et 
al. 2012, Eraly et al. 
2006, Sweet et al. 
2002) 
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OATP4C1  
(SLC) 
Basolateral 
(apical?) 
membrane 
Organic anions 
including many 
drugs and uremic 
toxins. 
e.g. estrone-3-
sulfate, digoxin, 
methotrexate 
- Involved in the 
uptake of anionic 
oligopeptides and 
various drugs from 
blood 
(Bleasby et al. 
2006, Yamaguchi et 
al. 2010, Mikkaichi 
et al. 2004, Kuo et 
al. 2012). 
 
OCT2 
(SLC) 
Basolateral 
membrane 
Organic cations 
and many drugs 
as around 40% of 
drugs are cationic 
at their 
physiologic pH. 
e.g. metformin  
- Regulates the 
entrance of 
endogenous and 
exogenous organic 
cations from blood  
- Involved in drug-
drug interactions 
(Motohashi et al. 
2002, Belzer et al. 
2013) 
 
AQP1 
Apical and 
basolateral 
membranes 
Water 
- Provides the chief 
route for proximal 
nephron water 
reabsorption 
- Functions as a water-
selective 
transporting protein 
that excludes small 
solutes  
- Represents more 
than 25% of 
membrane proteins 
(Nielsen et al. 1999, 
Ma et al. 1998). 
 
 
 
1.2.3 Megalin and cubilin endocytic system 
Megalin and cubilin are defined as endocytic receptors with multiligand properties that are 
co-expressed in the apical membrane of the PT, and play an important role in the receptor-
mediated endocytosis of proteins and peptides (Christensen and Birn 2002, Nagai and 
Takano 2010, Christensen et al. 2009). Specifically, they are fundamental for the 
reabsorption of albumin (Figure 1.3), which is the most abundant protein in plasma (Cui et 
al. 1996, Zhai et al. 2000). In healthy adults, the daily glomerular filtration rate is 150-180 
litres and therefore the daily filtered load of albumin is in the range of 3300 - 5760 mg 
(Renal Tubule Albumin Transport, Gekle 2005). Hence, without an efficient recovery 
system, the human body would eventually face proteinuria. Other ligands include insulin, 
vitamin D-binding protein, haemoglobin, and epidermal growth factor amongst other 
important carrier proteins, hormones and enzymes (Christensen et al. 2009). Thus, its 
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presence in the PT is critical to recover a wide range of proteins and peptides that would 
otherwise be discarded in the urine. Nonetheless, megalin and cubilin scavenger 
capabilities are also responsible for the uptake of exogenous substrates such as 
aminoglycoside antibiotics that, when accumulated in the PT, can induce nephrotoxicity 
(Nagai and Takano 2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
1.2.4 PT toxicity 
The elimination of drugs and their metabolites from the system depends on three 
developments: glomerular filtration, tubular secretion and tubular reabsorption.  (Nagai 
and Takano 2010). First, the unbound drugs escape from the glomerular filtration barrier 
and arrive at the PT. This is the main elimination route for most compounds. Additionally , if 
the drugs are hydrophilic they are uptaken from the blood flow and pass directly to the PT 
via OATs and OCTs (Inui et al. 2000). In contrast, the drugs already filtered by the 
glomerulus might be reabsorbed by active transporters or via receptor-mediated 
Figure 1.3 Schematic of albumin endocytosis via megalin and cubilin endocytic system. 
During the process of endocytosis, (A) small invaginations in the plasma membrane are 
formed that contain cubilin and megalin receptors bound to albumin. The endocytic 
invaginations detach from the membrane (B) to form endocytic vesicles that will 
eventually merge with lysosomes. Finally, (C) the receptors are recycled and brought back 
to the plasma membrane (Gekle 2005). 
 
A 
B 
 C 
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endocytosis from the luminal side of the renal PT, causing an accumulation of potential 
damaging drugs in this section of the nephron. As a result, drug-induced nephrotoxicity is a 
significantly important event in the PT, and a limiting factor for the use of several drugs 
(Nagai and Takano 2010). 
 
1.2.5 Classic PT cell lines  
In order to obtain a reliable in vitro cell model that can mimic the metabolic and molecular 
processes in the PT, various cell lines have been developed over the years.  These cell lines 
vary from animal kidney lines with poor transporter expression, to human PT lines that 
have retained most of their differentiated characteristics. This is due to the development of 
new isolating and immortalising techniques, and better culture conditions with hormonally 
supplemented media. 
 
1.2.5.1 Animal PT cell lines 
Proximal-like pig kidney (LLC-PK1) and renal distal-like dog kidney (MDCK) cells are 
spontaneously transformed animal cell lines that contain a mixture of proximal and distal 
cells (Gstraunthaler 1985) and have been described to maintain some features typical of 
the kidney epithelium (Perantoni and Berman 1979). They have been a useful model to 
assess protein trafficking and heterologous transporter expression (Bens and Vandewalle 
2008).  
Another important animal in vitro model is the opossum kidney (OK) cell line, originally 
developed to study chromosome X inactivation (Koyama et al. 1978). However, although it 
originated from the whole kidney, it was later identified to possess typical PT properties 
(Malstrom et al. 1987). OK cells have been shown to recreate a dome formation and 
paracellular permeability in culture, typical PT features not found in other animal renal cell 
Chapter One 
 
14 
 
lines such as LLC-PK1 (Liang et al. 1999). Furthermore, OK cells have been demonstrated to 
be a valuable PT model to study the functionality of some receptors and transporters. 
Megalin and cubilin were successfully identified as the receptors responsible for the 
albumin uptake in OK cells (Olson et al. 2000) and later used to develop a therapeutic 
strategy to prevent aminoglycoside-induced nephrotoxicity (Antoine et al. 2010) amongst 
other studies. 
Yet, these are animal-derived cell lines and as such they have important variations  in 
pharmacokinetics and pharmacodynamics compared to human cells (Ito 2008). To better 
predict and understand drug-induced nephrotoxicity, a more translational human PT model 
is required (Gunness et al. 2010).  
 
1.2.5.2 HEK 293 cells 
Human embryonic kidney (designated 293) cells (HEK 293 cells) were derived from exposing 
a primary HEK cell to sheared fragments of adenovirus type 5 (Graham et al. 1977). The 
transformation resulted in the incorporation of approximately 4.5 kb from the viral genome 
into human chromosome 19 of the HEK cells (Louis et al. 1997). Since then, they have been 
used in a vast number of transfection and recombinant expression studies, due to the high 
responsiveness and efficiency of transfection via different methods (Thomas and Smart 
2005). Furthermore, it has been speculated that HEK 293 cells do not have a kidney origin, 
but a neuronal one. Particularly, Shaw et al. claimed that HEK 293 cells are not typical 
kidney cells and so cannot be used to study normal kidney-related function. The same study 
showed  that this adenovirus transformed cell line had mRNA constructs and gene products 
typically found in neurons (Shaw et al. 2002).  
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Nonetheless, HEK 293 cells have efficiently been used to study drug uptake after the 
overexpression of PT and other cell transporters through transfection (Biermann et al. 
2006, Jong et al. 2011, Qadir et al. 2005).  
 
1.2.5.3 HK-2 cells 
In 1994, the first human immortalised PT cell line, human kidney-2 (HK-2), was developed 
by Ryan MJ et al. by infecting primary PT cells from the renal cortex with a human 
recombinant retrovirus containing the E6/E7 genes of the human papilloma virus. The cell 
line was described to retain characteristics of well-differentiated PT epithelium, such as 
staining positive for alkaline phosphatase and Na+ dependent/phlorizin sensitive sugar 
transport (Ryan et al. 1994). Further characterisation was performed and it was 
demonstrated that HK-2 cells were a good model to study drug efflux associated with 
transporters from the ABC family, since the cell line exhibited expression and functionality 
of some of its members such as MRP4 or P-gp (Tramonti et al. 2001). However, no 
expression of BCRP or MRP2 was observed and the presence of drug uptake transporters 
was defined as limited, with no detectable levels of OAT1, OAT3 and near zero levels of 
OCT2 (Jenkinson et al. 2012). 
In general, despite shedding some insight into drug transport and drug-induced 
nephrotoxicity (Sohn et al. 2013, Wang et al. 2007, Romiti et al. 2002, Matsui et al. 2013), 
HK-2 cells poorly predict in vivo clinical toxicity, mainly due to a lack of metabolic 
competence and transporter expression (Jenkinson et al. 2012). 
 
1.2.5.4 Primary isolated cells 
In 1998, Pfaller & Gstraunthaler pointed out that primary cultures of fresh isolated cells 
represented an attractive alternative to study long-term effects of nephrotoxins. Compared 
to their immortalised counterparts, they possess an optimum level of differentiation and 
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express the key functions and transport systems, such as gluconeogenesis and OATs. 
Nevertheless, on top of being time-consuming to develop, these cultures had a limited life 
span (days to weeks) and tended to suffer a quick loss of their in vivo metabolic properties 
in culture (Pfaller and Gstraunthaler 1998). However, despite of their disadvantages, when 
a good availability of kidney tissue is attainable, some research groups can afford to 
perform in vitro studies in primary PT cells. Their large array of transporters associated with 
major classes of important drugs is crucial in studying drug transport and drug-induced 
nephrotoxicity (Brown et al. 2008, Lash et al. 2006). 
 
1.2.6 Newly immortalised PT cell lines 
Although prior attempts to immortalise PT cells have been made (Kowolik et al. 2004, Orosz 
et al. 2004, Ryan et al. 1994), currently RPTEC/TERT1 (renal PT epithelial cells immortalised 
by the human telomerase reverse transcriptase (hTERT)) (Wieser et al. 2008) and ciPTECs (a 
conditionally immortalised PT epithelial cell line by hTERT and the simian virus 40 T antigen 
(SV40T)) (Wilmer et al. 2010) are considered superior options when assessing drug-induced 
nephrotoxicity in vitro due to their greater level of xenobiotic transporters, compared to 
alternative renal lines, and other typical markers of PT cells. Both cell lines have the 
advantages of being able to continuously grow with a high differentiation status, expressing 
endogenous receptors and transporters that mimic renal developments. As a result, they 
are considered a powerful tool for compound transport studies in pharmacology and 
physiology, as well as for drug screening and toxicology (Wieser et al. 2008, Wilmer et al. 
2010, Gorvin et al. 2013).  
1.2.6.1 RPTEC/TERT1 cell line 
RPTEC/TERT1 cells are a commercially available cell line developed by Weiser et al. in 
collaboration with Evercyte in 2008. Initially, RPTECs cells were isolated from a kidney 
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biopsy and split once before being infected with retroviral particles encoding the essential 
catalytic subunit of telomerase (hTERT). A resistance cassette for geneticin (G418) was also 
encoded, which is essential to select for positive transfectants. The immortalisation 
procedure is explained in detail in Figure 1.4.  
Weiser et al. demonstrated that hTERT transfection was sufficient to circumvent replicative 
senescence and avoid terminal growth arrest as well as DNA damage linked to senescence. 
RPTEC/TERT1 cells gained the ability to grow up to 70 population doublings without slowing 
down cell division. Importantly, they exhibited comparable excretory capacity to primary 
RPTECs, and better expression of transporting systems than HK-2 cells. A typical PT 
morphology was also observed, including microvilli, solitary cilia, tight junctions and domes. 
Furthermore, intact sodium-dependant phosphate uptake and a functional megalin/cubilin 
transport system were confirmed (Wieser et al. 2008). 
 
Figure 1.4 RPTEC/TERT1 cell line immortalisation procedure. 
Primary RPTECs from kidney tissue were infected with retroviral particles containing 
hTERT-coding cDNA and a resistance cassette to G418. After 24 h of infection, cells 
were passaged and cultured in a medium containing G418. Therefore, only the 
clones resistant to the antibiotic, and as a consequence also transfected with 
hTERT, were selected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hTERT 
RPTEC/
TERT1 
RPTECs 
Infection 
G148 selection 
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1.2.6.2 ciPTECs 
ciPTECs were established by transfecting RPTECs isolated from the urine of a healthy 
volunteer. The PT origin of the collected cells was first confirmed by cell morphology and 
typical transporter activity characteristic of that region of the nephron. In this case, the 
immortalisation procedure was much more elaborate. Following the same procedure 
carried out by Saleem et al. to immortalise podocytes, two temperature-sensitive mutants 
of the hTERT and SV40 large T antigen (SV40T) were used to transfect the cells using viral 
vectors (see Figure 1.5). While hTERT expression enables the continuous elongation of the 
telomeres, SV40T expression promotes cell division (Saleem et al. 2002). However, since 
the promoters of both genes were temperature-sensitive, their expression is restricted to 
the permissive low temperature of 33°C. Therefore, the subcloning and further culture of 
these cells is performed at 33°C and they are only transferred to 37°C to inactivate gene 
expression, and induce cell differentiation (Wilmer et al. 2010).  
 
 
 
 
 
 
 
 
 
Figure 1.5 ciPTECs immortalisation procedure. 
RPTECs collected from urine were infected with retroviral vectors containing hTERT 
and SV40T-coding cDNA plus a resistance cassette to G418 and hygromycin B 
respectively. After 24 h of infection, cells were passaged and cultured in a medium 
containing G418 and hygromycin B for 10 days. Therefore, only the clones resistant 
to both antibiotics, and as a consequence also transfected with both hTERT and 
SV40T, were selected.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
hTERT 
ciPTECs 
RPTECs 
Infection 
Selection: 
G418 + hygromycin B  
SV40T 
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After immortalisation, further characterisation was performed to verify that the DNA 
insertion into the genome had not modified the cell phenotype. Expression of CD13, ZO-1 
and AQP1 was detected using antibody labelling techniques. The presence and/or absence 
of AQP1 was decisive in confirming that no other cell types, such as distal tubule cells, had 
been immortalised, as it is a PT specific transporter (Nielsen et al. 1999). Wilmer et al. also 
demonstrated that ciPTECs had a maintained expression of PT transporters involved in 
xenobiotic excretion and metabolite reabsorption for up to 45 passages. Specifically, they 
claimed to have developed the first human cell line to express active MRP4 combined with 
OCT2 and P-gp. In addition, despite being unable to provide evidence of the presence of the 
multi-ligand receptor megalin via western blotting or immunofluorescence (IF), they 
showed albumin uptake, competitive albumin uptake inhibition using non-labelled albumin 
and non-competitive inhibition using a receptor-associated protein (RAP), an inhibitor of 
prenylated GTP-binding proteins such as megalin (Ranghini et al. 2013). Other functional 
assays verified the activity of the sodium-dependent transporters NaPi-II and NaPi-IIc. The 
experiments were performed after 10 days maturation at 37°C. After this period, the 
expression of the oncogenes had completely ceased and hence, the influence of the 
transfection on cellular metabolism was minimised (Wilmer et al. 2010). 
Shortly after the creation of the first ciPTEC line, another line was developed from patients 
with cystinosis, an autosomal-recessive disorder that produces an abnormal accumulation 
of the amino acid cysteine in the lysosomes. Therefore, providing the opportunity to 
investigate in detail the cell metabolic changes involved in the pathogenesis of cystinosis 
(Wilmer et al. 2011, Peeters et al. 2011). 
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1.3  RENAL MITOCHONDRIAL TOXICITY 
1.3.1 Structure and morphology of the mitochondrion  
Mitochondria range from 0.5 to 1 μm in size and are composed of two organelle 
compartments. The inner compartment, the mitochondrial matrix, is enclosed by the inner 
mitochondrial membrane (IMM), an extensively folded membrane in which invaginations 
are known as cristae. PT cells have a densely packed cristae (Kohler et al. 2009) correlating 
with the high energy requirements of these cells. However, the density varies for each 
tissue and cell type as a result of the different roles played by the mitochondria in each 
case. The outer compartment is known as intermembrane space as it is situated between 
the IMM and the outer mitochondrial membrane (OMM). This second membrane is smooth 
and separates the mitochondrion from the cytosol (see Figure 1.6) (Dykens and Will 2008). 
 
 
 
 
 
 
Mitochondria are partially autonomous organelles that harbour their own mitochondrial 
DNA (mtDNA), which is found in the matrix sub-compartment. The mtDNA has a circular 
shape and encodes 37 genes with few non-coding regions. It is also highly conserved 
amongst species, which supports the endosymbiotic theory (Dykens and Will 2008). These 
organelles are also able to replicate their genome independently of cell division thanks to a 
Matrix 
Outer Mitochondrial 
Membrane (OMM) 
Inner Mitochondrial 
Membrane (IMM) 
Cristae 
Intermembrane Space 
Figure 1.6 Parts of the mitochondrion. 
The knowledge of the different parts of the mitochondria and its inner 
structure was mainly derived from electron microscopy techniques. 
Chapter One 
 
21 
 
self-encoding replication system. Mitochondrial half-life varies from days to weeks 
depending on the tissue (Dykens and Will 2007). They also have their own RNA and protein 
synthesizing machinery, but only 1% of their proteins are formed on ribosomes in the 
mitochondrial matrix and the bulk of mitochondrial proteins are translated in the cytosol 
and imported into the mitochondria (Endo and Yamano 2009).  
 
1.3.2 Mitochondrial composition and electron transport chain (ETC) 
The basic structure of both membranes is a phospholipid bilayer housing transporter 
proteins and enzymes. The OMM is the only membrane where cholesterol is found, and has 
a protein-to-phospholipid ratio similar to that of the cell membrane. It also contains a large 
number of integral membrane proteins known as porins or voltage-dependant anion 
channels (VDAC) that allow the free passing of compounds up to 5 kDa to the 
intermembrane space. As a result, the composition of the intermembrane compartment 
has a high similarity to the cytosol regarding low-molecular weight particles. However, the 
majority of these molecules cannot go through the impermeable IMM and reach the 
matrix, which only contains a highly selected set of molecules. The IMM is highly 
specialised, and it contains cardiolipin in high proportions, which contributes to the 
membranes impermeability to ions. Finally, the machinery responsible for energy 
production, the main mitochondrial function in the PT, is also found in the IMM. This 
machinery is composed by the entire ETC including the ATP synthase complex (see Figure 
1.7).  In operational normal conditions, the respiratory chain pumps protons to the 
intermembrane space creating a voltage gradient on both sides (membrane potential) 
ranging up to 180 mV (Dykens and Will 2007, Alberts B 2002) . 
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1.3.3 Distribution of the mitochondria 
These organelles form a mitochondrial network, and can be observed forming elongated 
threads when cells are transfected with a mitochondrial-targeted green fluorescent protein 
(Benard et al. 2007, Rossignol et al. 2004). Particularly, in the PT they are arranged forming 
a striated basolateral distribution (Hall et al. 2009). Nonetheless, it is not a static network 
and mitochondria are in continuous movement, migrating throughout the cell, constantly 
splitting and fusing with each other. These dynamics allow the mitochondrial recruitment 
to different cell compartments, a communication between mitochondria and cytosol, 
mitochondrial content exchange and mitochondrial quality control. As a result, fission and 
fusion mechanisms are highly regulated and essential to maintain a healthy mitochondrial 
population by quickly adapting to changes in cellular requirements, triggered by 
physiological needs (Chen and Chan 2009).  
 
 
+ + + + 
- - - - 
Figure1.7 Schematic of the ETC electron transfer. 
The ETC or mitochondrial respiratory chain catalyses electron transfer from the 
reduced donors NADH (nicotinamide adenine dinucleotide) and FADH2 (flavin 
adenine dinucleotide) to molecular oxygen (O2) from complex I to complex IV. The 
final product of this pathway is water (H2O). The energy derived from this process is 
used to pump protons (H+) across the IMM towards the intermembrane space, 
creating a membrane potential. This membrane potential eventually drives H+ 
through the ATP synthase (complex V), generating ATP from ADP and becoming the 
driving force of ATP production (Dykens and Will 2008).  
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1.3.4 Mitochondria in the PT 
Mitochondria consume 98% of the O2 taken in by the human body and have been described 
as the “powerhouse of the cell” due to their prime role in cellular bioenergetics (producing 
>90% of the cell energy) (Duchen 2004). Mitochondria are also involved in calcium 
signalling, regulation of cell death pathways, generation of reactive oxygen species (ROS) 
and the regulation of intracellular pH and redox state (Hall et al. 2009). In the PT, the 
mitochondria represent 33% of the volume in cells from the S1 segment, 39% in cells from 
the S2 segment and 22% in cells from the S3 segment. Along the segments, S1 and S2 have 
a different cell metabolism compared to other parts of the nephron, which are 
characterised by the complete absence of glycolysis (Weinberg and Molitoris 2009). This 
dependence on aerobic metabolism for energy supply is believed to be the main reason of 
PT high vulnerability to mitochondrial dysfunction from a wide variety of insults such as 
xenobiotic toxicity (e.g., antiretroviral drugs) (Hall et al. 2009, Izzedine et al. 2005). Only S3, 
although to a lower extent than distal tubules, can contribute to ATP production through 
glycolysis when there is an impairment in mitochondrial function (Weinberg and Molitoris 
2009). 
 
1.3.5 Mitochondria: a drug target 
Organ toxicity is one of the main issues jeopardising novel compounds during the pre-
clinical stages of drug development, and it is finally now recognised that mitochondrial 
impairment, as an “off-target” effect of drug exposure, will most likely lead to it (Dykens 
and Will 2007). As a result, drug-induced mitochondrial toxicity has recently become a focal 
interest by pharmaceutical companies to increase the probability of survival of a new 
compound during the process of drug discovery and development (Swiss et al. 2013). 
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1.3.6 Nucleotide reverse transcriptase inhibitors (NtRTIs) induce PT mitochondrial toxicity 
The most aerobically poised tissues or the ones that receive high drug concentrations, such 
as the kidney, are classically the most affected by mitochondrial impairment. In particular, 
the PT is the main section affected by drug accumulation and therefore, mitochondrial 
dysfunction will be of a greater concern in this area. Moreover, PT cells have an extensive 
mitochondrial density that is fundamental to satisfy their elevated energy demand, as well 
as a limited capacity to generate ATP anaerobically (Bagnasco et al. 1985). Consequently, 
mitochondrial impairment will highly distress the PT cell metabolism and trigger 
nephrotoxicity. 
For known renal toxins such as cisplatin, gentamicin, tobramycin, cyclosporine A or 
ifosfamide, the mitochondria has been shown to play a role in their mechanism of toxicity 
(Servais et al. 2008, Lopez-Novoa et al. 2011, Yao et al. 2007). However, only in specific 
compounds such as nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and 
NtRTIs) the mitochondria appear to be the primary target (Tanji et al. 2001, Herlitz et al. 
2010). Interestingly, it was not until the release of these compounds onto the market that 
drug-induced mitochondrial dysfunction as the main cause for organ toxicity was accepted 
(Dykens and Will 2007). 
Combinations of NRTIs and NtRTIs have been used for many years in the treatment of 
human immunodeficiency virus (HIV), with the name of highly active antiretroviral therapy 
(HAART), causing mitochondrial toxicity as an adverse effect (Kakuda 2000). Many NRTIs are 
known to inhibit the polymerase that replicates mtDNA (polymerase-), hence impeding 
mitochondrial replication and reducing mitochondrial function (Dykens and Will 2007). 
However, the mitotoxic pathogenic mechanism for the NtRTIs adefovir and tenofovir (TFV) 
(see Figure 1.8) remains to be elucidated. 
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1.3.6.1    Adefovir  
Adefovir dipivoxil, the oral prodrug of adefovir, was the first NtRTI drug of its class, and was 
initially developed to treat HIV. However, its elevated nephrotoxicity halted the approval of 
this drug for this indication  (Valle and Haragsim 2006). The incidence in adefovir PT toxicity 
ranged from 27 – 50%, and was the most important dose-limiting toxicity in patients with 
HIV (Izzedine et al. 2005). Nevertheless, it has been used since 2002 as a retroviral therapy 
against Hepatitis B in highly controlled doses (De Clercq and Holy 2005, Song et al. 2012).  
The antiviral mechanism of action relies on the incorporation of one molecule of adefovir at 
the 3’ end of the growing DNA chain to prematurely terminate DNA elongation. Therefore, 
it serves as a substrate for the reverse transcriptase enzyme. Additionally,  as a NtRTI, it 
only requires two phosphorylations to be converted to its active form (De Clercq and Holy 
2005). 
The proximal renal tubule is, in fact, the target of high drug concentration as a consequence 
of active adefovir uptake from circulating blood directly into the basolateral side of PT cells. 
This transport is, for the most part, dependent on OAT1 uptake (Ho et al. 2000), although 
TFV Adefovir  
Figure 1.8 Chemical structure of adefovir and TFV. 
TFV and adefovir are two NtRTIs described to induce mitochondrial toxicity. Adefovir 
is a non-chiral adenine derivative while the stereochemistry of its lower toxic acyclic 
nucleotide analogue TFV is crucial for its activity (De Clercq and Holy 2005). 
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OAT3 has also been shown to be involved in adefovir renal transport, albeit to a lesser 
extent (Uwai et al. 2007). Adefovir has also been shown to be a substrate for MRP2 and 
MRP4 transporters, which modulate the excretion of the intact drug molecule to urine 
(Imaoka et al. 2007). These transporters are located in the apical side of PT cells and are 
responsible for the transport of anionic compounds into urine (Vigano et al. 2011). Both 
influx and efflux transporters mediate adefovir accumulation, and therefore nephrotoxicity 
(Fu et al. 2012). 
An in vivo study revealed that adefovir causes PT necrosis with enlarged and dysmorphic 
mitochondria, as well as a loss and disorientation in their cristae. Moreover, they showed a 
deficiency in cytochrome C oxidase (complex IV of the ETC), which is in part encoded by 
mtDNA. On the contrary, no deficiency was observed in succinate dehydrogenase (complex 
II of the ETC), which is entirely encoded by nuclear DNA (Valle and Haragsim 2006). 
Therefore, it was suggested that adefovir induced nephrotoxicity via an inhibition of the 
mitochondrial DNA replication, hence polymerase- (Tanji et al. 2001). However, this study 
was highly criticised as it was performed on kidney biopsies from a single patient on 
multiple medications including staduvine and hydorxyurea, which are known to cause 
mitochondrial toxicity and impairment of tubular function respectively (Bendele and 
Richardson 2002). In  conclusion, adefovir nephrotoxicity mechanisms remain undisclosed 
although evidence suggests that renal tubule transporters, apoptosis and/or mitochondrial 
toxicity in the PT may be involved (Vigano et al. 2011). 
 
1.3.6.2   TFV  
One of the most extensively used NtRTIs for HIV-1 (human immunodeficiency virus 1) is 
tenofovir disoproxil fumarate (TDF) (Herlitz et al. 2010), which is the oral prodrug of TFV. 
Despite nephrotoxicity being a rare complication (0.02% incidence) (Izzedine et al. 2005), 
several studies have described PT toxicity with significant loss of kidney function with long 
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term TFV exposure (Cooper et al. 2011, Hall et al. 2011, Herlitz et al. 2010). Fanconi 
syndrome has also been described in some severe cases with a general incidence of <1% 
(Hall 2013). 
As described for adefovir, TFV mechanism of action is also based on early termination of 
retrotranscription, via the incorporation of one molecule of TFV at the 3’ end of the 
growing DNA chain (De Clercq and Holy 2005).  
The basolateral uptake of TFV is also regulated by OAT1 and OAT3, with OAT1 playing a 
quantitatively crucial role (Uwai et al. 2007). Subsequently, the efflux of TFV from the PT to 
the lumen is mediated by the apical membrane transporters MRP4 (Ray et al. 2006) and 
MRP2 (Rodriguez-Novoa et al. 2010). 
TFV nephrotoxicity is dose-dependent and characterised by reversible acute tubular 
necrosis that reveals swollen and misshapen mitochondria when renal biopsies are 
analysed by electron microscopy (Herlitz et al. 2010). Whilst severe PT toxicity with 
detectable changes in glomerular filtration rate (GFR) is relatively uncommon, sub-clinical 
PT dysfunction with no GFR abnormalities has a prevalence that could be greater than 20%. 
However, the pathogenic mechanism by which TFV causes PT dysfunction remains to be 
elucidated (Hall 2013). Two possible mechanisms have been postulated but definitive 
conclusions are yet to be established. Animal studies support that mitochondrial injury is 
the primary mechanism of TFV-induced tubular damage (Kohler et al. 2009). It was first 
suggested that TFV could act as a weak inhibitor of mtDNA synthesis. Despite being able to 
induce mitochondrial toxicity in a similar way to adefovir or cidofovir, the potential to 
interfere with mitochondrial function is low (Rodriguez-Novoa et al. 2010, Cihlar et al. 
2002). The second mechanism proposes that TFV could interfere with the normal function 
of transporter proteins such as MRP2/4 and trigger a reduced efflux of TFV and other toxic 
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compounds, which would eventually accumulate and cause cell damage (Rodriguez-Novoa 
et al. 2010). 
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1.4 URINE AS A SOURCE OF KIDNEY CELLS 
Given the massive tubular network present in the kidney, it could be anticipated that cells 
could be detached and detected in urine. In fact, it is calculated that approximately  5 x105 
– 35 x105 cells are dissociated from the renal system daily and can be collected in urine 
(Linder 1976). The first successful attempt to culture exfoliated epithelial-like cells from 
urine was carried out by Sutherland and Bain, who established cell cultures from neonatal 
urine (Sutherland and Bain 1972). Since then, numerous research groups have been able to 
reproduce this and have established renal cultures of different cell types from newborn 
babies, infants and adults (Linder 1976, Felix et al. 1980, Racusen et al. 1991, Dorrenhaus et 
al. 2000, Zhang et al. 2008, Wilmer et al. 2010). Hence, urine represents a limitless source 
of cells that have brought and will continue to bring new insights into renal toxicity and 
development. 
 
1.4.1 Initial urine cell classification vs. today 
Urine contains exfoliated cells from different sources of the renal system, starting from the 
kidneys, following with the ureter, bladder and finally urethra (Dorrenhaus et al. 2000). 
However not all these cells are viable, with many already degenerating and thus do not 
form attach with the surface when placed in culture (Felix et al. 1980). Cells were initially 
classified in two categories depending on their morphology. Type I cells were defined as 
randomly arranged and with irregular edges, whereas type II cells were characterised by 
smooth-edge contours and cobblestone-like appearance, resembling a renal tubular 
epithelium (Felix et al. 1980). Another classification was described in 1983 when Detrisac et 
al. distinguished five different morphologies, and suggested that urine could hold a 
diagnostic value as a biomarker for nephropathy in diabetes mellitus patients. This was also 
the first time that the kidney was proposed as the site of origin due to indirect evidence 
(Detrisac et al. 1983). Racusen et al. later showed that they could isolate PT cells from the 
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urine of patients with nephropathic cystinosis and hence confirmed the already postulated 
kidney origin. They published electron microscopy images of the brush border (Racusen et 
al. 1991) and used histochemistry to stain for the brush border enzyme gamma glutamyl 
transpeptidase (Racusen et al. 1995). The initial classification was applied again in 2000 by 
Dorrenhaus, who attributed a urothelial origin to type I cells and a renal origin to type II 
cells. Additionally, they added a type II subclassification: spindle-like and cobblestone-like 
type II cells, which were able to form domes, a feature typical of the PT) (Dorrenhaus et al. 
2000). In summary, these classifications gave only a vague idea of the site of origin. 
However, it was evident that urine was becoming an interesting non-invasive source of 
renal cells for in vitro studies in toxicological and preclinical research. 
Currently, cells isolated from the urine are characterised using gene and protein expression 
assays in order to classify them as specific cell types. For instance, cells expressing CD13 
and AQP1 could be defined as renal PT cells (Wilmer et al. 2010), whereas cells expressing 
uroplakin 3A (UPK3A)  and uroplakin 1A (UPK1A) could be defined as urothelial (Rahmoune 
et al. 2005). Nevertheless, recalling the initial classification, Zhou et al. established a 
protocol to generate induced pluripotent stem cells (iPSCs) from urine samples and 
renovated the idea. It was stated that type I colonies have smooth-edged contours and 
cobblestone-like morphology, whereas type II colonies are randomly arranged. Based on 
mRNA and IF analysis, it was established that both types expressed renal epithelial markers, 
with no expression of the urothelial marker UPK3A (Zhou et al. 2012). Consequently, based 
on the gene expression profile, they stated that even though urine cells most frequently 
originate from the renal epithelium, urothelial origin is still possible and has been detected 
in other studies (Rahmoune et al. 2005). 
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1.4.2 Diversity of cells in urine - applications 
 The diversity of cells from various regions of the renal system has allowed the formation of 
different cell lines from urine cultures (Figure 1.9). The culture of podocytes and PT cells 
has been key in understanding the molecular mechanisms behind genetic diseases such as 
nephropathic cystinosis (Peeters et al. 2011), performing toxicological studies and gaining a 
better understanding of basic renal cell biology (Sakairi et al. 2010b, Zhang et al. 2013, 
Rahmoune et al. 2005), including the discovery that podocytes are able to endocyte 
albumin (Eyre et al. 2007). However, further improvements are necessary in cell 
transformation and/or culture conditions to fully reproduce the in vivo characteristics of 
podocytes (Sakairi et al. 2010b). Stable urine-derived PT cell lines have been used as a tool 
to investigate uremic excretion in kidney disease models (Gorvin et al. 2013, Mekahli et al. 
2012). In particular, Gorvin et al. have used conditionally immortalised PT epithelial cells 
from the urine of Dent’s disease patients to identify impaired endosomal acidification and 
receptor-mediated endocytosis. Nevertheless, the most revealing finding so far has been 
the detection of urine-derived stem/progenitor cells (USCs/UPCs).  
 
 
 
 
 
 
 
 
Figure 1.9 Cell types available in voided urine. 
Urine collects different types of cells that for different reasons may detach from 
the site of engraftment. Amongst them we can find podocytes, PT cells, 
squamous cells (differentiated cells that do no attach in culture), non-renal cells 
and putative renal progenitor/stem cells.   
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1.4.3 Urine-derived progenitor cells (UPCs) 
UPCs were isolated for the first time by Zhang et al. from healthy individuals and patients 
with vesicoureteral reflux. The isolating frequency of UPCs was calculated to be 0.2%, 
colonies formed from a single cell and they were capable of extensive expansion. 
Additionally, they were described as progenitors since they expressed progenitor cell 
surface markers, and demonstrated differentiation potential towards various cell lineages 
such as osteocytes, adipocytes and chondrocytes. However, Zhang et al. did not classify 
them as stem cells due to a lack of proof for unlimited self-renewal capability, and 
suggested a urothelial origin. Notwithstanding, in the following years other groups were 
able to reproduce the findings and defined the isolated cells as USCs (Bharadwaj et al. 2011, 
Wu et al. 2011). These studies were all able to use the urine-derived cells to give rise to 
urothelial-like cells, which displayed typical markers, such as UPK3A. Therefore, highlighting 
the potential of using UPCs/USCs as a cell source for urological tissue engineering (Zhang et 
al. 2008). Most recently, a renal origin for USCs was demonstrated by Bharadwaj et al., who 
also stated that different degrees of undifferentiated cells could be found in human urine 
(Bharadwaj et al. 2013).   
In summary, these studies confirmed the importance of urine as a non-invasive source of 
viable cells with potential for cell therapy, cytotoxicity and pharmacological studies. 
Furthermore, the use of these cells would entail less ethical concerns and, most 
importantly, reduce the immune response and rejection for autologous cell-based 
approches (Bharadwaj et al. 2013, Wu et al. 2011).  
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1.5 AIMS 
There is a significant predictive gap between preclinical (2%) and clinical studies (19%) in 
terms of drug-induced nephrotoxicity incidence, which may result in drug attrition or 
market withdrawal. Additionally, it has recently been revealed that mitochondria play an 
important role in organ toxicities. It is therefore important to identify nephrotoxicity early 
during the drug development process and to investigate the underlying pathologic 
mechanisms for this or that could predispose individuals to a safety risk. This would 
facilitate the development of risk mitigation and minimisation strategies to reduce the 
likelihood of nephrotoxicity during development and after marketing authorisation of the 
drug.  
Consequently, the aims of the research presented within this thesis were to: 
 Characterise the recently developed ciPTEC cell line to revalidate its potential as a 
nephrotoxicity model for further experiments. 
 Implement the glucose replacement strategy for galactose in ciPTECs in order to 
develop a sensitive in vitro model to detect renal mitochondrial impairment. 
 Interrogate ciPTECs cellular bioenergetics when exposed to adefovir and TFV as a 
strategy to uncover the molecular events responsible of renal mitochondrial 
toxicity triggered by these two NtRTIs.  
 Isolate UPCs and derive them into PT cells to establish a novel patient-specific 
model to identify diverse nephrotoxicity events. 
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2.1 INTRODUCTION 
 
Nephrotoxicity in vitro studies require suitable cell models that accurately reflect in vivo 
functionality and express a high range of transport systems to extend our knowledge in 
drug metabolism and to deliver rigorous toxicity information.  Therefore, validation of in 
vitro PT models is essential to enable accurate interpretation of drug-induced 
nephrotoxicity experiments. 
To be able to prove that ciPTECs are an alternative model that is fit for purpose to study 
nephrotoxicity and that the received cell line from our collaborative partners holds the 
same expression levels reported in the literature (Wilmer et al. 2010), a phenotypical and 
functional validation is required as well as a comparison of these data with appropriate 
controls (Figure 2.1). Comparator renal derived cell lines reported in the literature include, 
OK CELLS 
 
 ? CONTROL 
 
HEK 293 CELLS 
 
CONTROL 
CIPTECS 
 
TO VALIDATE 
PHENOTYPICAL AND FUNCTIONAL ANALYSIS 
BEST NEPHROTOXICITY MODEL 
Figure 2.1 Diagram representing the validation process implemented in Chapter 2 
to confirm the reliability of ciPTECs as a nephrotoxicity model. 
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HEK 293, LLC-PK1, OK and MDCK cells. HEK293 cells have been derived from primary 
cultures of human embryonic kidney but have been reported to barely retain any 
characteristics of a PT cell (Shaw et al. 2002). To date, most drug transport studies have 
focused on immortalised renal epithelial cell lines such as pig kidney cells (LLC-PK1), dog 
kidney cells (MDCK) or opossum kidney (OK) cells. These cell lines are of non-human origin 
and there might be rate-limiting factors that could influence the drug transport and 
metabolites (Verhulst et al. 2004, Ito 2008). However, they have been well studied 
regarding the albumin uptake mechanism through megalin and cubilin endocytic system. 
Albumin is the main protein in human plasma and has the important physiological role of 
maintaining an oncotic pressure difference between plasma and the interstitial space. 
Moreover, albumin also serves as a carrier for different metabolites and drugs (Gekle 
2005). As a result, a good PT cell model (see Table 2.1) should hold this uptake mechanism 
on top of other important PT transporters involved in drug kinetics mentioned previously in 
Chapter 1. In the literature, ciPTECs appear to comply with most of these just defined  
standards. However, functional experiments are only performed after cells have spent 8 – 
10 days at 37°C. The rationale for this decision is that at 37°C ciPTECs undergo a maturation 
 
Table 2.1 List of desirable characteristics for a good nephrotoxicity model. A comparison 
between different cell lines. 
CELL 
LINE 
MORPHOLOGY 
EXPRESSION 
OF PT GENES 
PT 
MARKERS  
(EX. CD13) 
DRUG 
TRANSPORTERS 
FUNCTIO-
NALITY 
HUMAN 
ORIGIN 
CHARACTE-
RISTICS 
MAINTAINED 
IN CULTURE 
HEK 
293 
dissimilar poor           
OK comparable too high --         
ciPTECs comparable good           
Primary 
PT cells 
ideal ideal           
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that enables cells to reach a higher stage of PT differentiation while the expression of 
SV40T is downregulated and therefore cell division slows down. Nevertheless, no functional 
data is shown when the cells are at 33°C (Wilmer et al. 2010). Consequently, it would be 
interesting to interrogate ciPTECs at both temperatures. 
In summary, phenotypical and functional assays will be a focus of the worked presented 
within this chapter with the specific interest of verifying the uptake of key substrates for 
drug uptake transporters to define which PT model would be fit for purpose to investigate 
the mechanistic basis of clinically relevant drug-induced nephrotoxicity in vitro. 
 
2.1.1 Aims and hypothesis 
Hypothesis:  
Based on the specific aims of this chapter, our objective was to test the hypothesis that 
ciPTECs display a higher resemblance to the PT complexion than HEK 293 and OK cells, and 
that they would represent a more valuable and specific model to study clinically relevant 
nephrotoxicity in vitro. 
 
The aims of this chapter were to: 
 Phenotypically and functionally characterise the parent ciPTEC line at 33°C and 37°C 
and to compare the results with other established kidney cell lines.   
 Confirm that ciPTECs express the necessary functional transporters to be a valuable 
nephrotoxicity model. 
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2.2 MATERIALS AND METHODS 
 2.2.1 Materials 
The HEK 293 line was obtained from American Type Culture Collection (Manassas, VA, USA). 
The OK cell line was purchased from the European Collection of Cell Cultures (ECACC) and 
ciPTECs were received from the Department of Pharmacology and Toxicology in Radboud 
University Nijmegen (Nijmegen, Netherlands). RNA from human kidney tissue and a human 
kidney tubular fraction at passage 2 were received from the Department of Cellular and 
Molecular Physiology in University of Liverpool (Liverpool, UK). Tissue culture reagents 
Dulbecco’s modified Eagle’s medium (DMEM)/F-12 (1:1), fetal bovine serum (FBS), 
phosphate buffered saline (PBS) as well as Hoechst 33342, ProLong® Gold Antifade 
Mountant, CellTracker™ Green carboxy dimethyl fluorescein diacetate (CMFDA) Dye, qPCR 
reagents and primers, DNase treatment and reverse transcription reagents were purchased 
from Life Technologies (Paisley, UK). The HotStarTaq Master Mix Kit for PCR and QIAzol 
Lysis Reagent were purchased from QIAGEN (Manchester, UK). Cover slides (13 mm ) 
were purchased from VWR (Lutterworth, UK). Microscope slides, chloroform, isopropyl 
alcohol (IPA) and absolute ethanol were obtained from Thermo Fisher Scientific 
(Loughborough, UK). 100 bp DNA Ladder and 6x Gel Loading Dye were purchased from New 
England BioLabs (Ipswich, MA, USA). Precision Plus Kaleidoscope Standards (molecular 
weight markers) and non-fat milk were purchased from Bio-Rad Laboratories Ltd (Hemel 
Hempstead, UK). Amersham Hybond ECL membrane and Amersham Hyperfilm ECL were 
purchased from GE Healthcare (Little Chalfont, UK). Western Lightning Plus-ECL was 
purchased from Perkin Elmer (Beaconsfield, UK). Rap1A antibody was purchased from 
Santa Cruz (Ca, USA). All other reagents and chemicals were purchased from Sigma Aldrich 
(Dorset, UK). 
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2.2.2 Cell culture 
HEK 293 cells and OK cells were cultured at 37°C in 5% CO2 in DMEM and DMEM/F-12 (1:1) 
respectively. Both media were supplemented with FBS (10% v/v) and penicillin-
streptomycin solution (1% v/v). HEK 293 cells were used up to passage 20 and OK cells used 
up from passage 48 to passage 54. 
ciPTECs were maintained at 33°C under humidified air containing 5% CO2 in their growth 
medium prepared with DMEM/F-12 (1:1) medium supplemented with FBS (10% v/v), 
penicillin-streptomycin solution (1% v/v), hydrocortisone (36 ng/ml), insulin-transferrin-
sodium selenite (ITS) (I=5 µg/ml; T=5 µg/ml; S=5 ng/ml), epidermal growth factor (EGF) (10 
ng/ml) and 3,3’,5-Triiodo-L-thyronine sodium salt (40 pg/ml). Cells were used up from 
passage 39 to passage 45. 
 
2.2.3 RNA isolation 
From a 90% confluent T75, cells were washed with PBS, tripsinized and spun down to get a 
pellet. The pellet was resuspended in PBS and cells were spun down twice. After the second 
time, the PBS was removed and cells were resuspended with QIAzol lysis reagent and the 
solution was transferred to pyrogen-free microcentrifuge tubes. Then, 0.2 ml of 100% 
chloroform per 1 ml of QIAzol were added. Tubes were shaken intermittently for 2 minutes 
and then left still at the upright position for 5 minutes. After 15 minutes of centrifugation at 
12,000 xg at 4°C, the top phase was carefully transferred to new microcentrifuge tubes. 
Then 0.2 ml of 100% IPA per 1 ml of QIAzol were added. Again, the solution was centrifuged 
at 12,000 xg for 10 minutes at 4°C. RNA precipitated as a gel droplet on the side of the 
tube, hence the supernatant was removed and then the pellet was washed with cold 75% 
ethanol. The RNA solution was spun down for the last time at 7,500 xg, the supernatant 
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was removed and the pellet was air dried to remove last ethanol traces. Finally, the pellet 
was dissolved in RNase free dH2O. 
 
2.2.4 DNase treatment of RNA 
To remove any traces of DNA, a DNase treatment was performed on the RNA solution (see 
2.2.3 section). A ratio of 44 : 5 : 1 μl (RNA solution : 10x DNase buffer : DNase) was 
prepared and left at 37°C for 30 minutes. Then, 5 μl of DNase inactivation reagent were 
added and the solution was spun down for 1 minute at 14,000 xg. The inactivation reagent 
precipitates and the supernatant containing purified RNA was transferred into a new tube. 
RNA quantification was performed using a NanoDrop (Labtech International Ltd).  
 
2.2.5 Reverse transcription 
The synthesis of complementary DNA (cDNA) from RNA was achieved using a reverse 
transcription procedure. Up to 5 μg of DNase treated RNA were incubated for 5 minutes at 
65°C with random primers and a deoxynucleotide (dNTP) solution mix. Then, the solution 
was placed on ice for 1 minute. After the ice treatment, 5x first strand buffer, dithiothreitol 
solution (0.1 M) and the superscript III enzyme were added in this order. RNAse free dH2O 
was used to get to 20 μl of final volume. Finally, samples underwent the following 
temperature treatment in a PCR System 9700 block (GeneAmp): 
 25°C – 5 minutes 
 50°C – 50 minutes 
 70°C – 15 minutes 
 4°C – 10 minutes and then storage 
cDNA quantification was performed using NanoDrop (Labtech International Ltd, UK). 
NanoDrop analysis also gives information about the purity of the samples through the 
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260/280 absorbance ratio. Only samples with a ratio higher than 1.8 were selected to use 
for PCR (polymerase chain reaction) or qPCR (quantitative real-time PCR).  
 
2.2.6 Design of the PCR primers 
A set of primers for each PT marker of interest plus a housekeeping gene (GAPDH) were 
created (see Table 2.2).  
Table 2.2 List of primers used for PCR to detect mRNA expression of PT genes plus GAPDH 
as a positive control 
Gene Primer pairs Amplicon (bp) TM (°C) 
AQP1 
 Fwd:  5’ TTGTCTTCATCAGCATCGGTTCTG 3’ 
Rev:  5’ GATGAAGTCGTAGATGAGTACAGC 3’ 
620  
61.2 
61.2 
LRP2 
Fwd:  5’ ATGCTTGCAACTATCCGACCTG 3’ 
Rev:  5’ GGAAGCTCCTTCCATGAATATCAC 3’ 
600 
60.3 
60.6 
Cubilin 
Fwd: 5’ CATGGCTAAGTTCAGTGCTGAG 3’ 
Rev:  5’ GAGCTGTGGTAATAGGGCATC 3’ 
806 
60 
59.9 
MRP2 
Fwd: 5’ ACTGAAGCTAGTGAATGACATCTTC 3’ 
Rev:  5’ CTATCCACCAGGACATAACCAG 3’ 
730 
59.9 
60.3 
MRP4 
Fwd: 5’ TGACTCATCAGTTGCAGTACCTC 3’ 
Rev:  5’ TCCAGTGAGCACCAGCTCTG 3’ 
366 
60.6 
61.4 
OAT1 
Fwd: 5’ GCACAGAAGCCAATGGCACAG 3’ 
Rev:  5’ GAGACCAGTAGCTGCAGGTG 3’ 
487 
61.8 
61.4 
OAT3 
Fwd: 5’ AACAGCACCAAGGACTCCATTG 3’ 
Rev:  5’ CTTCCTTCTTGCCATTGAAGACAG 3’ 
559 
60.3 
61 
OATP4C1 
Fwd: 5’ GCTATGTATTGGGAGGACAACTG 3’ 
Rev:  5’ GCAGTTTCGCACAATGAGTTTCAC 3’ 
891 
60.6 
61 
GAPDH 
Fwd: 5’ GAGTCAACGGATTTGGTCGTAT 3’ 
Rev:  5’ CAGGAGGCATTGCTGATGATCT 3’ 
435 
58.5 
60.3 
 
 
 
To ensure a good amplification and annealing, the primers were designed with the 
following considerations:  
- A GC percentage higher than 40% and lower than 60%. 
- Avoiding several nucleotide or sequence repetitions. 
Both forward (Fwd) and reverse (Rev) primers were designed with a GC percentage higher 
than 40% and lower than 60%. The length of the amplicon or amplification product is 
represented in base pairs (bp) and TM refers to the primers melting temperature.  
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- Ensuring that there were no other complementary regions in the genome. 
- A similar melting temperature to be able to run them all in the same PCR reaction. 
- A number of base pairs longer than 19 and shorter than 24. 
- Ensuring that there was a guanine (G) or cytosine (C) at the 3’ end to improve the 
annealing. 
Oligo Calc: Oligonucleotide Properties Calculator Software was used for the primers design 
and the mRNA sequence of each gene was taken from the NCBI Reference Sequence 
Database. See Table 2.2. 
 
2.2.7 PCR to detect PT genes expression 
PCR reactions contained 100 ng of cDNA, 0.2 μM forward and reverse primers, 2.5 units of 
HotStarTaq DNA Polymerase, 1x PCR Buffer and 200 μM of each dNTP. The total reaction 
volume was readjusted to 50 μl with dH2O. Thermal cycling parameters used can be found 
in Table 2.3. and the amplification was performed using the heating block from an ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems). 
Table 2.3 Steps and cycles using a HotStarTaq DNA Polymerase amplification from cDNA 
sequences 
Steps Time Temperature Cycles  Process 
1 15 minutes 95°C 1 Heat activation 
2 30 sec 94°C 
2 - 34 
Denaturation 
3 30 sec 55°C Annealing 
4 1 minute 72°C Extension 
5 10 minutes 72°C 35 Final extension 
 
2.2.8 DNA electrophoresis 
The PCR products were resolved in a 2% agarose gel dissolved in 1x Tris/borate/EDTA (TBE) 
buffer, supplemented with a 1:20,000 dilution of ethidium bromide, at 100 V for 1 h. The 
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PCR product (5 μl) was combined with 5 μl of 1x Gel Loading Dye prior to loading onto the 
gel. PCR samples were resolved alongside a 100 bp DNA Ladder to enable estimation of 
DNA band sizes. Bands were visualized using a UV Transillumination system (Syngene 
Bioimaging System). 
 
2.2.9 qPCR 
TaqMan technology was used to perform the qPCR experiment. In contrast with other qPCR 
methods, this technology is characterized by an extra probe (TaqMan probe) that is also 
complementary to the gene fragment amplified by a specific set of primers. TaqMan probes 
contain a covalently attached fluorophore at the 5’-end and a quencher at the 3’-end. 
Therefore, when Taq polymerase starts synthetizing the nascent strand, its 5’ to 3’ 
exonuclease activity is able to degrade the annealed TaqMan probe. As a result, the 
quencher and fluorophore are released, breaking their close bond and thus allowing the 
fluorescence of the fluorophore. Consequently, the amount of fluorescence becomes 
directly proportional to the amount of amplified DNA. 
The qPCR reactions contained 50 ng of cDNA, 1x TaqMan Gene Expression Assays (see 
Appendix 1) and 1x TaqMan Universal Master Mix II. The total reaction volume was 
readjusted to 20 μl with dH2O and the thermal cycling parameters can be found in Table 
2.4. The experiment was performed in a Viia 7 qPCR machine (Applied Biosystems). 
Table 2.4 Thermal cycling parameters for qPCR experiments 
Steps Time Temperature Cycles  Process 
1 10 minutes 95°C 1 Heat activation 
2 15 sec 95°C 
2 - 40 
Denaturation 
3 1 minute 60°C Annealing 
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2.2.10 PPARα agonist treatment to increase megalin mRNA levels 
ciPTECs were seeded in a 6-well plate at 1.2x105 cells/well. After 24 h, they were treated 
with WY 14643, a peroxisome proliferator-activated receptor –alpha (PPARα) agonist, at 
100 μM in their own medium with different concentrations of FBS (1%, 5% and 10%). The 
exact same design was repeated but cells were treated with a vehicle instead (DMSO, final 
volume lower than 1% v/v). The treatment lasted another 24 h and then RNA was isolated, 
followed by a DNase treatment, reverse transcription and qPCR (see 2.2.3 - 5 and 2.2.9 
sections). 
 
2.2.11 Western blotting – simvastatin treatment and whole cell lysates 
To evaluate if simvastatin was functional and therefore could inhibit the prenylation of 
Rap1A, ciPTECs were seeded in a 6-well plate at 5x105 cells/well. After 48 h at 33°C, ciPTECs 
were treated with simvastatin at different concentrations (0 μM, 0.01 μM, 0.03 μM, 0.1 
μM, 0.3 μM, 1 μM, 3 μM and 10 μM) for 24 h. After the drug treatment, cells were washed 
twice with 1 ml of cold PBS before lysis in 100 μl of RIPA buffer.  
 
2.2.12 Western blotting – protein quantification 
For western blotting, the total protein content of whole cell lysates was measured using the 
bicinchoninic acid (BCA) assay. This assay relies on the fact that protein peptide bonds 
reduce Cu+2 ions to Cu+. Therefore, the amount of reduced Cu2+ is proportional to the 
amount of protein and when the molecules of BCA chelate with each Cu+ ion, they form a 
purple-coloured product that absorbs at a 562 nm wavelength. A standard curve ranging 
from 0.125 – 2 mg/ml of albumin was prepared and 9 µl of each concentration were 
transferred in duplicate into a new 96-well plate as well as 3 µl of dH2O (blank) and 3 µl of 
lysed cells from each well. Freshly prepared BCA reagent solution was added into each well 
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(200 µl/well) and the plate was incubated for 35 minutes at 37°C. The absorbance was read 
at 570 nm on a plate reader (Varioskan, Thermo Scientific). The blank reading (dH2O with 
BCA reagent) was subtracted from all sample and standard readings and the protein 
concentration was extrapolated from the equation of the linear regression. 
 
2.2.13 Western blotting – Rap1A  
To detect the amount of unprenylated Rap1A in the whole cell lysates, 20 µg of cell lysate 
from each condition were mixed with reducing agent and sample buffer and then 
denatured at 85°C for 5 minutes. Samples were then loaded onto 10% acrylamide gels and 
proteins separated by electrophoresis in a Tris-Glycine running buffer. Proteins were then 
electro-transferred onto a nitrocellulose membrane using 20% MeOH buffer for 1 h at 80 V. 
Successful transfer and even loading was checked using Ponceau Red. Membranes were 
washed with 0.1% Tween-TBS and blocked with 10% non-fat milk for 1 h. Then, the 
membrane was cut in two parts around 30 kDa, leaving the expected band for Rap1A (22 
kDa) in one half and the expected band for β-actin (41.7 kDa) in the other half. The 
membrane containing proteins up to 30 kDa was incubated overnight with a goat polyclonal 
antibody raised against unprenylated Rap1A (1/1,000 in 10% milk) while the other 
membrane was left in blocking solution also overnight, both with shaking at 4°C. Next day, 
the membrane containing proteins from 30 kDa was incubated for 1 h with mouse 
monoclonal anti-actin (1/10,000 in 10% milk). Membrane was then washed (4x 5 minutes) 
with 0.1% Tween-TBS and the secondary antibody anti-mouse IgG (1/10,000 in 10% milk) 
was incubated for 1 h at room temperature (RT). Meanwhile, the other part of the 
membrane was washed (4x 5 minutes) with 0.1% Tween-TBS and later incubated with the 
secondary antibody anti-goat (1/10,000 in 10% milk) for 1 h at RT. After the secondary 
antibody incubation, both membranes were washed again with 0.1% Tween-TBS and 
treated with enhanced chemiluminescence (ECL) reagent for 1 minute. Proteins were 
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visualised using exposure to X-ray film. After developing, films were scanned using a 
densitometry scanner (GS800, Bio-Rad).  
 
2.2.14 Densitometry 
ImageJ software was used to calculate the area and density of each protein band from the 
image obtained with the scanner. The software represented each band with a density peak 
and gave the percentage of that peak compared to the sum of the peaks from all selected 
bands. Results were then corrected by normalizing them to the percentage values from β-
actin. Finally, the relative density was calculated by comparing the percentage of each band 
to the percentage of the control one (0 μM).  
 
2.2.15 Megalin and cubilin albumin uptake assay 
The assay was performed based on the work that Zhai et al. (2000) and Ranghini et al. 
(2013), published in OK cells and mouse developing nephrons respectively using albumin–
fluorescein isothiocyanate conjugate (FITC-BSA) (Zhai et al. 2000, Ranghini et al. 2013). HEK 
293 cells were seeded at 5.5x104 cells/well, OK cells were seeded at 2.5x104 cells/well (both 
cultured at 37°C) and ciPTECs were seeded at 5x104 cells/well (cultured at 33°C) in 12-well 
plates. Cells were left to grow to confluence in their own medium, which took 4-5 days. 
However, to analyse the functionality at 37°C, two extra 12-well plates at 5x104 cells/well of 
ciPTECs were cultured for 24 h at 33°C and then transferred at 37°C for 5 or 10 days. Then, 
cells were washed 3x with PBS and cultured overnight with their own medium without FBS 
and with their own medium without FBS plus 1 μM of simvastatin. Next morning, cells were 
incubated with 20 μg/ml of FITC-BSA, 20 μg/ml of FITC-BSA plus 4 mg/ml of unlabelled BSA 
or 20 μg/ml of FITC-BSA plus 1 μM of simvastatin (added to the ones that had been pre-
treated overnight) for 15 minutes at 37°C. A negative control was also added where no 
FITC-BSA was used. 
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2.2.16 Assessment of FITC-BSA fluorescence - microscope 
Previously to seeding the cells, to be able to analyse them under the microscope, cover 
slides (13 mm ) were placed in wells of a 12-well plate and coated with 0.5% of gelatine 
for 30 minutes. The gelatine was removed and cells were seeded at the designated 
concentration in 2.2.15. Then, megalin and cubilin functionality assay was performed also 
following 2.2.15 section. Right after, cells were washed 3x in warm PBS and fixed with 2% 
paraformaldehyde (PFA) for 15 minutes at RT in the dark. After cells had been fixed, 2x PBS 
washes were performed. Then, the nuclei were stained with 2 μg/ml of Hoechst 33342 for 
10 minutes at RT protected from light. Finally, after 3x PBS washes, the cover slides were 
mounted onto a microscope slide with Prolong Gold. Results were visualized at 40x 
magnification using an inverted fluorescence microscope (Axio Observer.Z1, Zeiss). 
 
2.2.17 Assessment of FITC-BSA fluorescence – flow cytometry 
Flow cytometry is a laser based technology that allows to simultaneously analyse in real 
time different physical and chemical characteristics of particles and cells. A single cell 
suspension is required, as the flow cytometer analyses every single particle but it can 
process thousands of particles or cells per second. Here, flow cytometry was used to detect 
the fluorescence of cells. FITC has an excitation and emission spectrum with peak 
wavelengths of approximately 495/519 nm. If cells have uptaken the FITC-BSA, when the 
laser hits them they will release fluorescence that will be measured by a detector. 
After the megalin and cubilin functionality assay (see 2.2.14 section) cells were washed in 
warm PBS, trypsinized and spun down. The pellet of cells was resuspended in PBS and cells 
were spun down again. Cells were again resuspended in PBS and transferred to FACS tubes. 
The voltage parameters in the flow cytometer (FACSCalibur, BD Biosciences) were set up 
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using the negative control sample and FL1-H channel was selected to measure cell 
fluorescence. 
 
2.2.18 Flow cytometry data analysis 
Data was analysed using Flowing Software. From the general cloud of particles, the 
population that represented single cells was selected, excluding debris and duplets of cells. 
Then, the median of the peaks for each condition in the FL1-H channel was measured. The 
fluorescence data from cells only treated with FITC-BSA (control) was established as 100%. 
Finally, data was compared with the positive control and expressed as a percentage. 
 
2.2.19 CMFDA dye as a method to analyse MRP2/4 and P-gp functionality  
This fluorescent assay relies on the fact that CMFDA can freely enter inside the cells but 
once inside, undergoes what is believed to be a glutathione S-transferase–mediated 
reaction (Barhoumi et al. 1993), producing a cell-impermeant reaction product that can 
only be excreted by selected transporters such as MRP2, MRP4 or P-gp (see Figure 2.2 A). 
Furthermore, CMFDA is non fluorescent until its acetate groups are cleaved by intracellular 
esterases; hydrolysis of the acetates yields a product with an excitation/emission spectra of 
(492/517 nm). As a result, the analysis of CMFDA fluorescence can be used to study the 
activity of specific membrane transporters upon inhibition (see Figure 2.2 B) (Jenkinson et 
al. 2012).To perform the assay, cells (HEK293, OK cells or ciPTECs) were grown in a T75 and 
left until 90 – 95% confluence. Then, cells were split and 1/3 of the total pool of cells was 
seeded in a 96-well plate (ciPTECs and HEK cells had a concentrations of 9,000 cells/well 
while OK cells had a concentration of 4,500 cells/well). HEK 293 and OK cells were cultured 
in the 96-well plate for 72h at 37°C, and the same was done for ciPTECs at 33°C. However, 
to analyse the functionality at 37°C, an extra 96-well plate of ciPTECs was cultured for 24 h  
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Figure 2.2 Representation of the developments that occur during the CMFDA assay. 
(A) In normal conditions, the CMFDA dye enters the cells freely, but once inside, 
esterases transform it into an impermeable fluorescent molecule. Consequently, it can 
only be pumped out of the cell by specific transporters such as MRP4, MRP2 or P-gp.   
(B) When inhibitors for P-gp (PSC833) or MRP2/4 (MK571) are added, the cells are 
unable to excrete the fluorescent CMFDA molecule and the dye gets accumulated in the 
cytosol. This fluorescent accumulation can be detected and it is an indicator of the 
functionality of the inhibited transporter/s.  
A. CMFDA uptake and metabolism 
B. Inhibition of MRP2/4 and P-gp 
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at 33°C and then transferred at 37°C for 5 days. Once these incubations were finished, cells  
were washed twice in Krebs buffer and the same buffer was used to prepare CMFDA 
solution at a concentration of 1.25 μM. Then, the buffer was removed and half of the plate 
was treated with increasing concentrations of MK571 (0 μM, 1.25 μM, 3.13 μM, 6.25 μM, 
12.5 μM and 25 μM), which is an inhibitor of MRP transporters (Weiss et al. 2007), in 
CMFDA solution. The other half was treated with PSC833, which inhibits P-gp transporter 
(Boesch et al. 1991, Bezombes et al. 1998), in CMFDA solution (0 μM, 0.16 μM, 0.49 μM, 
1.48 μM, 4.44 μM and 13.33 μM). The 96-well plate was left at 37°C in the dark for 30 
minutes. Then, it was washed with Krebs buffer twice and cells in the dark at 37°C for 
another 30 minutes. Finally, the fluorescence was recorded using a plate reader (Varioskan, 
Thermo Scientific). 
 
2.2.20 Hoechst 33342 dye as a method to analyse P-gp and BCRP functionality  
The essence of the Hoechst 33342 uptake assay was the same as the CMFDA assay. Hoechst 
33342 is a cell-permeable DNA stain that is excited by ultraviolet light and emits blue 
fluorescence at 460 to 490 nm. Hoechst 33342 is a non-fluorescent substrate for BCRP and 
P-gp (Shapiro et al. 1997, Scharenberg et al. 2002, Kim et al. 2002). However, it acquires 
fluorescence when bound to DNA, but not on the aqueous medium. With no inhibitors, the 
accumulation and therefore the fluorescence increase slowly, as the efflux pumps 
persistently excrete the dye (Jenkinson et al. 2012). In contrast, when inhibitors are added, 
it should result in a faster accumulation of Hoechst 33342 and therefore greater 
fluorescence.  
HEK 293, OK cells or ciPTECs were grown in a T75 and left until 90 – 95% confluence. Then, 
they were split and 1/3 of the total pool of cells was seeded in a 96-well plate (ciPTECs and 
HEK cells had a concentrations of 9,000 cells/well while OK cells had a concentration of 
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4,500 cells/well). After 72 h at 37°C, cells were washed twice in Krebs buffer and the same 
buffer was used to prepare a Hoechst solution at a concentration of 1.25 μM. Then, the 
buffer was removed and half of the plate was treated with increasing concentrations of 
KO143 (0 μM, 0.47 μM, 0.94 μM, 1.88 μM, 3.75 μM and 7.5 μM), which is an inhibitor of 
BCRP (Allen et al. 2002), in Hoechst 33342 solution. The other half was treated with 
PSC833, which inhibits P-gp transporter (Boesch et al. 1991, Bezombes et al. 1998), in 
Hoechst 33342 solution (0 μM, 0.16 μM, 0.49 μM, 1.48 μM, 4.44 μM and 13.33 μM). The 
96-well plate was left at 37°C in the dark for 30 minutes. Then, it was washed with Krebs 
buffer twice and the fluorescence was recorded using a plate reader (Varioskan, Thermo 
Scientific). 
 
2.2.22 Statistical analysis 
Statistical analysis of data was performed using StatsDirect software. All results were 
represented as the mean ± standard error of the mean (SEM) or as the mean ± standard 
deviation (SD) of three independent experiments. The choice of SEM vs. SD was only based 
on obtaining a better visual representation of the figures. Data was first assayed for 
normality using the Shapiro-Wilk test. When assaying differences amongst at least three 
groups, if data was normal, statistical analysis was performed using One Way ANOVA with 
Dunnet as a post-hoc comparison, as this test is specifically designed to compare each 
treatment against a single control. If there was no evidence of normality, Kruskal-Wallis test 
was applied instead. To test for differences amongst two groups, a t-test was performed if 
data was classified as normal and a Mann-Whitney test when data showed no evidence of 
normality. Only when p values <0.05 the results were considered significant.  
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2.3 RESULTS 
2.3.1 Validation of self-designed PCR primers 
As previously described, HEK 293 cells have been demonstrated as a poor PT model to 
perform toxicity studies as they lack the expression of key drug transporters,  metabolic 
enzymes and proteins essential for PT specific functions such as organic cation transporters 
and the Na+/K+-ATPase pump (Shaw et al. 2002). To verify this fact, we checked the mRNA 
expression of PT markers in this cell line through PCR. See Appendix 2 for a full list of gene 
names and their respective proteins. 
Moreover, to make sure the primer design was accurate and they were able to amplify the 
desired fragment from the gene of choice, we first tested the primers on cDNA re-
transcribed from human kidney tissue mRNA (Figure 2.3). In fact, the electrophoresis gel of 
PCR products revealed that each set of primers amplified only one band and that band was 
found at the right molecular weight position for each gene (see Table 2.2). For example, 
LRP2 fragment was located around 600 bp as expected by the amplicon length. Some bands 
were thicker and brighter than others, indicating qualitatively possible greater mRNA 
expression of those genes in the kidney tissue sample such as CUBN and OATP4C1. OAT1 
showed the lowest expression of all represented by a fainter band. The fact that only one 
band was amplified per gene indicated the melting temperature was appropriate and the 
primers showed high specificity, ergo they did not amplify any other cDNA region. 
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  GAPDH    LRP2      AQP1    CUBN MRP2                   OAT1     OAT3  OATP4C1  MRP4 
1000 bp -    
500 bp -    
Figure 2.3 PCR products run in agarose gel electrophoresis for the validation of self-
designed primers.  
The cDNA was retro-transcribed from kidney tissue mRNA, amplified in a PCR reaction for 
35 cycles and the resulting amplification products were run in a 2% agarose gel. 5 μl of 
PCR product and 5 μl of 1x Gel Loading Dye were added per lane. From left to right, the 
1st and 7th lanes correspond to the molecular weight ladder and each band has a 
separation from the next of 100 bp. The gene names that correspond to the amplified 
fragments are displayed at the top of each lane. Data is representative of n = 3 
experiments. 
 
Chapter Two 
 
55 
 
2.3.2 mRNA expression of PT markers in HEK 293 cells 
In order to confirm the lack of expression of important PT transporters in HEK 293 cells and 
use them as a negative control, we isolated mRNA, retro-transcribed it and performed a 
PCR with the previously validated primers. 
The electrophoresis gel in Figure 2.4 showed no mRNA expression of LRP2, AQP1, CUBN, 
MRP2, OAT1, OAT3 and OATP4C1. A fine line just under 400 bp was detected for MRP4 
transporter, which corresponds with MRP4 amplicon length (366 bp) and indicates a low 
gene expression. A strong band for GAPDH (435 bp) in both electrophoresis gels proved 
that the PCR worked fine and the lack of bands could definitely be attributed to a lack of 
expression. 
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  GAPDH    LRP2      AQP1    CUBN MRP2                   
1000 bp -    
500 bp -    
  GAPDH    OAT1     OAT3   OATP4C1   MRP4 
- 1000 bp    
- 500 bp    
Figure 2.4 PCR products run in agarose gel electrophoresis to detect expression of PT 
markers in HEK 293 cells.  
The cDNA was retro-transcribed from mRNA extracted from HEK 293, amplified in a PCR 
reaction for 40 cycles and the resulting amplification products were run in a 2% agarose 
gel. 5 μl of PCR product and 5 μl of 1x Gel Loading Dye were added per lane. The 1st lane 
of gel A and the 6th lane of gel B correspond to the molecular weight ladder and each 
band has a separation from the next of 100 bp. The gene names that correspond to the 
amplified fragments are displayed at the top of each lane. Data is representative of n = 3 
experiments. 
 
B 
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2.3.3 mRNA expression of different kidney markers in ciPTECs 
In contrast to HEK 293 cells, ciPTECs are known to express a variety of PT transporters 
(Wilmer et al. 2010). To corroborate this fact and to validate the cell line for subsequent 
studies, a qPCR at both 33°C and 37°C was performed. In this case, the method of choice 
was qPCR instead of PCR in order to quantify and compare the mRNA expression of 
different kidney markers. 
Figure 2.5 represents the ciPTECs expression of different kidney markers from different 
kidney cell types normalised to a tubular fraction at passage 2. Therefore, the graph only 
represents the relative expression of different genes compared to their expression in the 
tubular fraction. Meaning that, if the value is 1, ciPTECs and the tubular fraction had the 
same expression, which would be ideal. See Table 2.5 for the actual Ct values to have an 
idea of cell abundance. 
The first 7 genes correspond to PT markers. Only BCRP, OATP4C1 and CUBN showed 
differences between 33°C and 37°C. BCRP exhibited a higher expression at 33°C and, in 
contrast, OATP4C1 and CUBN expression was significantly higher at 37°C. Except for MRP2 
at 37°C, CUBN at 33°C and AQP1, all PT genes analysed had a greater or similar mRNA 
expression to the tubular fraction. It was also important to note that the expression of 
some key PT transporters was not detected, these included LRP2, OAT1 and OAT3. 
The expression of some genes that are specific to other parts of the nephron was also 
evaluated. SYNPO is expressed specifically in podocytes. Therefore, low expression of this 
marker was expected in this PT cell line. Surprisingly though, compared to the tubular 
fraction, ciPTECs displayed an increase in expression of 10 fold. Other markers from other 
nephron segments such as AQP3 (collecting duct) or NCCT (distal convoluted tubule) 
showed similar or lower mRNA levels compared to the normalised baseline. No significant 
differences were observed between both temperature conditions. 
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Table 2.5 Ct values of the renal markers analysed by qPCR 
Data are mean ± SEM (n = 3) 
 
 
 MPR4 MRP2 Pgp BCRP AQP1 OATP4C1 CUBN SYNPO AQP3 NCCT 
33°C Ct 
value ± 
SEM 
27.52 
± 0.07  
37.71 
± 
0.55 
29.31 
± 
0.09 
32.84 
± 0.2 
34.82 
± 
0.51 
31.33 ± 
0.17 
34.25 
± 
0.21 
27.27 
± 0.08 
34.5 
± 
0.33  
35.81 
± 
0.22 
37°C Ct 
value ± 
SEM 
27.54 
± 0.02 
39.38 
± 
0.58  
29.08 
± 
0.11 
35.04 
± 
0.28 
35.09 
± 
0.32 
29.78 ± 
0.07 
33.56 
± 
0.24 
26.98 
± 0.23 
35.5 
± 
0.39 
35.56 
± 
0.31 
Figure 2.5 Relative expression of kidney markers in ciPTECs. 
The relative expression of PT genes as well as other kidney markers in ciPTECs at 33°C and 
37°C was analysed by qPCR. Gene names are displayed under each set of bars. Data was 
normalised against a human tubular fraction at passage 2. Data are mean ± SEM (n = 3). 
Statistical significance was determined between both temperature conditions by Mann-
Whitney test, *p<0.05. 
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2.3.4 Failure to upregulate megalin mRNA levels with a PPARα agonist 
Although Wilmer et al. had previously published in 2010 that ciPTECs expressed megalin at 
a protein level and it was functional, we could not detect any mRNA expression (Figure 2.5). 
To see if we could upregulate the expression and therefore have detectable levels of LRP2 
mRNA, we dosed ciPTECs with WY 14643, a PPARα agonist known to upregulate LRP2 
mRNA expression (Cabezas et al. 2011). 
Cells were treated with the PPARα agonist for 24 h at different percentages of FBS (0%, 1%, 
5% and 10%) since it has been revealed that high concentrations of albumin can contribute 
to the downregulated expression of megalin (Gekle et al. 1998). The qPCR results did not 
display any increase in LRP2 mRNA expression, which remained undetectable for every 
single condition (Table 2.6). Nevertheless, this fact might not be as surprising since no 
expression was either found in the tubular fraction at passage 2. We could only detect the 
presence of LRP2 in mRNA isolated from human kidney tissue (hKid tissue) with a ∆Ct of 
16.32 ± 3.42. 
 
 
Table 2.6 Detection of LRP2 mRNA by qPCR in human kidney tissue, in a tubular fraction 
and in ciPTECs treated with a PPARα agonist.  
Data are mean ± SD (n = 3). Key: hKid indicates human kidney, the percentages refer to the 
amount of FBS and “—“ indicates undetermined value. 
 
 
 
 
 
  
 ciPTECs 33°C ciPTECs 37°C 
 
hKid tissue Tubular fraction 1%  5%  10%  1%  5%  10%  
∆Ct value 
± SD 
16.32 ± 
3.42 
-- -- -- -- -- -- -- 
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2.3.5 Assessment of megalin and cubilin functionality 
Even though no LRP2 expression was detected, since we found important levels of CUBN 
expression and their corresponding receptors function together (see Figure 1.3), we 
decided to confirm their presence by assessing protein function. To study the functionality 
of the megalin and cubilin endocytic system, we measured the capacity of ciPTECs to 
uptake fluorescently labelled albumin: FITC-BSA. Furthermore, to determine how specific 
the uptake was to this system, we submitted the cells to a competitive inhibition with BSA 
and to a non-competitive inhibition with simvastatin. Simvastatin is an inhibitor of 3-
hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase in the PT, which supresses the 
conversion of HMG-CoA to mevalonate, a rate limiting step in the sterol pathway. As a 
result, the cellular sterol pool is depleted and the post-translational modifications of GTP-
binding proteins such as Rap1a are blocked (Sidaway et al. 2004, Verhulst et al. 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6 Schematic of megalin/cubilin endocytosis inhibition caused by simvastatin. 
Renal uptake of albumin is dependent on the interaction between megalin/cubilin 
system with prenylated GTP-binding proteins such as Rap1A by isoprenoids 
pyrophosphates from the mevalonate pathway. Therefore, by inhibiting the synthesis of 
mevalonate we are indirectly inhibiting the albumin uptake.  
Key: CoA = coenzyme A; HMG-CoA = hydroxymethylglutaryl coenzyme A. 
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Without the interaction between Rap1a to megalin/cubilin, the system is not ready to 
receive ligands. Therefore, simvastatin indirectly inhibits the receptor-mediated 
endocytosis by increasing the intracellular level of unprenylated GTP-binding proteins (see 
Figure 2.6). 
To determine if the batch of received simvastatin was pharmacologically active, we 
investigated whether the HMG-CoA reductase inhibitor was still able to inhibit GTP-binding 
protein (Rap1A) prenylation in ciPTECs (Antoine et al. 2010). Western blotting revealed a 
clear dose dependent increase of unprenylated Rap1A when ciPTECs were treated with 10 
μM of simvastatin for 24 h (Figure 2.7 A). The β-actin blot confirmed an equal loading of 
protein content. These results were later corroborated by densitometry (Figure 2.7 B). At 
the two lowest concentrations of simvastatin, the amount of unprenylated Rap1A was 
nearly indiscernible and, therefore, the relative density was close to 1; as was the control.  
After establishing that simvastatin was pharmacologically active, we proceeded to treat the 
negative control (HEK 293) and the positive control (OK) cell lines with FITC-BSA, FITC-BSA + 
BSA and FITC-BSA + simvastatin for 15 minutes. Cells were then fixed, the nuclei were 
stained and the fluorescence was evaluated under the microscope. In HEK 293 cells, no 
difference was observed amongst all three different conditions (Figure 2.8). Some non-
specific fluorescence could still be detected, especially in samples treated only with FITC-
BSA, however it was clear that it was not due to megalin or cubilin uptake since the typical 
dot pattern of endocytosis could not be detected (Ranghini et al. 2013). In contrast, OK cells 
displayed a clear uptake of FITC-BSA (Figure 2.9 A), with the endocytic vesicles filled with 
fluorescent albumin clearly visible surrounding the nuclei. In some areas, the amount of 
accumulated FITC-BSA was so high that the image looked saturated. When BSA or 
simvastatin were added to the treatment (Figure 2.9 B, C), the general amount of 
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fluorescence was reduced in both conditions indicating that the competitive and non-
competitive inhibitions had taken place as expected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7 Western blotting (A) and densitometry (B) of the amount of 
unprenylated Rap1A after 24 h of simvastatin treatment in ciPTECs. 
ciPTECs were incubated with simvastatin (0 - 10 μM) for 24 h. (A) Equal amounts 
of protein were separated by SDS-PAGE from whole cell RIPA lysates. The 
presence of unprenylated Rap1A (22 kDa) was determined by western blot and 
compared to a β-actin loading control. (B) Densitometry for each simvastatin 
concentration was performed by ImageJ software and the relative density of the 
complexes was normalized to the relative density of the corresponding β-actin 
band (n=1).  
 
Dose dependant inhibition
of Rap1a prenilation
Simvastatin concentration (M)
R
e
la
ti
ve
 b
an
d
 d
e
n
si
ty
0
0.
01
0.
03 0.
1
0.
3 1 3 10
0
5
10
15
20
25
0
 0
.0
1 
0
.0
3 
0
.1
 
0
.3
 
1
 
3
 
1
0 
β-actin 
Unprenylated Rap1A 
Simvastatin concentrations (μM) 
B 
A 
Chapter Two 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.  FITC-BSA 
B.  FITC-BSA + BSA 
C.  FITC-BSA + Simvastatin 
Figure 2.8 Albumin uptake assay in HEK 293 cells. 
HEK 293 cells were incubated with (A) FITC-BSA, (B) FITC-BSA + BSA and (C) FITC-BSA + 
simvastatin for 15 minutes. Nuclei were stained with Hoechst 33342 and FITC-BSA was 
visualized at 488 nm. A phase contrast image of the same area was also added to locate 
the cells. Images were taken using a 40x objective. Scale bar is 20 μm. Data is 
representative of n = 3 experiments.    
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Figure 2.9 Albumin uptake assay in OK cells 
OK cells were incubated with (A) FITC-BSA, (B) FITC-BSA + BSA and (C) FITC-BSA + 
simvastatin for 15 minutes. Nuclei were stained with Hoechst 33342 and FITC-BSA was 
visualized at 488 nm. A phase contrast image of the same area was also added to locate 
the cells. Images were taken using a 40x objective. Scale bar is 20 μm. Data is 
representative of n = 3 experiments.    
 
A.  FITC-BSA 
B.  FITC-BSA + BSA 
C.  FITC-BSA + Simvastatin 
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Once the negative and the positive controls for albumin uptake had been established, the 
functionality of the megalin and cubilin endocytic system in ciPTECs was assessed. Although 
the results demonstrated albumin uptake, they were not clearly distinguishable due to a 
fluorescent background network, most likely due to FITC-BSA stuck in the extracellular 
matrix (ECM) created by this PT cell line (Figure 2.10 A). This phenomenon was also 
observed when ciPTECs were incubated with FITC-BSA + BSA (Figure 2.10 B). Based on these 
data, we did not study the effect of simvastatin using this technique since it seemed 
ineffective in ciPTECs to evaluate the uptake of FITC-BSA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10 Albumin uptake assay in ciPTECs at 33°C. 
ciPTECs were incubated with (A) FITC-BSA and (B) FITC-BSA for 15 minutes. Nuclei were 
stained with Hoechst 33342 and FITC-BSA was visualized at 488 nm. A phase contrast 
image of the same area was also added to locate the cells. Images were taken using a 
40x objective. Scale bar is 20 μm. Data is representative of n = 3 experiments. 
A.  FITC-BSA 
B.  FITC-BSA + BSA 
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Alternatively, to tackle the fluorescent ECM problem in ciPTECs observed by 
immunocytochemistry (ICC), we decided to analyse the FITC-BSA uptake using flow 
cytometry. The rationale for this line of methodology is that after tripsinization, the ECM 
would be dissolved and we would be able to selectively quantify the albumin fluorescence 
of each cell. The experiment was also repeated in HEK 293 and OK cells. 
The flow cytometric analysis for HEK 293 cells did not show any significant difference 
between the control and cells treated with simvastatin. However, a significant 20% 
reduction in fluorescence was detected in HEK 293 cells treated with non-labelled BSA 
(Figure 2.11 A). Note that the fluorescence of the control condition was only represented as 
100% to compare the effect of the inhibitions. It is not a reflection of the real percentage of 
cells containing FITC-BSA. In OK cells, the uptake of fluorescent albumin was significantly 
reduced to 50% under both inhibitory conditions compared to control (Figure 2.11 B). 
These data also correlated with the results obtained using the fluorescence microscope 
(Figure 2.9).  
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Figure 2.11 Flow cytometric analysis of FITC-BSA uptake. 
(A) HEK 293 cells and (B) OK cells were treated with FITC-BSA, FITC-BSA + BSA and FITC-
BSA + 10 μM of simvastatin for 15 minutes. Results are expressed as a percentage 
compared to control. Data are mean ± SEM (n = 3). Statistical significance was determined 
by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001  
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Finally, the albumin uptake in ciPTECs was analysed. The obtained results were similar to 
what we had previously seen in OK cells. Simvastatin was able to downregulate the FITC-
BSA uptake down to 60% at 33°C and down to 50%-55% at 37°C (Figure 2.12 A, B, C) and 
the BSA competitive inhibition down to around 40% (Figure 2.12 A, B) or 55% (Figure 2.12 
C). In summary, ciPTECs showed similar levels of megalin/cubilin functionality at both 
temperatures as well as at different incubation treatments. 
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Figure 2.12 Flow cytometric analysis of FITC-BSA uptake. 
(A) ciPTECs at 33°C, (B) ciPTECs at 37°C for 5 days and (C) ciPTECs at 37°C for 10 days were 
treated with FITC-BSA, FITC-BSA + BSA and FITC-BSA + 10 μM of simvastatin for 15 
minutes. Results are expressed as a percentage compared to control. Data are mean ± 
SEM (n = 3). Statistical significance was determined by One Way ANOVA test, *p<0.05, 
**p<0.01, ***p<0.001  
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2.3.6 CMFDA as a tool to study MRP2, MRP4 and P-gp functionality in ciPTECs  
As represented in Figure 2.2, CMFDA dye can enter the cells through the cell membrane but 
once inside, the molecule is cleaved by esterases, becoming fluorescent and impermeable. 
As MRP2, MRP4 and P-gp are capable of excreting the impermeant dye, we hypothesized 
that if these transporters were functional and were inhibited with MK571 or PSC833, an 
increase in fluorescence would be detected due to CMFDA accumulation inside the cells 
(Jenkinson et al. 2012). On the other hand, if the transporters were not present or 
functional, the addition of inhibitors would not affect the intracellular fluorescence. 
When MK571 was added in HEK 293 cells, no increase in CMFDA fluorescence was detected 
in the two lowest concentrations. However, from 6.25 μM a small but significant increase 
was observed (Figure 2.13 A). Instead, when HEK 293 cells were dosed with PSC833 no 
changes were seen (Figure 2.14 A). As expected, HEK 293 cells showed inexistent or very 
low levels of functionality. 
In OK cells, after inhibiting MRP transporters, the fold in CMFDA fluorescence increased 
more than 3 times, even at the lowest concentrations of MK571 (Figure 2.13 B). At 25 μM, a 
minor setback in fluorescence could be observed, which could be due to changes in pH as 
CMFDA dye is very sensitive to it. P-gp inhibition also caused a rise in fluorescence, 
duplicating at 1.48 μM of PSC833 and reaching values 4 times higher at 4.44 μM and 13.33 
μM (Figure 2.14 B).  
The results for ciPTECs were very similar at both temperatures investigated. A dose 
dependent increase in CMFDA fluorescence was detected for both inhibitors. MK571 
triggered a fold increment of 3 at the two highest concentrations (Figure 2.13 C, D), which 
was comparable to the highest values obtained in OK cells. However, PSC833 only induced a 
significant 1.7 fold change peaking at 13.33 μM (Figure 2.14 C) as well as 4.44 μM (Figure 
2.14 D). In summary, these fold increases observed were lower than the ones obtained in 
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OK cells but higher than in HEK 293 cells, indicating that ciPTECs have functional levels of 
MRP2, MRP4 and P-gp transporters and these are not excessively high as detected in the 
multidrug resistant OK cell line. 
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Figure 2.13 Study of MRP2 and MRP4 function using CMFDA dye 
(A) HEK 293 cells, (B) OK cells, (C) ciPTECs at 33°C and (D) ciPTECs at 37°C were cultured in 
CMFDA solution (1.25 μM) at increasing concentrations of MK571 (0 - 25 μM). Data are 
represented in fold change and compared to the control (0 μM) for each cell type. Data are 
mean ± SEM (n = 3). Statistical significance was determined by One Way ANOVA test, 
*p<0.05, **p<0.01, ***p<0.001  
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Figure 2.14 Study of P-gp function using CMFDA dye 
A) HEK 293 cells, (B) OK cells, (C) ciPTECs at 33°C and (D) ciPTECs at 37°C were cultured in 
CMFDA solution (1.25 μM)  at increasing concentrations of PSC833 (0 - 13.33 μM). Data are 
represented in fold change and compared to the control (0 μM) for each cell type. Data are 
mean ± SEM (n = 3). Statistical significance was determined by One Way ANOVA test, 
*p<0.05, **p<0.01, ***p<0.001  
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2.3.7 Hoechst 33342 uptake does not offer functional information 
In order to acquire a further understanding about ciPTECs transporters, we used Hoechst 
33342 to study BCRP function. Hoechst 33342 is a substrate of BCRP but also of P-gp 
(Jenkinson et al. 2012), thus P-gp was additionally analysed and used as an assay reference 
by comparing the results to the ones obtained for the same transporter using CMFDA.  
The results obtained with HEK 293 showed no upregulation of Hoechst 33342 fluorescence 
after inhibiting neither BCRP (Figure 2.15 A) nor P-gp (Figure 2.16 A), which correlated with 
the data obtained with CMFDA and it could be translated into an absence of these two 
transporters in this particular cell line. Nevertheless, even though we were expecting to 
detect higher levels of functionality in OK cells, when they were dosed with the BCRP 
inhibitor (Figure 2.15 B) or the P-gp inhibitor (Figure 2.16 B) we could not observe any 
significant increment in fluorescence.  
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Figure 2.15 Study of BCRP function using Hoechst 33342 
A) HEK 293 cells and (B) OK cells were cultured in Hoechst solution (1.25 μM) at increasing 
concentrations of KO143 (0 - 7.5 μM). Data are represented in fold change and compared 
to the control (0 μM) for each cell type. Data are mean ± SEM (n = 3). Statistical 
significance was determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001  
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To determine if the reason why no difference in fold change could be detected was the 
achievement of a plateau in fluorescence, we cultured OK cells in increasing concentrations 
of Hoechst 33342 with no inhibitors, with PSC833 at 13.33 μM and with KO143 at 7.5 μM 
(Figure 2.17). The data evidenced that no plateau had been attained as cells could 
accumulate greater levels of fluorescence than observed with cells in the presence of 1.25 
μM of Hoechst 33342 (Figure 2.17 A). Moreover, a plateau was only starting to become 
discernible at the highest concentrations of the dye (20 μM to 25 μM). A closer look of 
Hoechst 33342 fluorescence can be observed in Figure 2.17 B. At 1.25 μM, the difference of 
accumulated dye between all three conditions was small, but it seemed to increase around 
6.25 μM. Furthermore, although the differences between Km were not significant, the 
concentration of Hoechst 33342 needed to reach the maximal fluorescence intensity in the 
presence of inhibitors was considerably reduced (Table 2.7). As a result, the Hoechst 33342 
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Figure 2.16 Study of P-gp function using Hoechst 33342 
(A) HEK 293 cells and (B) OK cells were cultured in Hoechst 33342 solution (1.25 μM) at 
increasing concentrations of PSC833 (0 - 13.33 μM). Data are represented in fold change 
and compared to the control (0 μM) for each cell type. Data are mean ± SEM (n = 3). 
Statistical significance was determined by One Way ANOVA test, *p<0.05, **p<0.01, 
***p<0.001.  
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functional assay was repeated, increasing the concentration of the dye to 6.25 μM, to see if 
this could lead to a detectable fold difference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Dose dependent uptake of Hoechst 33342 in OK cells. 
OK cells were cultured in Hoechst 33342 solution at different concentrations (0 - 25 μM) 
with no inhibitors, with PSC833 at 13.33 μM and with KO143 at 7.5 μM. Graph B is an 
amplified version of graph A. Data are represented in fluorescence units. Data are mean ± 
SEM (n = 3).  
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In summary, OK cells were treated again with increasing concentrations of KO143 (Figure 
2.18 A) and PSC833 (Figure 2.18 B) in Hoechst 33342 solution (6.25 μM). Once more, no 
differences in fluorescence were observed after the addition of any inhibitor, with even 
more stable readings than the experiments previously performed at a lower concentration.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
No Inhibitors + KO143 + PSC833 
Km  ± SD 24.5 ± 5.4 μM 14.9 ± 3.6  μM 13.8 ± 1.8  μM 
p value -- N.S. N.S. 
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Figure 2.18 Study of BCRP and P-gp function using Hoechst 33342 in OK cells. 
OK cells were cultured in Hoechst 33342 solution (6.25 μM) at increasing concentrations 
of (A) KO143 (0 - 7.5 μM) and (B) PSC833 (0 - 13.33 μM). Data are represented in fold 
change and compared to the control (0 μM). Data are mean ± SEM (n = 3). Statistical 
significance was determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001 
 
Table 2.7 Comparison of Km values obtained from a non-linear analysis of Hoechst 33342 
retention in OK cells. 
Data are mean ± SD (n = 3). p value indicates significance (p<0.05) to control 
(No Inhibitors) by One Way ANOVA. Key: N.S. indicates not significant. 
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2.4 DISCUSSION 
 
In this chapter, the initial objective was to perform a phenotypical characterisation of 
ciPTECs and to compare the results obtained with other cell lines such as HEK 293 and OK. 
PCR and qPCR data elucidated how, in fact, HEK 293 do not represent an ideal PT model 
due to an evident lack of transporters involved in drug-induced nephrotoxicity such as the 
OATP4C1 (uptake transporter) or MRP2 (efflux pump) (International Transporter et al. 
2010, Nagai and Takano 2010). Therefore, drug toxicity studies in HEK 293 cells would not 
be representative. In contrast, ciPTECs expression profile was very similar to freshly isolated 
tubular cells at passage 2. This was the first time that such a large gene expression 
characterisation was performed in this cell line and results have been compared to freshly 
isolated renal tubular cells (Jansen et al. 2014, Wilmer et al. 2010). Additionally, comparing 
the results to HK-2 expression profile (Jenkinson et al. 2012) it became evident that ciPTECs 
overcome HK-2 cells as a PT model.  
Regarding differences at 33°C and 37°C, only three genes stood out. One of the big changes 
was the upregulation of BCRP, a transporter associated with breast cancer (Doyle and Ross 
2003), at 33°C, which could be due to the immortalisation cancer-like process induced at 
this temperature. CUBN and OATP4C1 were upregulated at 37°C instead, which could be 
either a sign of final cell differentiation or an upregulation due to cell contact stimuli 
(Sakairi et al. 2010a). However, no expression of OAT1, OAT3 or LRP2 was detected in 
ciPTECs or in the tubular fraction, which all play an important role in drug-induced toxicity 
studies (International Transporter et al. 2010, Nagai and Takano 2010). But since mRNA and 
protein levels do not always correlate directly, we could hypothesise that even with 
undetectable mRNA levels, they could still be present in protein form. Other markers like 
SYNPO showed high levels of mRNA. However, this does not mean that SYNPO is highly 
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expressed in ciPTECs, it just means that its expression in ciPTECs was 10 times higher than 
in the compared tubular fraction.  
The absent gene expression in HEK 293 cells was also supported by functional data such as 
megalin/cubilin uptake assays. In contrast, the albumin accumulation in OK cells correlated 
with previous studies that showed the colocalization of both multiligand receptors and 
their ability to uptake albumin (Zhai et al. 2000, Gekle et al. 1998, Gekle 2005). Finally, and 
despite the lack of detectable megalin mRNA, successful FITC-BSA uptake in ciPTECs 
matched the already published data for ciPTECs (Wilmer et al. 2010) as well as other data 
published in primary human kidney tubular cells (Verhulst et al. 2004). Moreover, the 
uptake inhibition through simvastatin indicated that the protein absorption was receptor 
specific and it was carried out via megalin/cubilin-mediated endocytosis. Simvastatin was 
the inhibitor of choice, instead of RAP (Christensen and Birn 2002), because it offers a 
potential therapeutic strategy for further studies against aminoglycoside-induced 
nephrotoxicity (Antoine et al. 2010) in our conditionally immortalised PT model.  
The OK cell line has been described to present multidrug resistant characteristics due to a 
much higher expression of xenobiotic transporters, such as MRP2, than other PT cell lines 
(Notenboom et al. 2006, Malstrom et al. 1987, Takano et al. 1996). Thus, as seen in the 
results, it could be predicted that they would have hold great levels of MRP and P-gp 
functional transporters. The functionality levels of MRP2, MRP4 and P-gp exhibited in 
ciPTECs confirmed that the received cell line exhibited the same properties and correlated 
to the experiments published by our collaborative partners (Wilmer et al. 2010). Therefore, 
we can conclude that the received ciPTECs are fit for purpose to study nephrotoxicity. 
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BCRP functionality assay using the uptake method published by Jenkinson et al. in 2012 in 
HK-2 cells proved unsuccessful. However, since P-gp results did not match the ones 
obtained in CMFDA, the problem could only be attributed to the assay basis (levels of 
background were too high) or to the performance. Nevertheless, the Km in the presence of 
these inhibitors decreased and the control Km was much higher than the one observed in 
HK-2 cells (Jenkinson et al. 2012). Therefore, a higher Km in ciPTECs could indicate a higher 
amount of BCRP and/or P-gp transporters than in HK-2 cells, since a larger number of 
transporters would handicap the accumulation of Hoechst 33342 inside the cells and hence, 
higher concentrations of the dye would be needed to acquire the maximum level of 
fluorescence. Furthermore, Jenkinson et al. barely detected a decrease in Km (around 16 
μM) in the presence of KO143 but had a significant decrease when they used  cyclosporin A 
(CSA), which inhibits P-gp. Then, the usage of more potent inhibitors might be an option to 
measure the functionality of P-gp and BCRP transporters using the Hoechst 33342 uptake 
assay. 
To further explore the functionality of other transporters and develop a better confidence 
in the ciPTECs as a nephrotoxicity model, additional transport assays could be considered. 
For instance, an organic anion uptake assay could be performed to test OAT1 and OAT3 
function by using probencebid, a potent OAT inhibitor, and the fluorescent anion 6-
carboxyfluorecein (6-CF) (Lawrence et al. 2015). Other interesting assays could be an 
organic anion efflux assay as well as an organic cation uptake assay. 
On a final note, it is important to consider that ciPTECs cultured at 33°C have proven to 
present very similar levels of functionality compared to ciPTECs cultured at 37°C for 5 or 10 
days. These data challenges the statements made by Wilmer et al., where they only 
performed functional assays after 8 - 10 days at 37°C as they reasoned that it was the time 
required to achieve a mature state, which also correlates with the cease of oncogene 
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expression. However, our results suggest that this is not the case, ciPTECs had very similar 
levels of expression and functionality at both temperatures and therefore further 
experiments will not need to be performed after ciPTECs have undergone “maturation”. 
In summary, it was confirmed that ciPTECs express the necessary functional transporters to 
be a potentially valuable and specific physiologically based model to study nephrotoxicity in 
vitro. Based on the data presented from the investigations of this chapter, ciPTECs will be 
the cell line of choice to perform the mechanistic nephrotoxicity studies within Chapters 3 
and 4. 
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3.1 INTRODUCTION 
 
In culture, evaluating drug-induced renal mitochondrial dysfunction is a challenging task. As 
discussed previously, newly immortalised cell lines, of human origin, such as ciPTECs have 
become the current state of the art alternative to assess cell function in vitro and 
potentially mechanistic drug-induced nephrotoxicity (Wilmer et al. 2010, Wieser et al. 
2008). This cell line was characterised in Chapter 2, in which the expression and 
functionality of some important drug transporters was confirmed. Nonetheless, it has been 
shown that cancer and immortalised cell lines are metabolically adapted to proliferate in 
supraphysiological levels of glucose and therefore prone to fall into the Crabtree effect and 
hence complicates the interpretation on toxicants that might mechanistically operate via 
intracellular bioenergetic pathways. The Crabtree phenomenon is based on a 
downregulation of the mitochondrial oxidative phosphorylation (OXPHOS) route to mainly 
rely on glycolysis for cell energy production (Figure 3.1) (Rodriguez-Enriquez et al. 2001, 
Guppy et al. 1993, Dell' Antone 2012). Consequently, even though cells are cultured in 
Figure 3.1 Simple representation of the Crabtree effect 
The Crabtree effect is a phenomenon observed in vitro that consists of cells deriving 
almost all their energy from glycolysis instead of OXPHOS. The conversion of glucose to 
pyruvate (Pyr) generates only two net ATP molecules (2ATP). However, in high 
concentrations of glucose as a substrate, glycolysis flux rate can be radically accelerated 
to overcome the low efficiency in ATP production. The mitochondria still remain slightly 
active but only around 5% of the glucose carbon enters the citric acid cycle.  
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abundant O2 and hold perfectly healthy mitochondria, since these organelles are not 
essential for cell energy production, cells can potentially become resistant to mitotoxins 
and stop representing a relevant model to evaluate mechanistic mitochondrial toxicity.  
To bypass the Crabtree effect and increase the potential susceptibility to mitotoxins in vitro, 
Marroquin et al. replaced glucose for galactose in the medium. They proved that after 8 
weeks in culture, this change in energy source forces anaerobically poised cells to rely on 
OXPHOS. Metabolically, when galactose becomes the main carbohydrate, the glycolytic 
activity becomes downregulated with barely any glycolytic intermediates detectable in the 
cells. Instead, almost all the galactose carbon is metabolised through the pentose 
phosphate cycle, a metabolic pathway parallel to glycolysis, yielding very little or no energy. 
Therefore, galactose plays an anabolic role rather than a catabolic one. However, cells are 
still able to grow at a constant rate, thus the energy has to come from an alternative 
source: L-glutamine (Figure 3.2). Along with sugar, L-glutamine is the most abundant 
carbon in the medium and can provide half of the energy in the presence of glucose and 
Figure 3.2 Representation of metabolic energy changes when galactose is the main 
carbohydrate in the medium. 
Circumventing the Crabtree effect by substituting glucose for galactose promotes a 
downregulation of glycolysis, with only very few of galactose molecules following this 
route. Therefore, cells are forced to use L-glutamine as their main source of energy. L-
glutamine skips glycolysis and it is directly incorporated into the citric acid cycle. As a 
result, OXPHOS is upregulated. 
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more than 98% of the energy in galactose conditions (Reitzer LJ 1979). This amino acid 
directly enters the citric acid cycle metabolism, avoiding glycolysis and stimulating 
mitochondrial OXPHOS (Figure 3.3). 
 
 
 
 
 
 
 
 
The media change technique based on replacing glucose for galactose, was first 
implemented in HepG2 cells and later repeated with human primary muscle cells 
(Marroquin et al. 2007, Aguer et al. 2011). It was also later modified by Kamalian, L., et al. 
(2015) (with whom we were able to collaborate), as they shortened the pre-treatment in 
both media conditions from 8 weeks to 4 h. The results showed an acceleration of O2 
consumption that reflected the metabolic shift towards mitochondrial respiration and a 
greater vulnerability in front of mitotoxins such as oligomycin, FCCP and rotenone. 
Furthermore, they also suggested that a comparison with respiration data between glucose 
and galactose conditions could be useful as a toxicity screen that would also offer 
mechanistic insight. Hence, if cytotoxicity is observed in galactose grown but not in glucose 
grown cells, that would provide an evidence for mitochondrial impairment as the 
Figure 3.3 Summarized diagram of the biochemical pathways followed by each 
energetic substrate (Reitzer LJ 1979). 
Glucose route of ATP production is delineated in green. When the glucose in the media is 
replaced by galactose, the ATP production pathway changes and it follows the purple 
route.  
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predominant pathway leading to cell death and toxicity. In contrast, when no difference 
could be detected, alternative pathways would most likely dictate the cell toxicity 
(Marroquin et al. 2007).  
 
3.1.1 Aims and hypothesis 
Hypothesis:  
We hypothesised that if ciPTECs were under the Crabtree effect, by implementing the 
glucose/galactose media change strategy we would be able to drive them to a higher 
aerobic metabolic state and use them as a model to evaluate in vitro renal mitochondrial 
impairment. 
 
The aims of this Chapter were to: 
 Metabolically characterise ciPTECs in glucose and galactose media conditions to 
assess if ciPTECs had fallen under the Crabtree effect following the media change 
strategy reported by Kamalian, L., et al.  
 Check the vulnerability of ciPTECs to model mitochondrial toxins in glucose vs. 
galactose conditions. 
 Test potential mitotoxic and nephrotoxic compounds in the established glucose vs. 
galactose PT cell model to validate its potential in discerning compounds that have 
mitochondria as its main toxicity target. Hence, validating its potential to be the 
first renal model able to screen for clinically relevant mitochondrial liabilities. 
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3.2  MATERIALS AND METHODS 
3.2.1 Materials  
The OK cell line was purchased from the European Collection of Cell Cultures (ECACC). 
ciPTECs were obtained from the Department of Pharmacology and Toxicology in Radboud 
University Nijmegen (Nijmegen, Netherlands). Tissue culture reagents DMEM/F-12 (1:1), 
FBS, dialyzed fetal bovine serum (DFBS), PBS, MitoSOX™ Red Mitochondrial Superoxide 
Indicator, Hoechst 33342 and ProLong® Gold Antifade Mountant were purchased from Life 
Technologies (Paisley, UK). DMEM – F12 without glucose was purchased from Biowest 
(Nuaillé, France). Seahorse consumables were purchased from Seahorse Biosciences (North 
Billerica, MA, USA). Cover slides (13 mm ) were purchased from VWR (Lutterworth, UK) 
and microscope slides were obtained from Thermo Fisher Scientific (Loughborough, UK). 
Gold Star liquid scintillation cocktail was purchased from Meridian Biotechonologies 
(Surrey, UK) and scintillation vials were obtained from Simport (Beloeil, Canada). 
Cytotoxicity Detection Kit was purchased from Roche Diagnostics Ltd (West Sussex, UK). 
CellTiter-Glo Luminescent Cell Viability Assay and CellTiter 96 Aqueous Non-Radioactive Cell 
Proliferation Assay were purchased from Promega (Southampton, UK). TFV was obtained 
from Toronto Research Chemicals Inc. (Toronto, Canada) and tritium labelled TFV was 
purchased from Moravek Biochemicals, Inc. (Brea, California). All other reagents and 
chemicals were purchased from Sigma Aldrich (Dorset, UK). 
 
3.2.2 Cell culture 
OK cells and ciPTECS were cultured as stated in Chapter 2.2.2.  
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3.2.3 Bioenergetic profile assessment in ciPTECs using Seahorse technology 
3.2.3.1 ciPTECs cultured at 33°C 
ciPTECs were plated on a XF 96-well microplate at 1x104 cells/well to determine the 
bioenergetic profile at 33°C. 24 h later, we defined four separate quarters in the microplate 
dedicated to four different conditions (see Figure 3.4). In two of them, media was changed: 
in one quarter the media was replaced by the original growth medium using DFBS (10% v/v) 
instead FBS and in the other quarter the media was replaced by ciPTECs galactose medium. 
The galactose medium was prepared with DMEM – F12 (1:1) without glucose 
supplemented with L-glutamine (2 mM), DFBS (10% v/v) and the rest of the cell culture 
supplements listed in the cell culture section (33°C, 5% CO2). The media of the other 
untreated two quarters was replaced following the same arrangement 20 h later:  
 
 
 
 
 
 
 
 
 
 
 
 
At 24 h after the first media change, the plate was washed twice with XF Base Medium 
supplemented with L-glutamine (1% v/v), sodium pyruvate (1 mM) and 25 mM glucose or 
10 mM galactose for glucose and galactose based media respectively and then 175 µl of 
Figure 3.4 Schematic of the plate design.  
The 96-well plate was divided into four sectors. The two sectors on the top had the 
media changed at 0 h and the ones on the bottom had the media changed 20 h later. 
Results were analysed 24 h after the first change in media. 
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glucose or galactose medium were added to the respective wells; media pre-warmed to 
37°C and pH adjusted to 7.4. Cells were left in a CO2 free incubator at 37°C for 1 h while 25 
µl of 8 µM rotenone stock were loaded/well to the sensor cartridge (final concentration 1 
µM) and the optical sensors were calibrated by the Seahorse machine. After loading the cell 
microplate, basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
were measured three times (OCR is reported in units of pmol/minute and ECAR in 
mpH/minute). Then rotenone was pneumatically injected into the media in each well. After 
gentle mixing, OCR and ECAR were measured three more times. 
3.2.3.2 ciPTECs cultured at 37°C for 5 days 
CiPTECs were plated on a XF 96-well microplate at 5000 cells/well and maintained at 33°C. 
After 24 h, the microplate was transferred to 37°C and cultured for 5 days at this 
temperature (5% CO2). After this period, the same protocol for glucose and galactose 
dosing from section 3.2.3.1 was followed.  
 
3.2.4 Normalization of Seahorse data by BCA assay 
To normalize the Seahorse experiment data, ciPTECs were washed twice with cold PBS and 
15 µl of RIPA buffer were added per well. A standard curve ranging from 0.125 – 2 mg/ml of 
albumin was prepared in separate tubes and 9 µl of each concentration was transferred in 
duplicate into a new 96-well plate as well as 9 µl of dH2O (blank) and 9 µl of lysed cells from 
each well. Freshly prepared BCA reagent solution was added into each well (200 µl/well) 
and the plate was incubated for 35 minutes at 37°C. The absorbance was read at 570 nm on 
a plate reader (Varioskan, Thermo Scientific). The blank reading (dH2O with BCA reagent) 
was subtracted from all sample and standard readings. Protein concentration in the 
samples was calculated using values obtained from the standard curve. 
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3.2.5 MitoSOX mitochondrial staining 
Four 13 mm  cover slides were placed in the wells of a 24-well plate and coated with 0.5% 
of gelatine for 30 minutes. The gelatine was removed and ciPTECs were seeded at a density 
of 4x104 cells/well. After 24 h, the medium was substituted for DFBS glucose medium on 
two cover slides and ciPTECs galactose medium on the other two. The cells were cultured at 
33°C for another 2 days and then transferred to 37°C for 5 days before the staining. When 
the ciPTECs were ready, they were washed twice with PBS and incubated with a 5 μM 
MitoSOX solution, also prepared in PBS, for 10 minutes protected from light. Then, the cells 
were washed 3x in warm PBS and fixed with 2% PFA for 15 minutes at RT in the dark. Two 
more washes with PBS were performed after cells had been fixed. Then, the nuclei were 
stained with 2 μg/ml of Hoechst 33342 for 10 minutes at RT protected from light. Finally, 
after three more washes with PBS, the cover slides were mounted onto a microscope slide 
with Prolong Gold. Results were visualized at 63x magnification using an inverted 
fluorescence microscope (Axio Observer.Z1, Zeiss). 
 
3.2.6 Rotenone - complex I inhibition 
ciPTECs were plated in four 24-well plates the day before the experiment at 8x104 cells/well 
and cultured at 33°C (5% CO2). After 24 h, cells were washed with PBS. Then, the media of 
two plates was replaced by the original growth medium using DFBS (10% v/v) instead of FBS 
and the media of the other two plates was replaced by ciPTECs galactose medium (33°C, 5% 
CO2). Rotenone concentrations were prepared in DMSO (final solvent concentration lower 
than 1% v/v) and 4 h after the media replacement, cells were dosed with rotenone for 2 h 
and 24 h in both glucose and galactose conditions, respectively (Figure 3.5). 
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3.2.7 Measurement of ATP levels to evaluate cell viability 
ATP content was assessed using the CellTiter-Glo Luminescent Cell Viability Assay. Briefly, 
25 µl of the CellTiter-Glo Reagent were added per well of a 24-well plate, the plate was 
placed in a shaker for 1 minute (750 rpm), left in the dark for 5 minutes and 50 µl of the 
mixture from each well were transferred to a 96-well opaque-wall plate per triplicate. ATP 
levels were defined as a percentage compared to control. Luminescence was recorded 
using a plate reader (Varioskan, Thermo Scientific). 
 
3.2.8 Cytotoxicity assessment by measuring LDH content  
The LDH content inside the cells and leakage into the medium was measured using the 
Cytotoxicity Detection Kit. In summary, 50 µl of the media were transferred to a new 96-
well plate. The rest of the media was removed from the wells and 200 µl of 1% Triton X-100 
solution in DMEM/F-12 serum free medium was added per well to lysate the cells. The cell 
lysate was also transferred into a new 96-well plate diluted 1/5 (final volume 50 µl). Finally, 
50 µl of the reaction mixture were added per well to the 96-well plates and they were 
incubated at RT protected from light for 30 minutes. Absorbance was measured at 490 nm 
(Varioskan, Thermo Scientific). 
Figure 3.5 Schematic design of the dosing strategy. 
Before each dosing, the media is changed for glucose with DFBS or ciPTECs galactose 
medium 4 h in advance. Then, cells are treated with the mitotoxic compound 
maintaining the same media composition during the treatment. 
Glucose medium 
Glucose 
medium (4 h) 
Galactose 
medium (4 h) 
Rotenone (2 h) 
Rotenone (24 h) 
Rotenone (2 h) 
Rotenone (24 h) 
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3.2.9 Tritium radiolabelled TFV uptake 
This experiment was performed with OK cells and ciPTECs. OK cells were seeded in three 
wells of a 12-well plate at 1x105 cells/well and cultured for 48 h at 37°C (5% CO2) in 
DMEM/F-12 (1:1) medium supplemented with FBS (10% v/v) and penicillin-streptomycin 
solution (1% v/v). To evaluate the uptake of radiolabeled TFV in ciPTECs at 33°C and 37°C 
with glucose or galactose medium, four different conditions were set up. The ones that 
were assessed at 33°C were seeded at 1x105 cells/well and cultured for 48 h at 33°C (5% 
CO2). The cells that were evaluated at 37°C were seeded at 8x10
4 cells/well, cultured at 
33°C for 24 h and then transferred to 37°C (5% CO2) for 5 days. At 24 h prior to the 
experiment, the medium was changed for either glucose or ciPTECs galactose medium 
(both containing DFBS). Three wells were analysed per condition. To perform the 
radiolabelled TFV uptake, cells were dosed with a solution of hot TFV (final concentration 
0.3 µCi/well) and TFV (final concentration 10 µM) and incubated for 1 h at 37°C (5% CO2). 
Then, 100 µl of each well were collected and placed into three scintillation vials. The rest of 
the media was removed, cells were washed with PBS twice and 100 µl of tap water were 
added to lyse the cells. The lysates were collected and 4 ml of scintillation cocktail were 
added into each scintillation vial, mixed upside down and the tritium radioactivity was 
measured using a scintillation analyser (Tri-Carb 3100TR, PerkinElmer). 
 
3.2.10 Toxicity screening of different compounds using the glucose vs. galactose method 
For antimycin A and cisplatin treatments, ciPTECs were seeded and dosed with these two 
compounds following the same indications and dosing strategy from section 3.2.6. The 
different concentrations were also prepared in DMSO and the results analysed after 2 h and 
48 h respectively. When ciPTECs were dosed with gentamicin (stock prepared in dH2O) and 
adefovir (stock prepared in DMSO) they were seeded at 4x104cells/well in 24-well plates. 
The same media change strategy from section 3.2.6 was also followed and ciPTECs were 
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dosed for 4 and 3 days correspondingly. Lastly, ciPTECs were seeded at 1x104 cells/well in 
24-well plates to be dosed with TFV (stock prepared in dH2O). Again, 3.2.6 section glucose 
and galactose dosing strategy was used and cells were dosed for 48 h, 8 days and 15 days 
with TFV changing the medium every two days. Note that every concentration was analysed 
in triplicate and all final solvent concentrations were lower than 1% v/v. 
 
3.2.11 Assessment of cell growth after gentamicin exposure 
ciPTECs were seeded at 1x105cells/well in a 24-well plate and maintained at 33°C (5% CO2). 
After 24 h, cells were dosed with different concentrations of gentamicin in glucose medium 
and cultured for 72 h. Then, a scratch with the tip of a 200 µl pipette was performed in each 
well and a picture was taken using an inverted microscope (Eclipse TS100, Nikon). Cells 
were incubated for another 18 h at 33°C and pictures were taken at the end of this period 
(Figure 3.6). ImageJ was used to analyse the amplitude of the scratch after 18 h and results 
were compared to the initial amplitude.  
 
 
 
 
 
 
 
 
3.2.12 Statistical analysis 
Statistical analysis of data was performed using StatsDirect software. All results were 
represented as the mean ± SEM or as the mean ± SD of three independent experiments. 
The choice of SEM vs. SD was only based on obtaining a better visual representation of the 
Figure 3.6 Simple representation of the study design. 
Cells were seeded and dosed with gentamicin after 24 h. Then, after 72 h of gentamicin 
treatment, a scratch through the center of the wells was performed and pictures were 
taken. ciPTECs were left to recover in the same medium and another set of pictures were 
taken 18 h after the scratches. 
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figures. Data was first assayed for normality using the Shapiro-Wilk test. When assaying 
differences amongst at least three groups, if data was normal, statistical analysis was 
performed using One Way ANOVA with Dunnet as a post-hoc comparison, as this test is 
specifically designed to compare each treatment against a single control. If there was no 
evidence of normality, Kruskal-Wallis test was applied instead. To test for differences 
amongst two groups, a t-test was performed if data was classified as normal and a Mann-
Whitney test when data showed no evidence of normality. Only when p values <0.05 the 
results were considered significant.  
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3.3  RESULTS 
3.3.1 Determination of ciPTECs bioenergetic profile and the Crabtree effect: glucose vs. 
galactose medium 
To assess any differences in energetic metabolism when cells were cultured in galactose 
medium (without glucose) and to investigate the hypothesis that ciPTECs are under the 
Crabtree effect, the OCR and ECAR were measured in both glucose and galactose 
conditions.  
The first assessment was performed at the growing temperature of the cells (33°C) at 4 h 
and 24 h after changing the media. At basal conditions, two different phenotypes could be 
detected. OCR was significantly upregulated in galactose cultured cells and it was also 
complemented with a reduction in the ECAR (Figure 3.7 A, B). When rotenone (complex I 
inhibitor) was added, oxygen consumption levels dropped drastically. Glucose grown 
ciPTECs also had a distinctive increase in medium acidification (ECAR values were doubled). 
In contrast, ECAR was maintained within similar parameters for galactose ciPTECs. All the 
changes seen at 24 h could also be detected at 4 h (Figure 3.7 A, B). 
The same energetically metabolic pattern seen at 33°C was also displayed at 37°C (Figure 
3.7 C, D). Therefore, disregarding the culturing temperature, switching to a galactose based 
medium induced ciPTECs to transition into a higher oxidative bioenergetic configuration.  
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Figure 3.7 Bioenergetic profile of ciPTECs measuring OCR and ECAR at basal conditions 
and after rotenone exposure.  
The Seahorse experiment was performed 4 h and 24 h of changing the medium. Three 
basal measurements were recorded before rotenone was injected and three more after 
the injection. The third value was used in each case because it represents the most stable 
measure. Arrows mark the shift in energy metabolism after ciPTECs are dosed with 
rotenone. Results have been normalised to the amount of protein per well. Data are mean 
± SD (n = 3). Statistical significance was determined by t-test, *p<0.05, **p<0.01, 
***p<0.001. 
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3.3.2 Assessment of mitochondrial distribution in galactose culture conditions 
In order to investigate if culturing ciPTECs in galactose instead of glucose would affect 
mitochondrial distribution, we stained the cells with a mitochondrial specific superoxide 
indicator (MitoSOX) (Figure 3.8). At both conditions, mitochondria appeared denser around 
the nucleus, becoming more scattered at the extremities. Mitochondrial number, even 
though more difficult to gauge, looked qualitatively similar and so did the organelle size. In 
summary, no major differences could be appreciated amongst both culture conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Mitochondrial distribution in glucose vs. galactose conditions. 
Mitochondria were stained with MitoSOX (visualized at 594 nm) and Hoechst after 7 days 
in ciPTECs galactose medium (A) and after 7 days in glucose medium (B). Images were 
taken using a 63x objective. Scale bar is 10 μm. Data is representative of n = 3 
experiments.    
B A 
GALACTOSE GLUCOSE 
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3.3.3 Greater susceptibility to mitotoxins detected in galactose cultured ciPTECs  
Previous results (Figure 3.7) showed how after a mitotoxic insult, galactose cultured ciPTECs 
were unable to activate glycolysis as a compensatory mechanism (ECAR values were 
maintained). In theory, this would render galactose cultured ciPTECS a more sensitive in 
vitro model to detect potential renal mitochondrial toxicity. To investigate this hypothesis, 
both glucose or galactose cultured ciPTECs were dosed with rotenone, a well-defined 
mitotoxin, at concentrations ranging from 0.01 μM to 100 μM. Cell viability was assessed 
measuring ATP levels and LDH leakage. After a 2 h incubation, a marked decrease in ATP 
levels was observed in galactose conditions between 0.01 μM and 0.1 μM (Figure 3.9 A). 
However, no variation in ATP content was detected in normal glucose medium (Figure 3.9 
C). LDH leakage into the medium was not detectable in either case, which implies that cell 
death had not occurred yet. A longer incubation of 24 h was also performed. In this case, 
galactose ciPTECs suffered a decrease in ATP levels at the same concentration range 
observed in the shorter incubation, but a dose dependant increase in LDH leakage was 
detected after 0.1 μM (Figure 3.9 B). In contrast, glucose-grown ciPTECs showed stable 
levels of ATP and no LDH leakage when exposed to rotenone concentrations up to 100 μM 
(Figure 3.9 D).  
All these data supports the above-mentioned hypothesis and confirms that galactose 
cultured ciPTECs are more vulnerable to mitotoxins, as they cannot sustain their basal 
energy needs once the mitochondria have been damaged.  
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Figure 3.9 Dose responses after 2 h and 24 h of rotenone exposure for glucose grown 
ciPTECs and galactose cultured ciPTECs.  
Cells were pre-cultured for 4 h in glucose or galactose conditions and then dosed with 
rotenone for (A,C) 2 h or (B,D) 24 h. ATP levels are represented in the left Y axis and LDH 
leakage in the right Y axis. Data are mean ± SEM (n = 3). Statistical significance in ATP 
levels (*) and LDH leakage (#) compared to the control (0 μM) was determined by One 
Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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3.3.4 Validation of glucose vs. galactose mitotoxicity method in ciPTECs 
To reassure the validity of the recently established model to detect mitotoxicity in PT cells, 
we dosed ciPTECs with another well-defined mitotoxin (antimycin A) as a positive control 
and two nephrotoxic compounds (cisplatin and gentamicin) as test compounds. Antimycin 
A is a potent inhibitor of the mitochondrial respiratory chain that binds to complex III 
(Huang et al. 2005), hence we would expect similar results to the observed response with 
rotenone. On the other hand, even though in the cisplatin and gentamicin toxicity 
mechanism mitochondria play an important role, alternative pathways have been 
postulated to be the critical mechanisms leading to cell death (Servais et al. 2008). 
Therefore, it would be anticipated that no differences should be detected in the glucose vs. 
galactose model. 
As seen with rotenone (Figure 3.10 A), antimycin A produced a severe drop in ATP levels 
from 0.01 μM in galactose conditions after 2 h (Figure 3.10 B). Cells cultured in glucose 
conditions did not show any decrease in ATP content. However, a small increase was 
detected at the highest concentration. After the cisplatin incubation for 48 h, a very similar 
dose response curve was observed for both conditions (Figure 3.10 C). No differences were 
observed after 4 days of gentamicin treatment between glucose and galactose media 
(Figure 3.10 D). In summary, the model was able to correctly discern between compounds 
that have mitochondria as the main toxicity target from compounds where mitochondria 
only play a secondary role in the toxicity pathway. 
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Figure 3.10 Effect of mitotoxic and nephrotoxic compounds on ATP levels in ciPTECs. 
Dose response curves after exposure of (A) rotenone for 2 h, (B) antimycin A for 2 h, (C) 
cisplatin for 48 h and (D) gentamicin for 4 days in ciPTECS. The experiments were 
performed in glucose grown vs. galactose cultured ciPTECs. (A) and (B) represent the 
positive controls whilst (C) and (D) are nephrotoxic negative controls.  Data are mean ± 
SEM (n = 3). 
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3.3.5 Gentamicin impairs ciPTECs cell growth 
Based on the balance of current literature evidence, ciPTECs are thought to be one of the 
best in vitro models to detect nephrotoxicity. Although gentamicin is a potent nephrotoxic 
agent in man and in animal models (Lopez-Novoa et al. 2011), in the results presented in 
section 3.3.4, exposure to gentamicin did not result in severe levels of cytotoxicity. 
Nevertheless, we have proven previously that ciPTECs possess satisfying levels of functional 
gentamicin transporters (Chapter 2, Figure 2.12). Here we then investigated whether 
gentamicin had other deleterious effects on ciPTECs such as cell growth impairment that 
may lead to cytotoxicity. 
The control wells showed nearly a full recovery of cell density 18 h after the scratch assay 
was performed (Figure 3.11 B). ciPTECs practically repopulated the whole area that had 
been scraped cell free. Similar results were observed at 0.5 mg/ml (Figure 3.11 C). At 1 
mg/ml of gentamicin, the scraped area was slightly wider (Figure 3.11 D), which became 
more obvious at 2 mg/ml and 3 mg/ml of gentamicin (Figure 3.11 E, F). After quantifying 
the scratch width, we could appreciate a significant delay in cell growth that was 
proportional to gentamicin dosage (Figure 3.12).  
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Figure 3.11 Assessment of cell growth after gentamicin exposure. 
ciPTECs were treated with gentamicin at concentrations ranging from 0 to 3 mg/ml for 72 
h and wells were scratched to analyse cell growth. (A) Scratch at 72 h + 0 h. 72 h + 18 h 
pictures correspond to: (B) 0 mg/ml, (C) 0.5 mg/ml, (D) 1 mg/ml, (E) 2 mg/ml and (F) 3 
mg/ml of gentamicin. 
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Figure 3.12 Quantified assessment of cell growth after gentamicin exposure. 
ciPTECs were treated with gentamicin at concentrations ranging from 0 to 3 mg/ml for 72 
h and wells were scratched to analyse cell growth. Data from 72 h refers to the initial 
amplitude of the scratch represented in percentage (%). 72 h + 18 h data plots the 
scratch amplitude (%) after 18 h of recovery. Data are mean ± SD (n = 3). Statistical 
significance was determined by Mann-Whitney test, *p<0.05. 
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3.3.6 Galactose cultured ciPTECs are more sensitive to adefovir triggered toxicity 
Once the mitochondrial toxicity model had been initially validated, we were interested to 
see if the glucose vs. galactose method could detect any differential toxicity when the 
ciPTECs were treated with adefovir. This NtRTI is still used in controlled doses to treat 
Hepatitis B patients but although never demonstrated in vitro, it is known to induce renal 
dysfunction (Ha et al. 2009). 
After 3 days of adefovir exposure, the dose response curves that corresponded to the two 
different medium conditions could be distinctively distinguished (Figure 3.13). ATP 
depletion in galactose cultured cells started around 0.3 μM, whilst ATP depletion for 
glucose cultured ciPTECs was not detectable until 5 μM. Although the effect was not as 
prominent as we had previously seen with rotenone (Figure 3.10 A), galactose cultured PT 
cells suffered a drop in ATP levels ahead of glucose grown cells. In other words, they were 
able to reveal adefovir toxicity earlier on (Figure 3.13). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13. The effect of adefovir on ATP levels in galactose cultured versus glucose 
grown ciPTECs.  
Galactose cultured and glucose grown ciPTECs dose response curves after adefovir 
exposure for 3 days at different concentrations (0.1 - 100 μM). ATP levels are 
represented as a percentage (%) and the results are compared to the control (0 μM) for 
each medium condition, expressed as 100%. Data are mean ± SEM (n = 3).  
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3.3.7 TFV mitochondrial toxicity evaluation using the glucose vs. galactose model 
To further investigate the mitochondrial implication in NtRTIs toxicity, the glucose vs. 
galactose experiment was repeated using TFV. This compound is a lower toxic analogue of 
adefovir with a higher relevance in the clinic since it is broadly used to treat HIV patients. 
However, although with a lower incidence, it has been reported to induce PT dysfunction 
but no clear toxicity pathway has been identified yet (Hall 2013, Herlitz et al. 2010). 
First, glucose grown and galactose cultured ciPTECs were exposed to TFV for 48 h (Figure 
3.14 A).  ATP levels remained at 100% for both conditions throughout all concentrations 
investigated. A longer incubation of 8 days was then performed (Figure 3.14 B). Although 
not significantly, a slight variation between glucose and galactose ATP levels was detected. 
In glucose grown ciPTECs, ATP content had a 10% reduction at the last two highest 
concentrations of TFV. Finally, a much longer TFV treatment of 15 days was performed in 
which cells spent 5 days at 33°C and 10 days at 37°C (Figure 3.14 C). Glucose grown ciPTECs 
expressed lower ATP levels compared to control and to galactose cultured cells. In general, 
the energy content for both conditions was below 100% and above 65% and lower than any 
of the prior treatments with the NtRTI. 
To confirm that ciPTECs were able to uptake the compound, cells were incubated with 
tritium radiolabelled TFV for 1 h and the amount of intracellular radioactivity was measured 
(Figure 3.14 D). The results were compared with the intracellular uptake in OK cells. TFV 
internalisation values varied from 20% to 30% amongst the two cell lines and the different 
temperature and medium conditions.  
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Figure 3.14. TFV uptake and cytotoxic impact on ciPTECs over time. 
The uptake was analysed at 33°C and 37°C in glucose (Glu) and galactose (Gal) 
conditions. ATP levels were measured in ciPTECs and represented as a percentage (%) 
compared to the control (0 μM) after TFV treatment for (A) 48 h, (B) 8 days and (C) 15 
days). TFV concentrations ranged from 1 μM to 100 μM. (D) Tritium radiolabelled TFV 
uptake in OK cells and ciPTECs. Data are mean ± SEM (n = 3).  
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3.3.8 Mitochondrial rearrangements after TFV exposure 
In order to detect if TFV had affected the mitochondria at a structural or morphological 
level, ciPTECs were stained with MitoSOX after they had been dosed with TFV for 15 days at 
100 μM. Since no important differences had been detected with the different media 
conditions, this time the experiment was only carried out in glucose medium. The control 
images (0 μM) showed evenly spread mitochondria. A slight tendency to accumulate 
around the nuclei could be appreciated, but mitochondria can clearly be seen in 
cytoplasmic elongations (Figure 3.15 A). In contrast, after 15 days of TFV exposure, not only 
some cells looked bigger but also the mitochondria had changed distribution. The 
accumulation around the nuclei appeared more obvious and some cells had lost the evenly 
spread arrangement seen at 0 μM. The mitochondrial density at the edges of the cytoplasm 
had also notably decreased (Figure 3.15 B). 
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Figure 3.15 Mitochondrial distribution after 15 days of TFV treatment. 
ciPTECs were stained with MitoSOX (visualised at 594 nm) and Hoechst after 15 days (A) in 
glucose medium and (B) 15 days of TFV treatment (100 μM). The arrows mark 
mitochondrial distribution changes compared to 0 μM. Images were taken using a 63x 
objective. Scale bar is 10 μm. Data is representative of n = 3 experiments.    
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3.3.9 Classification of mitotoxic and non-mitotoxic compounds  
Interestingly, it is known that the determination of ATP levels can unmask if a compound 
has potential to induce mitochondrial impairment long before cell death occurs (Kamalian 
et al. 2015). To specifically detect drug-induced mitochondrial toxicity, a cell viability assay 
was first established with a bone marrow cell line (K562 cells) (Swiss et al. 2013) and later 
published with a liver cell line (HepG2 cells) (Kamalian et al. 2015) by calculating the 
EC50ATP (compound concentration that causes a 50% drop in ATP levels) in glucose and 
galactose medium from dose response curves (Swiss et al. 2013). If the ratio value of 
EC50ATPglu divided by EC50ATPgal was ≥ 2 and the difference between the EC50ATP for both 
conditions was statistically significant (One Way ANOVA, p values lower than 0.05), then 
the compound was defined as mitotoxic (Swiss et al. 2013). Here, we apply the same 
rationale to our PT glucose vs. galactose model to classify the compounds previously tested 
(Table 3.1). 
The previously described method successfully classified rotenone (EC50ATPglu /EC50ATPgal > 
3125, p < 0.0001) and antimycin A (EC50ATPglu /EC50ATPgal > 14925, p < 0.0001) as 
mitotoxins in ciPTECs. Cisplatin and gentamicin, two known nephrotoxins, were used as 
negative controls. Cisplatin was correctly classified as non mitotoxic after 48 h of dosing 
with an EC50ATPratio of 0.976. However, after 4 days of gentamicin exposure, ciPTECs ATP 
depletion was not enough to calculate the EC50ATP and this was established as > 6.5 μM. A 
similar scenario happened after 15 days of TFV treatment (redosed every 3 days), both 
glucose and galactose EC50ATP were established as >100 μM. Nonetheless, adefovir was 
categorised for the first time in vitro as a mitotoxin with an EC50ATPgal 6.12 times lower 
than EC50ATPglu (p = 0.0049). 
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                                 Table 3.1 List of compounds that are known to cause nephrotoxicity plus rotenone and antimycin A as positive controls  
                              for mitotoxicity 
 
 
 
 
 
 
 
 
 
 
 
  
 
EC50ATP (μM) ± SD EC50ATPglu / 
EC50ATPgal 
P value Incubation time 
Glucose Galactose 
Rotenone > 100 0.032 ± 0.016 > 3125 < 0.0001 2 h 
Antimycin A > 100 
0.0067 ± 
0.0064 
> 14925 < 0.0001 2 h 
Cisplatin 24.7 ± 12.3 25.3 ± 11.6 0.976 N.S. 48 h 
Gentamicin > 6.5 > 6.5 1 N.S. 4 days 
Adefovir 15.3 ± 3.7 2.5 ± 1.4 6.12 0.0049 3 days 
TFV > 100 > 100 1 N.S. 15 days 
Data are mean ± SD (n = 3). P value indicates significance (p<0.05) between EC50ATPglu and EC50ATPgal values as tested by 
One Way ANOVA. Key: N.S. indicates not significant. 
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3.4  DISCUSSION 
 
As hypothesised, the bioenergetic profiles confirmed that ciPTECs were under the Crabtree 
effect and were mainly synthetizing ATP via glycolysis. The OCR was significantly 
upregulated in galactose conditions, hence galactose cultured ciPTECs were considerably 
more reliable on respiration at both 33°C and 37°C. Glycolytic activity, measured by looking 
at the ECAR, was also higher in glucose conditions. This is consistent with a higher ATP 
production anaerobically, as this pathway generates lactate in the cytosol and induces 
medium acidification. This trend is detectable at 24 h as well as 4 h after changing the 
medium. This suggests that in 4 h ciPTECs were able to readapt to the new energy source 
and modify their energetic metabolism correspondingly, which confirms that Kamalian, L., 
et al.’s variation of the medium replacement approach is also valid for our immortalised PT 
cell model. Subsequently, we can say that galactose medium confers the ability to bypass 
the Crabtree effect to ciPTECs in a short period of 4 h. Furthermore, the higher ECAR values 
observed at 33°C are most likely an indication that, at this temperature, ciPTECs need to 
derive even more energy from glycolysis as a quick ATP production route to maintain the 
high energy needs of rapid cell growth. In contrast, at 37°C the promoters that induce cell 
division are inactivated (Wilmer et al. 2010) and ciPTECs cell energy demand is 
downregulated.  
To take the metabolic characterisation further, the impact of rotenone on ciPTECs 
bioenergetic profile was analysed. The severe drop in OCR observed in glucose and 
galactose cultured ciPTECs indicated that rotenone could efficiently inhibit OXPHOS, as well 
as trigger a significant upregulation of glycolysis in glucose conditions. Conversely, no effect 
on the ECAR was detected in galactose cultured cells. Therefore, it can be reasoned that in 
normal glucose conditions and when respiration is inhibited, ciPTECs are able to upregulate 
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glycolysis as a compensatory mechanism to produce ATP. However, when lacking a 
profitable energetic source for glycolysis, galactose cultured cells cannot activate the 
anaerobic pathway to produce ATP. This will rapidly cause a breach in the basal energetic 
threshold and lead them to cell death. Therefore, in theory, galactose cultured ciPTECs 
should show an upgraded vulnerability to mitochondrial toxins compared to glucose 
conditions. It is also worth noting that other cell lines such as HepG2 did not show 
significant differences between both conditions until rotenone was added (Kamalian et al. 
2015). In contrast, here two significantly different bioenergetics configurations were 
discerned at basal conditions. Thus, ciPTECs have the potential to be and advantageous and 
highly reliable model to detect mitochondrial toxicity. 
Variations in mitochondrial distribution or morphology due to changes in energetic 
metabolism were also assessed. However, even though the mitochondria were more active 
in galactose conditions, no differences were observed using MitoSOX. This suggests that 
mitochondria do not need to adopt any rearrangements to increase their activity. 
Nonetheless, it has been proven before that this is not the case. In fact, Schmitt,S. et al. 
showed how “galactose mitochondria” from McA 777 cells appeared with increased matrix 
space and with better defined cristae structures, resembling typical rat liver mitochondria 
(Schmitt et al. 2013). It is also important to consider that although MitoSOX is advertised as 
a dye specifically targeted to mitochondria, it has been published that its selectivity is 
complicated due to autooxidation as well as other intracellular oxidation processes 
(Robinson et al. 2006). Therefore, electron microscopy should be applied to confirm any 
structural changes in the mitochondria.  
In light of addressing the second aim of this chapter and checking if galactose ciPTECs are 
more vulnerable to mitochondrial toxins, cell viability was analysed after rotenone 
exposure. As expected, when galactose ciPTECs were exposed to the complex I inhibitor, 
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ATP levels dropped significantly due to no alternative system to generate ATP. Moreover, 
extended exposure induced cell death due to a prolonged failure to sustain oxidative 
phosphorylation to meet basal energy needs. In contrast, since glucose grown cells can 
upregulate glycolysis as a compensatory mechanism of energy production, glucose ciPTECs 
remained perfectly healthy. Only after 24 h at the highest concentration, minor changes 
were detected that indicated the start of cell energy compromise. Previous studies have 
also shown similar glucose/galactose differences in other cell types (Kamalian et al. 2015). 
In summary, it was confirmed that galactose cultured ciPTECs are more vulnerable to 
mitotoxins, as they cannot sustain their basal energy needs once the mitochondria have 
been damaged.  
To validate rotenone results, antimicyin A (complex III inhibitor) was tested in the glucose 
vs. galactose model. Cisplatin and gentamicin were also tested as negative controls, as it is 
known that mitochondria play a role in their nephrotoxic mechanism but it is not the main 
toxicity target (Servais et al. 2008, Lopez-Novoa et al. 2011). Although it has been published 
that dissolving cisplatin in DMSO results in ligand displacement and reduces the cytotoxicity 
(Massart et al. 1993, Dernell et al. 1998), we still detected significant levels of ATP 
depletion. Cisplatin and gentamicin ATP dose response curves were completely overlapped 
compared to rotenone and antimycin A ATP curves. Therefore, the data confirmed that our 
glucose vs. galactose mitotoxicity model is able to discriminate between drugs that 
specifically target the mitochondria from other renal compounds that cause mitochondrial 
damage as a reflection of other detrimental pathways.  
Although gentamicin has been characterised as nephrotoxic and it is known that 
mitochondria play a role in its nephrotoxic mechanism (Servais et al. 2008, Lopez-Novoa et 
al. 2011), ATP levels did not reach 50% depletion after 4 days in culture. However, we have 
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demonstrated that gentamicin causes toxicity by impairing PT cell growth in a dose 
dependant manner. 
Once the model validation was concluded, we chose to submit TFV and its higher toxic 
analogue adefovir to mitochondrial toxicity evaluation. Both NtRTIs are known to cause PT 
toxicity with enlarged and dysmorphic mitochondria (Herlitz et al. 2010, Tanji et al. 2001). 
Therefore, these clinically relevant and presumable mitotoxic compounds were tested in 
our glucose vs. galactose model.  
First, adefovir toxicity was assessed in glucose vs. galactose conditions. Cells cultured in 
galactose medium demonstrated a significantly higher sensitivity in front of adefovir, as 
ATP levels dropped at a lower concentration of the drug. Comparing these data with the 
data obtained from rotenone or antimycin A, a similar but less pronounced tendency was 
observed. This suggests that adefovir is not only a PT toxin but also has mitochondria as one 
of the main toxicity targets. There is not yet any in vitro evidence showing this result. From 
these findings, a new thesis objective was established aiming to use the developed model 
to study the molecular mechanistic pathways leading to the observed mitotoxicity. 
Therefore, putative toxicity pathways will be discussed in Chapter 4 by investigating 
changes in mitochondrial respiration and OXHPOS complexes. 
After successfully identifying adefovir as a mitotoxic drug, a similar strategy was applied to 
detect TFV mitotoxicity. Although no changes were seen up to 8 days, after 15 days a small 
reduction in ATP content was observed, however it was not strong enough to confirm a 
clear cytotoxicity. Since in vivo renal toxicity only appears after prolonged TFV treatments 
(Hall 2013), these results were not unforeseen. Hence, longer incubations might be needed 
but these might not be compatible with in vitro cultures. A deeper analysis of TFV 
mitochondrial toxicity will be performed in Chapter 4. 
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TFV enters the cell through the same mechanisms as adefovir (Uwai et al. 2007) and 
therefore it was postulated that, although no toxicity had been previously detected, 
ciPTECs were uptaking the drug. In fact, the theory was confirmed by using a tritium 
radiolabelled version of the compound. However, this information is only relevant to 
confirm the uptake of the compound; data is not comparable between conditions because 
internalisation is dependent on cell number and cell volume and these two parameters vary 
for each situation and cell type.  
Mitochondrial distribution was reassessed after 15 days of TFV treatment in glucose 
medium. IF images showed some cells with localised mitochondria around the nucleus that 
had also lost the typical elongated tubules that formed an interconnecting network in 
healthy cells. When cells are under stress or before apoptosis is being triggered, 
mitochondrial fission is activated (Suen et al. 2008).  Furthermore, any changes in 
mitochondrial dynamics such as fission/fusion could influence cell bioenergetics and could 
be interpreted as an early sign of cell stress (Picard et al. 2013, Chen and Chan 2009).  More 
in detail results using electron microscopy would better elucidate structural and 
morphological changes. 
Finally, the classification established by Swiss, R. et al., was applied to the developed PT 
mitotoxicity model. Rotenone and antimycin A were correctly classified as mitochondrial 
toxins and cisplatin was also correctly categorised as not mitotoxic (EC50ATPglu/EC50ATPgal 
< 2). As discussed before, gentamicin ATP levels did not reach 50% depletion and as a result 
the ratio was defined as 1. Similar results were found with TFV after 15 days of dosing. 
Nevertheless, the method significantly classified adefovir again as a mitochondrial toxin; 
with an EC50ATPglu/EC50ATPgal ratio = 6.12 (p = 0.0049).  
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In conclusion, these findings represent a step forward towards refining in vitro models and 
eventually developing robust in vivo predictions that could be used during drug 
development to avoid organ specific toxicities. 
Future work should focus on further validating ciPTECs glucose vs. galactose mitotoxicity 
model by screening a larger pool of nephrotoxic as well as mitotoxic compounds. Swiss, R. 
et al, classification should be then applied to finally confirm that galactose cultured ciPTECs 
are a highly reliable model to identify renal mitochondrial toxicity. Moreover, it would also 
be interesting to use it as a tool to investigate the mechanism of toxicity for several drugs. 
Adefovir and TFV will be subjected to deeper evaluation in Chapter 4 in order to bring some 
mechanistic insight into their putative mitotoxicity pathways. 
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4.1  INTRODUCTION 
 
Within the previous chapter, we developed a screen using ciPTECs that was capable of 
detecting whether or not a compound will have a potential mitochondrial liability. This 
method was able to provide evidence, for the first time in vitro, that adefovir has mitotoxic 
potential. We also investigated this concept as part of the mechanism associated with TFV, 
a compound with a lower incidence of nephrotoxicity in man. We noted a slight 
downregulation in ATP levels but no clear cytotoxicity in this model. Therefore, more 
mitochondrial specific studies in ciPTECs could deliver important information about 
adefovir’s mitotoxicity pathway and help identify any signs of TFV mitochondrial 
impairment in our in vitro model.  
Causes of mitochondrial dysfunction are variable and include mtDNA depletion, generation 
of ROS, impairment of protein synthesis in the organelle, ETC inhibition and induction of 
mitochondrial permeability amongst others (Figure 4.1) (Dykens and Will 2007). 
Nonetheless, all of these mechanisms display the very same feature: an alteration in the 
Figure 4.16 Representation of some critical mitochondrial toxicity pathways. 
Mitochondrial function can be modulated in different ways, such as (1) electron transport 
chain inhibition, (2) induction of mitochondrial permeability, (3) generation of ROS, (4) 
mtDNA depletion or (5) impairment of protein synthesis.  
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respiratory parameters. As a consequence, mitotoxicity can be detected analysing changes 
in respiration, however, not all mitotoxic pathways affect the respiratory parameters 
equally and this must therefore be considered in a quantitative way. 
Studying the basic respiratory parameters can give insights from different aspects of 
mitochondrial function that may be applicable to understanding drug safety in man. 
Therefore, different mechanisms affecting mitochondrial toxicity will have a diverse impact 
on mitochondrial respiration, which will be represented as a modified cellular bioenergetic 
profile. The bioenergetic profile is built using a mitochondrial stress test, which is able to 
define mitochondrial function by a sequential addition of ETC inhibitors (Figure 4.2).  
The respiratory parameters forming the bioenergetic profile are: 
- Basal respiration: is the standard amount of oxygen used by cells in regular culture 
conditions. Variations in this parameter will be due to changes in ATP linked OCR, 
proton leak or non-mitochondrial respiration. 
- ATP linked respiration: is the amount of oxygen consumed to produce ATP. 
Changes in ATP linked respiration will indicate changes in ATP demand, which can 
be due to substrate availability or OXPHOS damage. 
- Proton leak: is the background level of protons (H+) that cross through the inner 
mitochondrial membrane. Proton leak can be affected by an uncoupling protein, 
impairment of the inner mitochondrial membrane or increased ion transport, which 
would dissipate the proton gradient.  
- Maximal Respiration: is the maximal OCR level that a particular cell line could 
reach if all mitochondria were functioning at 100% of their capacity. From here 
spare respiratory capacity can be derived, this is defined as the difference between 
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maximal respiration and basal respiration. Variations in this parameter could 
indicate changes in mitochondrial mass or integrity. Specifically, when a decrease is 
detected, it tends to be one of the first signs of mitochondrial impairment, as this 
parameter is closely linked to bioenergetic health.  
- Non-mitochondrial respiration (NMR): is the amount of oxygen consumed by 
external mitochondrial processes such as NADPH oxidases or lipoxygenases. An 
increase in NMR would indicate ROS formation in the cytosol, which could 
Figure 4.2 Schematic of the cellular bioenergetic profile. 
Time course representation of the mitochondrial stress test and breakdown into 
mitochondrial respiratory parameters. The first inhibitor added is oligomycin, which 
inhibits ATP synthesis by blocking the proton channel of complex V. Therefore, the OCR 
drops due to no ATP linked respiration. The second injection is FCCP, an uncoupling 
agent that permeates the inner mitochondrial membrane, giving free pass to protons 
(H+) and collapsing the membrane potential. This leads to a rapid consumption of energy 
and oxygen, without the generation of ATP. The third injection is a combination of 
rotenone (complex I inhibitor) and antimycin A (complex III inhibitor). This combination 
shuts down mitochondrial respiration and enables both the mitochondrial and non-
mitochondrial fractions contributing to respiration to be calculated. Each dot represents 
an OCR and ECAR measurement. 
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eventually cause mitochondrial dysfunction by targeting ETC complexes (Chacko et 
al. 2014, Hill et al. 2012).  
Another important mitochondrial parameter is the coupling efficiency, which measures the 
amount of ATP turnover in the mitochondria, compared to a baseline reading. If the 
coupling efficiency is depleted, that could be interpreted as a downregulated efficiency of 
the ETC complexes to produce ATP. Therefore, that would be translated into a loss of 
functionality from one or more OXPHOS complexes.  
 
4.1.1 Aims and hypothesis 
Hypothesis:  
The hypothesis under investigation within this chapter is that the molecular events 
underpinning both adefovir and TFV-induced mitotoxcity in ciPTECs could be determined by 
a thorough interrogation of cellular bioenergetics profiling.  
 
The aims of this chapter were to: 
 Implement the mitochondrial stress test in ciPTECs using Seahorse technology. 
 Use the information from the cellular bioenergetic profile to investigate the impact 
of adefovir on mitochondrial respiration. 
 Identify the molecular initiating events (MIEs) of adefovir-induced mitotoxicity. 
 Assess the bioenergetic profile after TFV exposure and see if there is any detectable 
mitochondrial damage. 
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4.2  MATERIALS AND METHODS 
4.2.1 Materials  
ciPTECs were obtained from the Department of Pharmacology and Toxicology in Radboud 
University Nijmegen (Nijmegen, Netherlands). Tissue culture reagents DMEM/F-12 (1:1), 
FBS, DFBS, PBS, MitoSOX™ Red Mitochondrial Superoxide Indicator, Hoechst 33342 and 
ProLong® Gold Antifade Mountant were purchased from Life Technologies (Paisley, UK). 
DMEM – F12 without glucose was purchased from Biowest (Nuaillé, France). Cover slides 
(13 mm ) were purchased from VWR (Lutterworth, UK) and microscope slides were 
obtained from Thermo Fisher Scientific (Loughborough, UK). Seahorse consumables were 
purchased from Seahorse Biosciences (North Billerica, MA, USA). Precision Plus 
Kaleidoscope Standards (molecular weight markers) and non-fat milk were purchased from 
Bio-Rad Laboratories Ltd (Hemel Hempstead, UK). Amersham Hybond ECL membrane and 
Amersham Hyperfilm ECL were purchased from GE Healthcare (Little Chalfont, UK). 
Western Lightning Plus-ECL was purchased from Perkin Elmer (Beaconsfield, UK). Total 
OXPHOS Human WB antibody cocktail was purchased from Abcam (Cambridge, UK). TFV 
was obtained from Toronto Research Chemicals Inc. (Toronto, Canada). All other reagents 
and chemicals were purchased from Sigma Aldrich (Dorset, UK) or Fisher Scientific 
(Loughborough, UK). 
 
4.2.2 Cell culture 
ciPTECs were cultured as described in Chapter 3.2.2.  
 
4.2.3 Cell dosing strategies 
Before performing the mitochondrial stress test, ciPTECs were dosed with different drugs. 
The selected time points were shorter than the ones used previously for ATP content since 
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mitochondrial impairment occurs before energy decline and the Seahorse-based 
technology works optimally with a monolayer to measure OCR and ECAR parameters 
accurately. Cisplatin was used as a model nephrotoxin that could act as a negative control 
for mitochondrial toxicity. Cells were seeded on a XF 96-well microplate in glucose growth 
medium with DFBS at 10,000 cells/well and dosed 24 h later with cisplatin for 24 h (0 μM, 
10 µM, 30 µM, 100 μM, 200 μM) in the same medium. The exact same seeding and dosing 
design was applied for adefovir and ciPTECs were dosed with 0 μM, 1 μM, 3 μM, 10 μM, 30 
μM and 100 μM of the compound. A different strategy was used for TFV. Cells were seeded 
in glucose growth medium with dialysed FBS at 500 cells/well and dosed 24 h later with TFV 
(0 μM, 10 µM, 50 µM, 100 μM, 200 μM, 300 μM) in glucose growth medium with DFBS. The 
medium was changed 4 h prior to dosing for glucose growth medium with DFBS. The cells 
were dosed for 15 days, the first 5 days ciPTECs were cultured at 33°C and the last 10 days 
they were transferred to 37°C to induce differentiation, which as a result gradually stops 
division (Wilmer et al. 2010). For TFV treatment, cells were re-dosed every 2 days. All final 
solvent concentrations were lower than 1% v/v. 
 
4.2.4 Mitochondrial stress test  
After dosing the cells (see 4.2.3 section) with cisplatin, adefovir or TFV, the medium was 
removed and the wells were washed x2 with pre-warmed XF Base Medium supplemented 
with L-glutamine (1% v/v), sodium pyruvate (1 mM) and 25 mM glucose; pH of 7.4. Then, a 
final volume of 175 µl of the same medium were added per well. Cells were left in a CO2 
free incubator at 37°C for 1 h while 25 µl of 8 µM oligomycin were loaded to port A, 25 µl of 
4.5 µM FCCP were loaded to port B and 25 µl of 10 µM rotenone and antimycin A solution 
were loaded to port C of each well of the sensor cartridge. Immediately after loading, the 
sensor cartridge was placed in the Seahorse instrument to calibrate. The calibration takes 
30 minutes and finished when the cells were ready to be analysed. When both the sensor 
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cartridge and the cell microplate were in the Seahorse instrument, the OCR and ECAR 
measurements started and were executed every 7 minutes. Three basal measurements 
were performed at the start. The oligomycin solution was then injected (port A) to the cells, 
followed by FCCP solution (port B) and finally rotenone and antimycin A solution (port C). 
Three measurements were recorded after each injection (Figure 4.2). 
 
 
4.2.5 Normalization of Seahorse data by BCA assay 
Seahorse data was normalised as described in Chapter 3.2.4.  
 
4.2.6 Seahorse data collection and analysis 
Data was recorded using Wave software from Seahorse Bioscience. Then, an Excel Macro-
Enabled Workbook was downloaded from the Seahorse Bioscience web page that allows to 
extract the data from the instrument and at the same time compute the respiration 
parameters. The third measurement after each injection was the one used to do the 
calculations as it is the most stable reading. Respiration parameters were calculated 
according to Table 4.1. 
 
Table 4.2 Description or formula for each respiration parameter 
PARAMETER DESCRIPTION / FORMULA 
Non mitochondrial respiration (NMR) = OCR 12
th
 reading 
Basal respiration = OCR 3
rd
 reading – NMR 
Proton leak = OCR 6
th
 reading – NMR 
ATP linked respiration = Basal respiration - Proton leak 
Maximal respiration = 9
th
 reading - NMR 
Spare respiratory capacity = Maximal respiration – Basal respiration 
Coupling efficiency (%) = (1 – (Proton leak/Basal respiration))x100 
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4.2.7 Western blotting – whole cell lysates 
For the measurement of the ETC complexes, ciPTECs were seeded in a 6-well plate at 5x105 
cells/well for adefovir treatment and at 5x104 cells/well for TFV treatment. ciPTECs were 
cultured at 33°C and dosed with different concentrations of adefovir (from 0 μM to 100 
μM) for 24 h. For TFV, ciPTECs were cultured for 5 days at 33°C in different concentrations 
of the NtRTI (from 0 μM to 300 μM) re-dosing every 2 days and then transferred to 37°C for 
10 days. After the drug treatment, cells were washed twice with 1 ml of cold PBS before 
lysis in 100 μl of RIPA buffer.  
 
4.2.8 Western blotting – protein quantification 
The total protein content of whole cell lysates was measured using the BCA assay. See 
Chapter 2.2.12.  
 
4.2.9 Western blotting 
To analyse the presence of the respiratory chain complexes after adefovir and TFV 
treatment, 20 µg of cell lysate from each condition were mixed with reducing agent and 
sample buffer and then denatured at 85°C for 5 minutes. Samples were then loaded onto 
10% acrylamide gels and proteins separated by electrophoresis in a Tris-Glycine running 
buffer. Proteins were then electro-transferred onto a nitrocellulose membrane using 20% 
MeOH buffer for 1 h at 80 V. Successful transfer and even loading was then checked using 
Ponceau Red. Membranes were washed with 0.1% Tween-TBS and blocked with 10% non-
fat milk overnight with shaking at 4°C. Next day, the membrane was incubated for 2 h at RT 
with a cocktail of mouse monoclonal antibodies for the OXPHOS complexes (1/500 in 10% 
milk). The membrane was then washed (4x 5 minutes) with 0.1% Tween-TBS before 
addition of secondary antibody anti-mouse IgG (1/10,000 in 10% milk) and incubation for 1 
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h at RT. The membrane was washed again with 0.1% Tween-TBS and treated with ECL 
reagent for 1 minute. Proteins were visualised using exposure to X-ray film. After 
developing, films were scanned using a densitometry scanner (GS800, Bio-Rad).  
 
4.2.10 Stripping and reprobing for β-actin 
To probe for β-actin (41.7 kDa), the membrane needs to be stripped first because the band 
would overlap with complex III (48 kDa). To do so, the membrane was submerged in 
stripping buffer and incubated for 30 minutes at 50°C. Then the membrane was washed (3x 
10 minutes) with 0.1% Tween-TBS and blocked with 10% non-fat milk for 1 h at RT. 
Incubation with mouse monoclonal anti-actin (1/10,000 in 10% milk) was performed for 1 
h. Membrane was then washed (4x 5 minutes) with 0.1% Tween-TBS and the secondary 
antibody anti-mouse IgG (1/10,000 in 10% milk) was incubated for 1 h also at RT. The 
membrane was washed again with 0.1% Tween-TBS and treated with ECL reagent for 1 
minute. Proteins were visualised using exposure to X-ray film. After developing, films were 
scanned using a densitometry scanner (GS800, Bio-Rad).  
 
4.2.11 Densitometry 
Densitometry was performed as described in section 2.2.14. 
 
4.2.12 ROS analysis - DHE incubation 
Cells were seeded at 4x104 cells/well in a 24-well plate and incubated at 33°C (5% CO2). 2 
days later, they were dosed with adefovir (0 μM, 0.5 μM, 1 μM, 10 μM, 50 μM) for 48 h at 
the same temperature. Then ciPTECs were washed with PBS and trypsinized to get a single 
cell suspension. Cells were washed with PBS and then resuspended with a 10 μM solution 
of dihydroethidium (DHE) and incubated at 37°C for 10 minutes protected from light. 
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Finally, the cell solution was transferred to FACS tubes and placed on ice protected from 
light. 
 
4.2.13 ROS analysis – Flow cytometry  
DHE fluorescence was analysed at 488 nm (excitation wavelength) and 512 nm (emission 
wavelength), which corresponds to the FL1-H channel on the flow cytometer instrument 
(FACSCalibur, BD Biosciences, Singapore). See Chapter 2.2.17 and 2.2.18 sections for further 
details. 
 
4.2.14 Detection of mitochondrial ROS 
MitoSOX was used to detect mitochondrial ROS levels after adefovir incubation. Cover 
slides (13 mm ) were placed in wells of a 24-well plate and coated with 0.5% of gelatine 
for 30 minutes. The gelatine was removed and ciPTECs were seeded at 4x104 cells/well and 
incubated at 33°C (5% CO2). After 48 h, they were dosed with adefovir (0 μM, 5 μM, 50 μM) 
for another 48 h. After the drug treatment, cells were washed twice with PBS and 
incubated with a 5 μM MitoSOX solution, also prepared in PBS, for 10 minutes protected 
from light. Then, the cells were washed 3x in warm PBS and fixed with 2% PFA for 15 
minutes at RT in the dark. Two more washes with PBS were performed after cells had been 
fixed. Finally, the cover slides were mounted on a microscope slide with Prolong Gold. 
Results were visualized at 63x magnification using an inverted fluorescence microscope 
(Axio Observer.Z1, Zeiss) with ApoTome (optical sectioning using structured illumination). In 
this experiment, samples could not be stained with DAPI or Hoechst to visualize the nuclei 
because the 396 nm excitation wavelength applied to visualise the MitoSOX compound 
would have also excited the nuclei dyes and both emission spectras would have 
overlapped.  
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4.2.15 Statistical analysis 
Statistical analysis of data was performed using StatsDirect software. All results were 
represented as the mean ± SEM or as the mean ± SD of three independent experiments. 
The choice of SEM vs. SD was only based on obtaining a better visual representation of the 
figures. Data was first assayed for normality using the Shapiro-Wilk test. When assaying 
differences amongst at least three groups, if data was normal, statistical analysis was 
performed using One Way ANOVA with Dunnet as a post-hoc comparison, as this test is 
specifically designed to compare each treatment against a single control. If there was no 
evidence of normality, Kruskal-Wallis test was applied instead. To test for differences 
amongst two groups, a t-test was performed if data was classified as normal and a Mann-
Whitney test when data showed no evidence of normality. Only when p values <0.05 the 
results were considered significant. 
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4.3  RESULTS 
4.3.1 Validation of ciPTECs mitochondrial respiration parameters 
Before analysing the mitochondrial effect of drugs based on changes in the respiratory 
parameters, a validation of the mitochondrial stress test was performed in normal 
conditions to confirm that ciPTECs would respond and follow the expected OCR pattern. 
One batch of cells was cultured for 24 h at 33°C and another one was cultured for 24 h at 
33°C plus 5 days at 37°C before performing the mitochondrial stress test. The validation 
time points were selected accordingly with previous experiments performed in Chapters 2 
and 3. 
The results confirmed that ciPTECs responded successfully to the injections of the different 
OXPHOS inhibitors and the OCR pattern was representative of a typical mitochondrial stress 
test (Figure 4.2). At both temperatures, the initial OCR had very similar levels (60 – 65 
pmol/min). After the addition of oligomycin (4th point), there was a marked decrease in 
OCR that was stable until FCCP was injected (7th point). Here, ciPTECs that had been 
cultured for 5 days at 37°C showed a greater maximal respiration, 25 pmol/min higher than 
at 33°C. Finally, when antimycin A and rotenone were added (10th point), the respiratory 
chain stopped working and oxygen consumption levels fell again leaving only a baseline of 
OCR resultant from oxidative procedures outside the mitochondria (Figure 4.3). 
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Figure 4.3 Mitochondrial stress test validation at 33°C and 37°C. 
ciPTECs were cultured at 33°C for 24 h and at 37°C for 5 days before performing the 
mitochondrial stress test with the Seahorse instrument. OCR is represented in pmol/min 
and readings were taken every 7 minutes. Oligomycin was added after the 3rd 
measurement, FCCP was added after the 6th measurement and antimycin A and rotenone 
were added after the 9th measurement. Data are mean ± SD (n = 3). 
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4.3.2 Effect of cisplatin toxicity on the respiratory chain 
Cisplatin (cis-diamminedichloroplatinum II) was chosen as a negative control to evaluate 
how a non-mitochondrial nephrotoxin would affect the established respiration parameters. 
However, although cisplatin causes toxicity through formation of DNA adducts and 
interfering with DNA synthesis (Wang and Lippard 2005), the mitochondria is believed to be 
a secondary target (Servais et al. 2008). The fact that possible mitochondrial impairment 
does not drive cisplatin toxicity was proven in Chapter 3 (Table 3.1).   
The Seahorse instrument requires a high level of cell confluence to measure OCR and ECAR 
parameters accurately. Therefore, the experiment was designed accordingly by dosing 
ciPTECs with cisplatin for 24 h at different concentrations; longer incubations would trigger 
cell death and loss of confluence. Furthermore, it was demonstrated in Chapter 3 that 
changes in ATP levels, and therefore mitochondrial respiration, happen before cell death. 
Hence we should be able to detect respiration changes with shorter dosing treatments. 
The respiratory parameters in Figure 4.4 were calculated following Table 4.1 guidelines and 
results were normalised to cell protein content. OCR due to ATP production was maintained 
around 5 pmol/min/μg protein up until 30 μM of cisplatin but the levels fell drastically to 2 
pmol/min/μg at higher concentrations (Figure 4.4 A). The spare respiratory capacity 
followed a similar pattern and oxygen consumption was significantly reduced at 100 μM 
and 200 μM (Figure 4.4 B). In contrast, the levels of consumed oxygen related to proton 
leak remained fairly stable for every single dose (Figure 4.4 C).  No significant differences 
were observed in the coupling efficiency either (Figure 4.4 D).  
Finally, the results at the 3rd point of the mitochondrial stress test were represented in a 
bioenergetic phenograph (Figure 4.5) to study the cell energetic metabolism in terms of 
ECAR. The data also corroborates that no significant changes in OCR or in ECAR could be 
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detected from 0 μM to 30 μM of cisplatin. However, at 100 μM or higher the oxygen 
consumption drops significantly but it is not followed by any modifications in ECAR.   
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Figure 4.4 Representation of mitochondrial respiration parameters after cisplatin 
exposure. 
ciPTECs were dosed with cisplatin for 24 h (0 - 200 μM) and then Seahorse technology 
was used to perform a mitochondrial stress test. The amount of consumed oxygen linked 
to ATP production (A), spare respiratory capacity (B) and proton leak (C) are represented 
in pmol/min/μg protein. The coupling efficiency (D) was also determined and it is 
represented as a percentage (%). Data are mean ± SD (n = 3). Statistical significance was 
determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.5 Bioenergetic profile of ciPTECs measuring OCR and ECAR at basal conditions 
after cisplatin exposure.  
Data was taken from the 3rd point in the mitochondrial stress test (basal conditions). A 24 
h exposure with cisplatin had taken place before the experiment. Only data from ciPTECs 
treated with 0 - 200 μM of cisplatin has been plotted to simplify the graph. OCR is 
represented in pmol/min/μg protein and ECAR is represented in mpH/min/μg protein. 
Data are mean ± SEM (n = 3). Statistical significance was determined by One Way ANOVA 
test, *p<0.05, **p<0.01, ***p<0.001. 
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4.3.3 Assessment of adefovir-induced mitochondrial perturbation via Seahorse analysis 
In Chapter 3, it was demonstrated using the glucose vs. galactose in vitro model that 
adefovir treatment of cells displays the typical characteristics of a mitotoxin. To find out a 
little bit more about adefovir’s toxicity mechanism in a PT cell line, ciPTECs were dosed with 
an adefovir dose response for 24 h and changes in the mitochondrial respiration 
parameters were analysed using the Seahorse instrument. Again, a 24 h experiment rather 
than the 3 day experiment from Chapter 3, was executed to avoid cell death and measure 
OCR and ECAR accurately. Although the incubation was shorter, it should be possible to 
detect alterations in the OCR as they appear before cells reach energetic compromise. The 
experiment was carried out in glucose conditions since, even though at a lower degree, the 
mitochondria are still producing ATP and also the presence of glucose in the medium allows 
to measure changes in the ECAR. 
Table 4.1 definitions were used to calculate the respiratory parameters in Figure 4.6 and 
data was normalised to protein content. The amount of oxygen used to produce ATP 
decreased proportionally with increasing adefovir concentration, becoming significant 
between 30-100 μM. The basal OCR decreased from 4.5 to 1 pmol/min/μg protein from 0 
to 100 μM, respectively (Figure 4.6 A). Moreover, the spare respiratory capacity did not 
show a clear dose response but a significant drop in OCR was observed at 10 μM as well as 
100 μM of adefovir. Surprisingly, oxygen consumption levels at 30 μM were not different 
from the control (Figure 4.6 B). As observed previously with cisplatin, the amount of oxygen 
fated for proton leak processes was stable (Figure 4.6 C). Nevertheless, the coupling 
efficiency was significantly reduced from 80% to less than 60% from control cells to 100 
μM, respectively (Figure 4.6 D). 
Data from the 3rd time point in the mitochondrial stress test was plotted to generate a 
bioenergetic profile: OCR vs. ECAR (Figure 4.7). At basal conditions, a dose-dependent 
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decrease in OCR was detected, which correlated with the tendency seen for OCR linked to 
ATP production (Figure 4.6 A).  However, instead of detecting no change in ECAR, as it was 
observed with cisplatin (Figure 4.5) or an increase as observed with rotenone (Figure 3.6), a 
non-significant tendency towards ECAR downregulation was detected (Figure 4.7). 
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Figure 4.6 Representation of mitochondrial respiration parameters after adefovir 
exposure. 
CiPTECs were dosed with adefovir for 24 h (0 - 100 μM) and then Seahorse technology 
was used to perform a mitochondrial stress test. The amount of consumed oxygen linked 
to ATP production (A), spare respiratory capacity (B) and proton leak (C) are represented 
in pmol/min/μg protein. The coupling efficiency (D) was also determined and it is 
represented as a percentage (%). Data are mean ± SD (n = 3). Statistical significance was 
determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.7 Bioenergetic profile of ciPTECs measuring OCR and ECAR at basal conditions 
after adefovir exposure. 
Data was taken from the 3rd point in the mitochondrial stress test (basal conditions). A 24 
h exposure with adefovir had taken place before the experiment. Only data from ciPTECs 
treated with 0 μM, 30 μM and 100 μM of adefovir has been plotted to simplify the graph. 
OCR is represented in pmol/min/μg protein and ECAR is represented in mpH/min/μg 
protein. Data are mean ± SEM (n = 3). Statistical significance was determined by One Way 
ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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4.3.4 Quantification of respiratory chain complexes after adefovir treatment 
In light of the downregulation in ATP linked respiration and the decrease in coupling 
efficiency demonstrated with adefovir treatment, we decided to look at the protein level of 
various mitochondrial respiratory chain complexes.  Coupling efficiency was defined as a 
measure for the ATP turnover. Therefore, impairment in this parameter would indicate that 
one or more OXPHOS complexes have been targeted as part of the mechanism. To check if 
the altered functionality is due to a quantitative depletion of the mitochondrial redox 
carriers, a western blot was performed.  
After the 24 h treatment with adefovir, the western blotting results demonstrated no 
obvious differences in protein expression of complex V, III or II compared with the control. 
No noticeable differences could be observed for complex IV either. Nevertheless, complex I 
expression was qualitatively lower at 30 µM and 100 µM compared to control (0 µM) 
(Figure 4.8 A). Complex I results were corroborated by densitometry (Figure 4.8 B), where a 
50% decrease in band density was determined. Moreover, a slight depletion of complex IV 
levels was also detected at 30 µM and 100 µM (15-20% reduction). 
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Figure 4.8 Western blotting (A) and densitometry (B) of the electron transport chain 
complexes after 24 h of adefovir treatment in ciPTECs. 
CiPTECs were incubated with adefovir (0 - 100 μM) for 24 h. Equal amounts of protein 
were separated by SDS-PAGE from whole cell RIPA lysates. The presence of OXPHOS 
complex I (18 kDa), complex II (29 kDa), complex III (48 kDa), complex IV (22 kDa) and 
complex V (54 kDa) was determined by western blot and compared to a β-actin loading 
control (A). Densitometry of complex I and IV was performed by ImageJ software and the 
relative density of the complexes was normalized to the relative density of the 
corresponding β-actin band. Data are mean ± SEM (n = 3). Statistical significance was 
determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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4.3.5 Investigating the role of ROS in adefovir-induced mitotoxicity 
To further explore the mechanism of adefovir-induced mitotoxicity, we decided to 
determine whether or not ROS could be generated by the treatment of ciPTECs with this 
compound. Drug-induced oxidative stress has been implicated as a key contributor for 
mechanistically different toxicities such as cisplatin or azidothymidine toxicity, a nucleoside 
reverse transcriptase inhibitor (Deavall et al. 2012). Therefore, it would be plausible to 
think that adefovir exposure could elevate cellular ROS and cause oxidative stress that 
could eventually lead to mitochondrial dysfunction and cell death. 
ROS levels in glucose and galactose conditions were analysed using 10 μM of DHE after cells 
were treated with adefovir for 48 h (Figure 4.9). A dose-dependent increase in ROS was 
observed reaching values greater than 2-fold between 10 - 50 μM adefovir in glucose 
cultured cells. In galactose medium, ciPTECs also had a dose-dependent increase up to 3-
fold of ROS compared to basal glucose levels and up to 2-fold compared to basal galactose 
levels. It was also worth noting that under control conditions (0 μM), ciPTECs produced a 
significantly higher amount of ROS in galactose conditions compared to glucose.  
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Figure 4.9 Analysis of ROS levels by DHE fluorescence. 
ROS levels were determined after 48 h with adefovir (0 - 50 μM) in glucose and 
galactose conditions. Glucose data and galactose at 0 μM are compared to glucose 
control (*). Galactose data is compared to galactose control (+). Data are mean ± 
SD (n = 3). Statistical significance was determined by One Way ANOVA test when 
data was compared to the control and a t-test to analyse the significance between 
both controls (0 μM), *p<0.05, **p<0.01, ***p<0.001.  
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4.3.6 Mitochondrial ROS assessment 
Having identified elevated cellular levels of ROS during adefovir exposure and knowing that 
oxidative stress can also cause mitochondrial dysfunction, we decided to specifically look at 
ROS accumulation inside the mitochondria itself. 
ciPTECs were cultured for 48 h with exposure to adefovir at 0 μM (Figure 4.10) and 5 μM 
(Figure 4.11) in glucose conditions and later stained with MitoSOX (mitochondrial 
superoxide indicator). Two different excitation wavelengths were used to visualise 
superoxide (O2
.-) production. Cells were excited with a traditional 510 nm wavelength, 
according to manufacturer’s guidelines, and with a 396 nm wavelength to improve the 
selectivity of superoxide-oxidised MitoSOX (Robinson et al. 2006). No differences were 
observed between 0 and 5 μM at 510 nm in terms of fluorescence intensity. However, 
when looking at the images taken at 396 nm, distinctive colour intensification was detected 
at 5 μM of adefovir, which should correspond to an increase in mitochondrial superoxide 
levels. Unexpectedly though, the fluorescence pattern observed at 396 nm was different 
from 510 nm. At 510 nm it was distinguishable where the nuclei would fit in as a roundish 
less fluorescent area was appreciated in each cell. Instead, at 396 nm the fluorescence was 
more intense at the same nuclei area, which questions the specificity of the results. 
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Figure 4.10 Detection of mitochondrial superoxide in control conditions. 
ciPTECs were cultured without adefovir for 48 h and then stained with MitoSOX. Cells 
were visualised at 510 nm and 396 nm excitation wavelength. Images were taken 
using a 63x objective with the ApoTome. Scale bar is 10 μm. Data is representative of 
n = 3 experiments.    
Ex = 510 nm Ex = 396 nm 
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Figure 4.11 Detection of mitochondrial superoxide after 48 h with adefovir (5 μM). 
ciPTECs were cultured with 5 μM of adefovir for 48 h and then stained with MitoSOX. 
Cells were visualised at 510 nm and 396 nm excitation wavelength. Images were 
taken using a 63x objective with the ApoTome. Scale bar is 10 μm. Data is 
representative of n = 3 experiments.    
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4.3.7 Effect of cisplatin and adefovir in mitochondrial biogenesis in vitro 
Mitochondrial biogenesis can be triggered after an episode of oxidant injury that has led to 
mitochondrial loss (Rasbach and Schnellmann 2007), which as a result accelerates the 
return of mitochondrial functions (Funk et al. 2010). As we have previously demonstrated, 
adefovir caused oxidative stress in ciPTECs after 48 h of treatment; therefore we reasoned 
that mitochondrial biogenesis could also be induced as a counteractive mechanism of 
cellular oxidant damage. 
Here, we applied the strategy of Beeson et al. in ciPTECs to use Seahorse technology as a 
high-throughput respirometric assay to assess the role of mitochondrial biogenesis. Their 
method is based on using FCCP-uncoupled OCRs as a marker of mitochondrial biogenesis by 
comparing them with basal OCRs. Ergo, a stable basal OCR after compound exposure but 
with an enhanced FCCP-uncouple OCR would indicate that cells possess a higher spare 
respiratory capacity as a result of increased mitochondrial number (Beeson et al. 2010).  
A negative control experiment was first performed with cisplatin (Figure 4.12). Cells were 
dosed with cisplatin for 24 h and then analysed with Seahorse. No significant differences 
between FCCP-uncoupled OCRs were identified at 10 μM or 30 μM compared to the 
control. A decrease in basal OCR was seen at 30 μM and a strong reduction of both OCRs 
was seen at 100 μM (Figure 4.12). 
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Figure 4.12 Respirometric measurement of mitochondrial biogenesis after cisplatin 
exposure. 
A 24 h cisplatin treatment was performed in ciPTECs (0 - 100 μM). Basal and FCCP-
uncoupled OCRs (in pmol/min/μg protein) were analysed with Seahorse technology and 
normalized to basal OCR of untreated wells. Results are expressed as a percentage (%) 
compared to the basal. Data are mean ± SEM (n = 3). Statistical significance was 
determined by Kruskal–Wallis test, *p<0.05. An asterisk (*) represents a statistically 
significant difference from control basal. A cross (+) represents a statistically significant 
difference from control FCCP-uncoupled.  
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Based on these findings and to evaluate mitochondrial biogenesis after adefovir treatment, 
we followed the same protocol used with cisplatin. Cells were dosed with adefovir for 24 h 
and then changes in respiration were analysed with Seahorse. At the lowest concentrations 
(1 - 10 μM), no significant differences were observed in basal OCRs compared to the control 
and the same result was detected for FCCP-uncoupled OCRs compared to their control 
(Figure 4.13). The only significant changes were seen at 30 μM, where both basal and FCCP-
uncoupled OCRs suffered a substantial reduction. In summary, the lack of enhanced FCCP-
uncoupled OCRs indicated that no mitochondrial biogenesis was taking place after adefovir 
exposure. 
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Figure 4.13 Respirometric measurement of mitochondrial biogenesis after adefovir 
exposure. 
A 24 h adefovir treatment was performed in ciPTECs (0 - 30 μM). Basal and FCCP-
uncoupled OCRs (in pmol/min/μg protein) were analysed with Seahorse technology and 
normalized to basal OCR of untreated wells. Results are expressed as a percentage (%) 
compared to the basal. Data are mean ± SEM (n = 3). Statistical significance was 
determined by Kruskal–Wallis test, *p<0.05. An asterisk (*) represents a statistically 
significant difference from control basal. A cross (+) represents a statistically significant 
difference from control FCCP-uncoupled.  
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4.3.8 Investigating TFV toxicity using Seahorse technology – early signs of mitochondrial 
dysfunction? 
In Chapter 3 we established that no signs of mitotoxicity could be detected after 15 days of 
TFV incubation in the glucose vs. galactose ciPTECs model. We observed a 20% -25% 
downregulation of cellular ATP levels at the highest concentration investigated (100 μM). 
To further explore the mechanistic basis of potential mitochondrial involvement in TFV 
toxicity, we measured in ciPTECs potential variations on the respiration parameters and on 
the ECAR after 15 days of TFV treatment using the Seahorse technology.  
The definitions described in Table 4.1 were used to calculate the respiratory parameters in 
Figure 4.14 and data was normalised to protein content. At every concentration, respiration 
linked to ATP production (Figure 4.14 A) was much lower than the values obtained after 24 
h with adefovir (Figure 4.6 A). Furthermore, the amount of oxygen consumed remained 
stable over the investigated TFV dose response (Figure 4.14 A). No substantial changes 
were observed on the spare respiratory capacity, proton leak or coupling efficiency (Figure 
4.14 B, C, D). The first two parameters (Figure 4.14 A, B) also displayed lower oxygen 
consumption levels than in adefovir dose response treatment (Figure 4.6). 
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Figure 4.14 Representation of mitochondrial respiration parameters after TFV exposure 
in glucose conditions. 
ciPTECs were dosed with tenofovir for 15 days (0 - 300 μM) and then Seahorse 
technology was used to perform a mitochondrial stress test. The amount of consumed 
oxygen linked to ATP production (A), spare respiratory capacity (B) and proton leak (C) are 
represented in pmol/min/μg protein. The coupling efficiency (D) is represented as a 
percentage (%). Data are mean ± SD (n = 3). Statistical significance was determined by 
One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001 
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The typical respiration parameters did not confer any extra information regarding possible 
mitochondrial toxicity. Nonetheless, in Figure 4.15 a dose-dependent increase on ECAR 
values could be identified, which were preserved for the duration of the Seahorse 
experiment. Specifically, at 200 μM of TFV the ECAR was around 1.5 units (mpH/min/μg 
protein) higher than the control cells, which provides some evidence that TFV treated cells 
developed a higher glycolytic activity. 
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Figure 4.15 Measurement of ECAR throughout Seahorse experiment after TFV 
exposure. 
ciPTECs were dosed with tenofovir for 15 days at different concentrations (here only 
represented 0 μM, 50 μM and 200 μM) and then Seahorse technology was used to 
perform a mitochondrial stress test. The extracellular acidification rate was measured 
throughout the test and it is represented in mpH/min/μg protein. Data are mean ± 
SEM (n = 3). 
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4.3.9 Quantification of respiratory chain complexes after TFV treatment 
Having analysed the activity and respiration parameters derived from the OXPHOS 
complexes, we examined if we could detect any quantitative variations at a protein level 
after TFV exposure as we had observed with adefovir. The western blotting results (Figure 
4.16) did not reveal any alterations in protein content for any respiratory chain complex 
along the different TVF concentrations. β-actin levels confirmed a stable loading.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16 Western blotting of the ETC complexes after 15 days of TFV 
treatment in ciPTECs. 
ciPTECs were incubated with TFV (0 μM - 300 μM) for 15 days. Equal amounts 
of protein were separated by SDS-PAGE from whole cell RIPA lysates. The 
presence of OXPHOS complex I (18 kDa), complex II (29 kDa), complex III (48 
kDa), complex IV (22 kDa) and complex V (54 kDa) was determined by western 
blot and compared to a β-actin loading control. Data are representative of 
three independent experiments. 
Chapter Four 
 
151 
 
4.4  DISCUSSION 
 
Cellular bioenergetics have been previously investigated using Seahorse technology in other 
cell types such as HepG2 cells to demonstrate their importance in mitochondrial toxicity 
(Kamalian et al. 2015). However, this was the first time that a PT line such as ciPTECs was 
successfully energetically interrogated.  
Based on the OCR pattern described at both 33°C and 37°C, ciPTECs energetic metabolism 
in basal conditions was concordant with other established cell lines (Dott et al. 2014, 
Chacko et al. 2014). However, as highly aerobically poised cells, in vivo energy requirements 
of PT cells would probably differ from the pattern observed and present a much higher 
FCCP stimulated rate (Hill et al. 2012). 
Before looking into the perturbation of respiratory parameters by adefovir and TFV, we 
analysed the bioenergetic changes triggered by a renal non-mitotoxic compound such as 
cisplatin. Even though ATP-linked OCR and spare respiratory capacity were affected, that 
could be attributed to OXPHOS damage caused by ROS and activation of the apoptotic 
intrinsic pathway (Servais et al. 2008). In contrast, since the anticancer drug has not been 
described to have uncoupling effects or to target a particular complex, it was expected that 
mitochondrial permeability and coupling efficiency would be unaffected. Moreover, the 
observed failure to upregulate glycolysis by ciPTECs after cisplatin treatment might be an 
indication that the apoptotic mechanism had already been activated and the cell energetic 
metabolism was focused on other pathways (Brdiczka et al. 2006). 
In light of addressing which mitochondrial mechanism was responsible for adefovir 
mitotoxicity, ciPTECs cellular bioenergetics were thoroughly interrogated. Although the 
repercussions in respiratory parameters were quite similar to the ones observed in the 
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negative control, a distinctive decrease in the coupling efficiency indicated that one or 
more respiratory complexes had been hampered and the ETC efficiency downregulated as a 
result. Protein levels of the ETC complexes showed that, in fact, the decrease in coupling 
efficiency could be due to a lower protein content of complexes I and IV. It is known that 
electron transport chain complexes have a mix of nuclear and mitochondrial encoded 
subunits (Figure 4.17), and in particular complex I and complex IV are the only two 
complexes with an important mtDNA encoded core (Schon et al. 2012). Therefore, if 
adefovir was either targeting mtDNA as Tanji et al. postulated (Tanji et al. 2001) or 
mitochondrial protein synthesis as other NRTIs (Dykens and Will 2007), the most affected 
complexes would most likely be complex I and IV, as the lack of mitochondrial subunits 
would not allow protein assembling and they would be degraded by the mitochondrial 
protein quality control system (Amm et al. 2014, Fox 2012). To confirm which of the two 
hypotheses is actually taking place, further experiments would be required. Levels of 
mtDNA could be measured by qPCR as well as levels of mitochondrial mRNA. Furthermore, 
ciPTECs could be dosed with a mitochondrial protein synthesis inhibitor, such as 
Figure 4.17 Mitochondrial encoded subunits of the ETC complexes. 
The ETC complexes are encoded by nuclear and mitochondrial DNA. The subunits encoded 
by mtDNA are represented in a different colour and the names have been added. Complex 
I has 7 mtDNA subunits compared to 39 from the nDNA (7/39), complex II has 0/4, complex 
III has 1/10, complex IV has 3/10 and complex V has 2/14 (Schon et al. 2012). 
I II III IV V 
Chapter Four 
 
153 
 
oxazolidinones (McKee et al. 2006), and western blotting results should be compared with 
the ones obtained after adefovir exposure.  
As seen with other retroviral agents (Deavall et al. 2012), DHE results confirmed that 
oxidative stress via ROS production also plays a role in adefovir toxicity. In addition, the 
galactose-dependent increase in ROS levels corroborated a greater activity of the ETC 
(Brand et al. 2004). In most cell types, mitochondria are one of the highest contributors to 
the generation of ROS through the generation of unpaired electrons in OXPHOS, which 
interact with oxygen and form superoxide ions (Duchen 2004). However, the specificity of 
the IF results was questionable due to a higher nuclei fluorescence at 396 nm and ROS 
increased production could not be directly associated to the mitochondria. Other 
experiments using new methods for mitochondrial ROS detection such as hydroxylamine 
spin probes could be applied to tackle this problem (Dikalov and Harrison 2014). 
Additionally, to test the significance of ROS in adefovir toxicity, it would be interesting to 
incubate ciPTECs, prior and during adefovir exposure, with clinically relevant ROS 
scavengers such as N-acetyl cysteine (NAC) (Sun 2010, Bavarsad Shahripour et al. 2014) and 
measure if a delay in toxicity or ATP levels depletion could be detected. Moreover, to take 
things a step further, the type of ROS, such as superoxide or peroxides, responsible for 
oxidative stress could be identified using ROS fluorescent sensors (Dikalov and Harrison 
2014). 
It is known that, after an event of oxidative stress that leads to mitochondrial loss, a cell 
response can be activated capable of inducing mitochondrial biogenesis to recover full 
organelle functionality (Rasbach and Schnellmann 2007, Funk et al. 2010). Although we 
previously showed that adefovir induces oxidative stress, no mitochondrial biogenesis was 
detected. We followed the same dosing strategy as Beeson et al., when he showed some 
compounds capable of inducing biogenesis after 24 h. Nevertheless, adefovir might need a 
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longer exposure time (48 h) to produce a strong enough oxidant injury to ciPTECs and some 
recovery time for the cells to react and induce mitochondrial biogenesis.  
The impact of TFV, a less toxic nucleotide analogue of adefovir but highly used in the clinic 
(Herlitz et al. 2010), on the respiratory parameters was also assessed. Even though the 
effect of TFV on ATP levels was investigated in Chapter 3 without any clear indication of 
mitotoxicity, we were interested in determining whether we could detect any changes at a 
molecular level. The stable level of ETC complexes supported the theory that some NtRTIs 
might induce mitochondrial injury through a mechanism that is distinct from inhibiting DNA 
polymerase- (Ross 2014). However, to confirm this hypothesis, mtDNA should be 
quantified through qPCR. Moreover, Seahorse results did not match the slight ATP 
reduction observed in Chapter 3. Instead, levels of ATP-linked OCR were quite low and no 
variations compared to control were detected. One theory to explain it would be that TFV 
hampers cell growth, and that is why the not normalised results from Chapter 3 showed 
lower amounts of total ATP. Hence, when the results are normalised to protein content the 
difference disappears. However, if what TFV actually hinders is protein synthesis (Zhang et 
al. 2015), normalising the Seahorse results to protein content would show misleading 
information. Specifically, in this case, it would look like ciPTECs were producing more ATP 
than they actually were. To address this issue, a simple solution would be to normalise the 
data against cell number. For the same reason, western blotting results might have not 
been representative. If ciPTECs are in fact not generating enough ATP, the shift towards 
higher levels of ECAR (dependant on TFV concentration) to upregulate glycolysis energy 
production fits with the metabolic energetic scenario.  
In summary, these results represent the first step to perform further mitotoxicity related 
studies and to explore different mitochondrial toxicity pathways from other nephrotoxic 
compounds. Therefore, future studies will be designed to elucidate some key features of 
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the adefovir and TFV metabolism and toxicity. Uptake and metabolism of both NtRTIs could 
be assessed through mass spectrometry, which would give an idea of the concentration 
inside the cells compared to the extracellular dose. It would also be interesting to look at 
changes in membrane potential using a fluorescent probe (JC-1) or to analyse cytochrome c 
release with IF. Moreover, a collaboration has been established with the intention of 
repeating these experiments on ciPTECs that overexpress human OAT1 and OAT3, which 
are the key transporters involved in adefovir and TFV uptake (Uwai et al. 2007).  
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5.1 INTRODUCTION 
 
The existence of a distinct stem cell population in the kidney that would be responsible for 
repopulating the damaged tubule area after injury is highly controversial. It was first 
accepted that the source of the cells capable of repairing injured nephrons was intrinsic and 
not derived from other niches such as bone marrow-derived stem cells (Vogetseder et al. 
2008, Humphreys et al. 2008). Nonetheless, it was unclear if the repopulating cells were 
differentiated PT cells that were able to dedifferentiate and start proliferating to repair the 
damage, or alternatively, there was a latent progenitor/stem cell population responsible for 
the repair. Using a co-labelling strategy, Humphreys et al. brought some light on the matter 
by confirming that any surviving cell was able to proliferate and restore the tubules 
(Humphreys et al. 2011). However,  the same year, another study appeared to contradict 
this work by  demonstrating that there was a scattered population of PT cells within the 
tubules that co-expressed CD24 and CD133 and displayed stem/progenitor characteristics 
in vitro (Lindgren et al. 2011). In addition, it was later shown that when SCID mice with 
acute tubular injury were injected intravenously with CD24 and CD133 positive cells, these 
double positive cells would engraft into the kidney, help tubular repair and cause a 
significant improvement in renal function (Angelotti et al. 2012). 
Since the isolation of the first designated progenitor cells from urine (Zhang et al. 2008), 
other groups have claimed that they were able to isolate urine-derived stem cells (USCs) of 
kidney origin (Wu et al. 2011, Bharadwaj et al. 2011).  Even though Bharadwaj and 
colleagues confirmed the presence of cells at varying stages of differentiation in human 
urine, which supports the concept described by Humphreys et al., they were able to 
differentiate the urine-derived cells into the three germinal lineages, including neurogenic 
and urothelial cells. These data therefore demonstrated that these cells had stem cell 
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features (Bharadwaj et al. 2013). Furthermore, the simple cost-effective isolation 
technique, their high reprogramming efficiency and their excellent differentiation potential, 
promoted the generation of induced pluripotent stem cells (iPSCs) from urine-derived 
progenitor cells (UPCs) (Zhou et al. 2012, Zhou et al. 2011).  
The studies described in the preceding chapters were first designed to use the already 
characterised ciPTECs in Chapter 2 as a control for future pharmacological assays in newly 
developed PT lines. These new PT cell lines were supposed to have originated from kidney 
stem/progenitor cells (KSPCs) isolated from kidney tissue that had been differentiated using 
specific medium treatments and biomaterials into PT cells. However, the isolation of KSPCs 
using CD133 and CD24 markers and their differentiation by collaborative groups within our 
Institution suffered several unexpected delays. Despite this inconsistency, we decided to 
follow the published protocol of Zhang et al. to pursue the isolation of progenitor/stem 
cells from urine to later differentiate them into PT cells that may ultimately be utilised as 
predictive in vitro toxicological models (Figure 5.1). Although differentiation experiments 
have been previously performed in these types of cells (Bharadwaj et al. 2013), the 
possibility to attain a PT fate had not been explored. To do so, we chose to follow a 
protocol designed for human embryonic stem cells (Narayanan et al. 2013). 
 
 
 
 
 
 
 
 
 
Figure 5.1 Schematic of the strategy to develop a patient-specific proximal tubule model 
from urine cultures. 
The first step (1) would consist of isolating the cells from a urine sample and culture them 
to get a single urine-derived progenitor cell (UPC) in one well, which is key to generate a 
clonal cell line. Then, (2) after detecting a colony formation, UPCs would be expanded and 
characterised. Finally, (3) a proximal tubule (PT) differentiation treatment should be 
applied to obtain PT-like cells, which would be functionally tested against ciPTECs. 
 
1 2 3 
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We postulated that if the isolation and differentiation treatment were successful, given that 
individuals often respond differently to the same drug, the differentiated PT-like cells might 
become a powerful tool to analyse patient-specific nephrotoxicity. In comparison, the 
published ciPTEC lines, and their pharmacological/toxicological response, previously used in 
preceding chapters may only be typical of a subset of the human population. Additionally, 
autologous urine-derived progenitor/stem differentiated PT cells could potentially be 
obtained from patients in whom renal injury can be anticipated, and hence be used in the 
future for the development of personalised medicine. 
 
5.1.1 Aims and hypothesis 
Hypothesis:  
Many published and developed renal cell lines available poorly predict in vivo toxicity due 
to low metabolic competence and low transporter expression. Over recent years, this 
problem has been circumvented to some extent by the generation of conditionally 
immortalised PTCs (ciPTECs). Nevertheless, urine is also a good and non-invasive source of 
kidney cells as well as UPCs. Therefore, we aim to test the hypothesis that UPCs can be 
derived and differentiated into PT cells from different donors and retain efficient 
transporter expression that can be used to establish patient-specific models for in vitro 
nephrotoxicity exploration. 
 
The aims of this chapter were to: 
 Isolate and characterise UPCs from different donors. 
 Direct the differentiation of isolated UPCs towards PT cells. 
 After differentiation, perform a phenotypical characterisation and apply the 
functional assays developed in Chapter 2 to evaluate if the PT differentiated UPCs 
have acquired functionality levels similar to ciPTECs.    
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5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Urine was obtained from healthy volunteers with informed ethical consent obtained for 
studies to be conducted within the Centre for Drug Safety Science, University of Liverpool. 
Conditionally immortalised podocytes were obtained from Saleem et al. group in Bristol, 
UK. RNA from human kidney tissue was obtained from the Department of Cellular and 
Molecular Physiology, University of Liverpool (Liverpool, UK). Tissue culture reagents 
Hamm’s F12 medium, keratinocyte serum free medium, FBS, bovine pituitary extract, PBS 
as well as Hoechst 33342, ProLong® Gold Antifade Mountant, CellTracker™ Green CMFDA 
Dye, BMP2, BMP7, qPCR reagents and primers, DNase treatment, reverse transcription 
reagents, Alexa Fluor® 594 Goat Anti-Mouse IgG2b and Alexa Fluor® 488 Goat Anti-Rabbit 
IgG were purchased from Life Technologies (Paisley, UK). QIAzol Lysis Reagent was 
purchased from QIAGEN (Manchester, UK). Cover slides (13 mm ) were purchased from 
VWR (Lutterworth, UK). Microscope slides, chloroform, isopropyl alcohol (IPA) and absolute 
ethanol were obtained from Thermo Fisher Scientific (Loughborough, UK). Renal epithelial 
cell growth medium (REGM) Bulletkit was purchased from Lonza (Slough, UK). Activin A was 
purchased from R&D Systems (Abingdon, UK). CD133/1 and CD24 antibodies for flow 
cytometry were purchased from Miltenyi Biotec (Surrey, UK). Synaptopodin mouse 
monoclonal antibody was obtained from PROGEN (Heidelberg, Germany). Podocin rabbit 
monoclonal antibody was purchased from Abcam (Cambridge, UK). Megalin mouse 
monoclonal antibody was obtained from Acris (Herford, Germany). All other reagents and 
chemicals were purchased from Sigma Aldrich (Dorset, UK). 
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5.2.2 Cell culture 
Urine derived cells were cultured in a mixture of keratinocyte serum free medium and 
progenitor cell medium in a 1 : 1 ratio (Zhang et al. 2008), that we will refer to as urine stem 
cells medium. Keratinocyte medium was supplemented with EGF (5 ng/ml), bovine pituitary 
extract (50 ng/ml), cholera toxin (30 ng/ml) and penicillin-streptomycin solution (1% v/v). 
Progenitor medium is a mixture of 75% DMEM and 25% Hamm’s F12 medium and it was 
also supplemented with FBS (10% v/v), hydrocortisone (0.4 μg/ml), cholera toxin (10-10 M), 
insulin (5 ng/ml), adenine (1.8x 10-4 M), transferrin (5 μg/ml), 3,39,5-triiodo-L-tyronine (2x 
10-9 M), epidermal growth factor (10 ng/ml) and penicillin-streptomycin solution (1% v/v).  
 
5.2.3 Isolation of urine derived cells 
Sterile fresh mid-stream urine samples (50 – 200 ml) were collected from a total of 5 
healthy volunteers aged from 18 to 30 years old. No morning urine was used and the 
volunteers were asked to drink 500 ml of water before sample collection to favour cell 
shedding (Zhou et al. 2012). The isolation of urinary cells was performed using a 
combination of Zhou et al. (2012) and Bharadwaj, S. et al. (2013) procedures. Briefly, 
immediately after collection, urine was transferred to 50 ml falcon tubes and spun down at 
1000 rpm for 5 minutes inside a sterile environment. Carefully, the supernatant was 
aspirated leaving around 1 ml of urine in the tube. The pellets were gently resuspended and 
then pooled down to a single 50 ml falcon tube. Cells were later washed twice by adding 
PBS up to 50 ml and centrifuged at 1000 rpm for 5 minutes. Finally, the supernatant was 
discarded, leaving only around 0.2 ml of PBS, the pellet was gently resuspended and 6 – 12 
ml (depending on the pellet size) of the urine stem cells medium was added. Straight after, 
0.5 ml of the cell solution were seeded per well in a 24-well plate and left at 37°C (in 5% 
CO2) for 3 days (Figure 5.2).  
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5.2.4 Cell cloning and proliferation 
After 3 days in culture, the medium was changed for fresh urine stem cell medium and after 
that it was changed again every other day. Differentiated squamous epithelial cells did not 
stick to the well surface. Therefore, they were eventually washed away and only putative 
progenitor cells would remain, which in our study represented less than 1% of the total cell 
pellet obtained from urine. Colonies did not start appearing until a week later.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 Schematic of the isolation process and propagation of UPCs. 
The first step was a sterile isolation of cells contained in urine followed by an initial 
culture in urine stem cells medium. Colonies started appearing a week later. In this stage, 
colonies were at passage 0 (P0). The next step was a clone selection, where only the 
wells that contained one colony were transferred to a 6-well plate. This was considered 
passage 1 (P1). Finally, a last step of propagation for each colony was performed by 
transferring the colony to a T75 flask. From passage 2 (P2) onwards, urine progenitor 
cells were propagated in T75 flasks. 
Fresh 
urine 
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Once spotted, they were left to grow until they occupied at least half of the well in the 24-
well plate. Only wells that contained a single colony were harvested by trypsin collection 
and then transferred to one well of a 6-well plate. Since colonies come from a single cell, 
this can be considered a cloning step. Once the cells occupied 90% of the well, they were 
transferred to a T75 flask. After that, cells were split in ¼ to different T75 every time the 
confluence reached 90% (Figure 5.2).  
 
5.2.5 Clonogenicity assay  
To detect the capacity of urine-derived progenitor colonies to generate a colony from a 
single cell, a single cell solution was prepared (1 cell/100 μl) and 100 μl/well were added in 
a 96-well plate. The urine stem cell medium was changed 2 days later and after that 
changed every other day. Wells that contained no cells or more than one cell were not 
used. After 10 days, we counted the wells that had a colony of cells and divided them by 
the total number of wells initially containing 1 cell. Finally, clonogenicity was expressed as a 
percentage.  Other studies call it plating efficiency (PE) but the formula used is the same 
(Franken et al. 2006): 
 Clonogenicity =
no. colonies formed
no. cells seeded − no. failed wells  
× 100% 
 
5.2.6 Preparation of UPCs for flow cytometry  
UPCs were detached to form a cell suspension and distributed in various microfuge tubes 
(around 2x105 cells in each) to analyse different characterisation markers. The cells with the 
microfuge tubes were spun down at 2000 rpm for 3 minutes. The supernatant was 
aspirated and the pellet was resuspended in 30 μl of FACS buffer (0.1% of NaN3 and 1% BSA 
in PBS). Then, 3 μl per antibody were added (if analysing co-expression they were added 
together) and samples were incubated for 10 minutes in the dark at 4°C. After incubation, 
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200 μl of FACS buffer was added per microfuge tube and samples were centrifuged again 
(2000 rpm, 3 minutes). The supernatant was carefully aspirated and cells were resuspended 
in 100 μl of FACS buffer and transferred to FACS tubes. Samples were finally analysed in the 
flow cytometer (FACSCalibur, BD Biosciences). 
 
5.2.7 Flow cytometry data analysis 
Data was analysed using Flowing Software. From the general cloud of particles, the 
population that represented single cells was selected, excluding debris and duplets of cells. 
Then, the percentage of cells expressing a determined marker was calculated by 
representing the control population (no antibodies added) in a histogram and selecting an 
area on the right edge of the control peak. Next, the sample incubated with antibodies was 
represented in the same histogram and the cells that fell into this area were considered 
positive for the analysed marker. Finally, the software was able to plot them in a combined 
dot plot and expresses each marker as a percentage from the single cell population. 
 
5.2.8 RNA isolation 
See methods described in Chapter 2.2.3. 
 
5.2.9 DNase treatment of RNA 
See methods described in Chapter 2.2.4. 
 
5.2.10 Reverse transcription 
See methods described in Chapter 2.2.5. 
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5.2.11 Quantitative real-time PCR (qPCR) 
 See methods described in Chapter 2.2.9. 
 
5.2.12 Differentiation towards a PT state 
The PT differentiation medium used was based on that published by Narayanan, K. et al. 
(2013). The medium was composed of renal epithelial cell growth medium (REGM) plus 
Bulletkit supplements and it was additionally supplemented with BMP2 (10 ng/ml), BMP7 
(2.5 ng/ml), activin A (10 ng/ml) and retinoic acid (0.1 μM).  
UPCs in a T75 flask were split 1/9 and seeded in T25 flasks. After 24 h, the medium was 
changed for PT differentiation medium in one T25 and for urine stem cells medium in 
another T25, this was established as day 0. A third T25 was used to isolate the mRNA from 
day 0. The medium was changed every day and on day 3 mRNA was isolated from both 
flasks.  
 
5.2.13 Assessment of MRP2/4 and P-gp function using CMFDA dye   
UPCs in a T75 flask were split 1/3 and seeded in a 96-well plate. After 24 h, the medium was 
changed for PT differentiation medium in one plate and for urine stem cells medium in 
another plate. The medium was changed again every 24 h for 3 days. On the last day, an 
experiment using CMFDA dye was performed to analyse the function of MRP2, MRP4 and 
P-gp. See Chapter 2.2.19 section for the assay details. 
 
5.2.14 Immunofluorescence (IF) 
Cover slides (13 mm ) were placed in wells of a 24-well plate and coated with 0.5% of 
gelatine for 30 minutes. The gelatine was removed and cells were seeded at 4x104 
cells/well. The plate was incubated for 72 h at 37°C (5% CO2). Cells were washed 3x in warm 
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PBS and fixed with 4% PFA for 10 minutes at RT. Then, cells were washed again with PBS 3x 
and later permeabilised with PBS containing 0.2% Triton X-100 for 10 minutes at RT. Cells 
were washed 2x with PBS and blocked for 1 h with 10% serum (from the animal the 2nd 
antibody had been raised in) diluted in PBS. Primary antibodies were then added in PBS 
solution containing 10% serum and 0.1% Triton X-100 O/N at 4°C in the dark using the 
following dilutions: 
- Megalin mouse monoclonal (1/300) 
- Podocin rabbit monoclonal (1/500) 
- Synaptopodin mouse monoclonal (no dilution) 
After an overnight incubation, cells were washed 3x with PBS and later incubated with the 
secondary antibodies in PBS solution containing 10% serum and 0.1% Triton X-100 for 2 h at 
4°C in the dark using the following dilutions: 
- Goat anti-mouse (1/500, 594 nm) 
- Goat anti-rabbit (1/500, 488 nm) 
After the incubation, 3x washes with PBS were applied and then the nuclei were stained 
with 2 μg/ml of Hoechst 33342 for 10 minutes at RT protected from light. Finally, after 3 
more washes with PBS, the cover slides were mounted onto a microscope slide with 
Prolong Gold. Results were visualized at 40x magnification using an inverted fluorescence 
microscope (Axio Observer.Z1, Zeiss). 
 
5.2.15 Statistical analysis 
Statistical analysis of data was performed using StatsDirect software. All results were 
represented as the mean ± SEM or as the mean ± SD of three independent experiments. 
The choice of SEM vs. SD was only based on obtaining a better visual representation of the 
figures. Data was first assayed for normality using the Shapiro-Wilk test. When assaying 
differences amongst at least three groups, if data was normal, statistical analysis was 
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performed using One Way ANOVA with Dunnet as a post-hoc comparison, as this test is 
specifically designed to compare each treatment against a single control. If there was no 
evidence of normality, Kruskal-Wallis test was applied instead. To test for differences 
amongst two groups, a t-test was performed if data was classified as normal and a Mann-
Whitney test when data showed no evidence of normality. Only when p values <0.05 the 
results were considered significant.   
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5.3 RESULTS 
5.3.1 Morphological characterization and evolution of UPC colonies over passages 
In order to isolate UPCs, different urine collections were performed as described previously. 
Published methods have shown that the success rate to isolate this type of cell was very 
low (Zhang et al. 2008). These observations were also supported by our analysis showing 
that the vast majority of isolated colonies (90%) were incapable of continual proliferation 
past passage 5. However, based on their cobblestone-like morphology and high growth 
rates, we identified 3 colonies from 3 different healthy individuals that displayed 
progenitor-like qualities and could be kept in culture for up to 10 - 11 passages.  
One of the typical features described for a progenitor colony was a uniform and compact 
cluster of cells at the origin of the colony formation (Zhang et al. 2008). To analyse the 
morphology of different colonies at their generation and at later passages, phase contrast 
images were taken with an inverted microscope (Eclipse TS100, Nikon). Colonies A and C 
(Figure 5.3 A and Figure 5.5 A) were good examples of a compact cell formation, both 
showed how the origin of the clone was a compact cluster of cells that displayed smooth 
and well-defined edges. These features were in concordance with what had been defined in 
a previous report as type I colonies (Zhou et al. 2012). Particularly, the image from Figure 
5.3 A was taken after 6 days of seeding and no more than 20 cells could be counted at that 
stage. The daily monitoring of the wells allowed us to establish that the colony had 
originated from a single cell, as such a cell cluster could not be detected after the initial 
seeding. Colony A yielded millions of cells passages later. In the same image, remaining 
squamous cells could still be observed. They were not attached to the well and did not 
divide; they were eventually washed away after consecutive medium changes (Suppl. 
Figure 5.1). Figure 5.5 A was taken 2 weeks after seeding, just before splitting the cells to 
the next passage, and a much bigger cluster of cells could be appreciated. The formation of 
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colony B occurred close to the edge of the well and the picture was therefore not as clear 
due to light refraction limitations (Figure 5.4 A). However, a more scattered arrangement 
could still be seen, which would classify the colony as type II (Zhou et al. 2012). The two 
different cell morphology classifications were also detected on the formation of other 
colonies (Suppl. Figure. 5.2 - 5.3), which stopped proliferating before passage 5. 
Regarding the general morphology of these 3 clonal cell lines, after passage 0 they all 
exhibited a slightly elongated rice grain shape but became cobblestone-like when 
confluent, forming a compact monolayer (Figure 5.3 – 5.5). Cells stayed small in size up 
until passage 8. After this stage, they started to slow down division and become bigger by 
increasing the area of the cytoplasm. At passage 10, nearly all the cells had stopped division 
and were clearly bigger compared to other passages (Figure 5.3 E, 5.4 E and 5.5 E). 
Exceptionally, in some areas a subpopulation of smaller cells were detected and although 
they were still able to divide and resembled the same cells at a lower passage, they 
ultimately differentiated (Figure 5.4 E).  
The population doubling times represented in Table 5.1 were very similar for all 3 colonies 
(32.1 h to 33.6 h).  
 
 
 
 
 
 
 
 
 
Chapter Five 
 
171 
 
Colony A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
E 
P0 P1 
P2 P7 
P10 
Figure 5.3 Evolution of colony A morphology.  
These phase contrast images were taken just before splitting the colony. (A) The 
image regarding the formation of the colony at passage 0 was taken using a 10x 
objective. Black arrows mark squamous cells and the white arrow marks the urine 
progenitor-like colony. Scale bar is 100 μm. The other images were taken at (B) 
passage 1, (C) passage 2, (D) passage 7 and (E) passage 10 using a 4x objective. Scale 
bar is 100 μm. 
 
Squamous 
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Colony B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
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E 
P0 P1 
P2 P7 
P10 
Figure 5.4 Evolution of colony B morphology 
These phase contrast images were taken just before splitting the colony. Image (A) 
captures the formation of the colony and the other images were taken at (B) passage 
1, (C) passage 2, (D) passage 7 and (E) passage 10 using a 4x objective. (E) The arrow 
marks a subpopulation of smaller cells. Scale bar is 100 μm. 
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Colony C 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5 Evolution of colony C morphology 
These phase contrast images were taken just before splitting the colony. Images were 
taken at (A) passage 0, (B) passage 1, (C) passage 2, (D) passage 7 and (E) passage 10 
using a 4x objective. Scale bar is 100 μm. 
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Table 5.1 Cell growth parameters calculated from passage 2 to passage 8. 
 
Average cell 
split rate 
(splits/week) 
Split ratio 
Population 
doubling time 
Colony A 1.25 1/4 33.6 h 
Colony B 1.31 1/4 32.1 h 
Colony C 1.27 1/4 33.1 h 
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5.3.2 Clonogenic capacity of UPCs  
Clonogenicity represents the ability of a single cell within a population to self-renew and 
undergo unlimited division. This capacity of self-renewal is one of the key features that 
define stem cells, whereas progenitor cells only preserve the clonogenic properties for a 
limited number of passages. Our previous results highlighted that the isolated colonies 
were not able to proliferate past passage 10 or 11, therefore we decided to calculate how 
the clonogenic capacity declined over passages. 
Cells were diluted to obtain a single cell solution and seeded in a 96-well plate. A week 
later, the number of colonies were counted and expressed as a percentage of clonogenicity 
(Table 5.2). While the cell growth was still exponential (passage 6), colony B presented a 
clonogenicity percentage of 31.91%. Nevertheless, at higher passages this percentage 
decreased considerably. At passage 8, colony A displayed a clonogenic capacity of 8.23% 
and only  3.37% of colony C cells retained the capacity to produce colonies at passage 9. 
 
Table 5.2 Overview of clonogenic capacity (%) over passages. 
 Clonogenicity (%) Colonies/valid wells  
Colony A (P8) 8.23% 7/85 
Colony B (P6) 31.91% 30/94 
Colony C (P9) 3.37% 3/89 
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5.3.3 Isolated urine progenitor colonies have a kidney origin 
To rule out the possibility that the isolated urine colonies were of urothelial origin instead 
of originating from the kidney, we analysed the expression of UPK1A via qPCR. UPK1A is 
expressed in the urothelium which comprises ureter, bladder and urethra, but not in the 
kidneys (Wu et al. 2009).  
cDNA from ureter cells was isolated and used as a positive control to evaluate UPK1A 
expression. A ∆Ct value of 12.28 ± 0.046 was obtained in these cells. Instead, no UPK1A 
expression was detected in the tubular fraction or in any of the isolated colonies (Table 
5.3).  
 
 
Table 5.3 UPK1A mRNA detection by qPCR in ureter cells, in a tubular fraction and in 
colonies A, B and C. 
Data are mean ± SD (n = 3). Key: “--“ indicates undetermined value. 
 
 
 
 
 
 
 
 
 
 
 
 Ureter cells Tubular fraction Colony A Colony B Colony C 
∆Ct value ± 
SD 
12.28 ± 
0.046 
-- -- -- -- 
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5.3.4 Assessment of CD133 and CD24 co-expression 
Co-expression of CD133 and CD24 has been previously linked to a population of renal 
stem/progenitor cells in the human adult kidney (Lindgren et al. 2011). CD133 is a 
glycoprotein widely expressed in immature cells as well as in differentiated cells. However, 
we used an antibody for the human glycosylated epitope CD133/1, which has only been 
detected in immature cells (Corbeil et al. 2000, Kemper et al. 2010).  In contrast, CD24 is 
only detected in immature cells and absent in differentiated ones (Shirasawa et al. 1993). 
To assess if these 2 markers were also expressed in our UPC colonies, we used flow 
cytometry to screen for the presence of both markers on the cell surface at different 
passages.  
Flow cytometry was performed for each colony at passage 6 and passage 9 to assess any 
variations in the co-expression of both markers at a high proliferative state compared to 
the cell growth plateau.  
 
 
 
 
 
 
 
 
 
 
 
 
Colony A 
Figure 5.6 Flow cytometric analysis of CD24 vs. CD133 in colony A. 
Cells from colony A at (A) passage 6 and (B) passage 9 were represented in a combined dot 
plot divided in 4 quarters. The top left quarter represents cells only positive for CD24 
(CD24+), the bottom left quarter represents negative cells, the bottom right quarter holds 
the cells only positive for CD133 (CD133+) and the top right quarter contains the double 
positive cells (CD24+ and CD133+). 
Passage 6 Passage 9 
A B 
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Table 5.4 Statistics data from colony A flow cytometric analysis.  
 
 
 
 
 
 
 
 
A very high percentage of colony A cells were CD24+ at both passages. However, only 1.25% 
were single positive for CD133 and a 13.87% were double positive. This decreased to 0.87% 
and 4.53% respectively at passage 9 (Table 5.4). Therefore, cells lost their CD133 expression 
at the highest passage, while increasing their expression of CD24. This shift in the markers 
expression can be clearly observed in Figure 5.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD24+ CD133+ CD133+ & CD24+ 
Passage 6 70.93% 1.25% 13.87% 
Passage 9 94.51% 0.06% 4.53% 
Colony B 
Passage 6 Passage 9 
A B 
Figure 5.7 Flow cytometric analysis of CD24 vs. CD133 in colony B. 
Cells from colony B at (A) passage 6 and (B) passage 9 were represented in a combined dot 
plot divided in 4 quarters. The top left quarter represents cells only positive for CD24 
(CD24+), the bottom left quarter represents negative cells, the bottom right quarter holds 
the cells only positive for CD133 (CD133+) and the top right quarter contains the double 
positive cells (CD24+ and CD133+). 
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Table 5.5 Statistics data from colony B flow cytometric analysis.  
 
 
 
 
 
 
The expression of CD133 and CD24 in colony B was quite different from colony A. Double 
negative cells comprised the 72.4 – 73.8% of the whole cell population and only around 1% 
of cells were CD24+ and CD133+ (Table 5.5). Moreover, the expression barely changed 
between passages (Figure 5.7). Around 30% of the cells were only CD24 positive and around 
2% only CD133 positive (Table 5.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD24+ CD133+ CD133+ & CD24+ 
Passage 6 31.29% 1.96% 1.37% 
Passage 9 29.31% 2.36% 0.75% 
Colony C 
A B 
Passage 6 Passage 9 
Figure 5.8 Flow cytometric analysis of CD24 vs. CD133 in colony C. 
Cells from colony C at (A) passage 6 and (B) passage 9 were represented in a combined dot plot 
divided in 4 quarters. The top left quarter represents cells only positive for CD24 (CD24+), the 
bottom left quarter represents negative cells, the bottom right quarter holds the cells only 
positive for CD133 (CD133+) and the top right quarter contains the double positive cells (CD24+ 
and CD133+). 
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Table 5.6 Statistics data from colony C flow cytometric analysis.  
 
 
 
 
 
 
 
Finally, colony C was the only one with a very high percentage of double positive cells. 
Precisely, 98.53% of cells co-expressed CD24+ and CD133+ at passage 6 and 98.58% of cells 
co-expressed CD24+ and CD133+ at passage 9. Scarcely any cells were positive for only one 
of the markers (Table 5.6). As it can be appreciated in Figure 5.8, the expression pattern 
was maintained even when the cell growth rate slowed down (passage 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CD24+ CD133+ CD133+ & CD24+ 
Passage 6 1.05% 0.21% 98.53% 
Passage 9 1.29% 0.12% 98.58% 
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5.3.5 Changes in kidney markers expression throughout passages 
To check if there were any differences in gene expression at different stages of the in vitro 
culture, we assessed the mRNA levels of different kidney markers over passages. We 
theorised that, as progenitors, the colonies might start differentiating towards the cell type 
that they were programmed to be and this would be reflected in a time-dependent manner 
by the expression of specific markers.  
RNA was isolated from every other passage, starting at passage 1 for colony A and passage 
3 for colonies B and C. After retrotranscription to cDNA, qPCR was performed using the 
same TaqMan Gene Expression Assays from Chapter 2. Genes that gave no amplification 
signal were not represented. Amongst them there was WT1, a gene linked to kidney 
progenitor cells during development (Kreidberg 2010), the expression of which could not be 
detected in colony A (Figure 5.9) and only at passage 3 in colony C (Figure 5.11). In colony 
A, the expression of most of the tested genes remained the same, but a significant increase 
in the expression levels of AQP1 and SYNPO was observed over time, while the expression 
levels of AQP3 decreased. In colony B, WT1 expression was more than a 100 times higher 
than the expression from the tubular fraction (Figure 5.10). In conjunction with P-gp and 
AQP3, WT1 expression visibly decreased over passages. On the other hand, OATP4C1 mRNA 
levels increased. In colony C, MRP2 expression significantly decreased over passages and 
although not significantly, so did BCRP. P-gp levels decreased and later recovered at 
passage 9. In contrast, a general increasing tendency was detected for AQP1, CUBN and 
SYNPO (Figure 5.11). See Appendix 6 for Ct numbers. 
Furthermore, at the first passage, 4 out of 7 PT markers in colony A had similar mRNA levels 
compared to the PT fraction at passage 2. The mRNA expression was higher when analysed 
at passage 3. In this case, 5 out of 7 markers showed a similar expression for colony A and 
B, however in colony C the expression of the analysed PT genes was equal or even higher 
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than the tubular fraction. Additionally, even though SYNPO levels appeared elevated 
compared to the levels detected in the cells from the tubular fraction, a similar expression 
level was detected for ciPTECs in Chapter 2 (Figure 2.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 5.9 Relative expression of kidney markers in colony A throughout passages. 
The relative expression of PT genes as well as other kidney markers in colony A was 
analysed by qPCR at passage 1 (P1), passage 3 (P3), passage 5 (P5) and passage 7 (P7). Gene 
names are displayed under each set of bars. Data was normalised against a human tubule 
fraction at passage 2 (P2). Data are mean ± SEM (n = 3). Statistical significance was 
determined amongst passages by Mann-Whitney test, *p<0.05. 
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Colony B 
Figure 5.10 Relative expression of kidney markers in colony B throughout passages. 
The relative expression of PT genes as well as other kidney markers in colony B was 
analysed by qPCR at passage 3 (P3), passage 5 (P5), passage 7 (P7) and passage 9 (P9). Gene 
names are displayed under each set of bars. Data was normalised against a human tubule 
fraction at passage 2. Data are mean ± SEM (n = 3). Statistical significance was determined 
amongst passages by Mann-Whitney test, *p<0.05. 
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Figure 5.11 Relative expression of kidney markers in colony C throughout passages. 
The relative expression of PT genes as well as other kidney markers in colony C was 
analysed by qPCR at passage 3 (P3), passage 5 (P5), passage 7 (P7) and passage 9 (P9). Gene 
names are displayed under each set of bars. Data was normalised against a human tubule 
fraction at passage 2. Data are mean ± SEM (n = 3). Statistical significance was determined 
amongst passages by Mann-Whitney test, *p<0.05. 
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5.3.6 Effect of PT differentiation: random or colony specific? 
After analysing the gene expression of all 3 colonies, we decided to investigate whether or 
not the fate of these cells could be directed towards better differentiated PT cells. 
Considering that in their basal medium quantitatively good expression of PT genes was 
observed (Figure 5.9 - 5.11), we hypothesised that these progenitor colonies might have 
already been committed to the PT lineage and the differentiation treatment would, 
therefore, be more effective.  
Cells from all 3 colonies at passage 6 were cultured for 3 days in the PT differentiation 
medium used by Narayanan et al. for human embryonic stem cells and compared to the 
same cells cultured for 3 days in their urine stem cell medium (control). After the 
treatment, all 3 isolated urine colonies in differentiation media exhibited a much more 
elongated morphology (Figure 5.12 A, Figure 5.13 A, Figure 5.14 A) compared to control 
cells, which had a more cobblestone-like shape (Figure 5.12 B, Figure 5.13 B, Figure 5.14 B). 
Nevertheless, the expression of PT markers showed extensive variation between colonies. 
Successfully, in colony A the expression of MRP4, P-gp, BCRP and OATP4C1 was significantly 
upregulated in differentiated cells compared to control cells at day 0 and at day 3. MRP2 
was also significantly upregulated compared to day 0 (Figure 5.12 C). The other PT genes 
had no significant changes in their mRNA levels.  
With respect to colony B, only MRP2 and CUBN were upregulated and WT1 downregulated, 
compared to day 0. No significant positive changes were seen at day 3 between both 
conditions. In contrast, P-gp and OATP4C1 mRNA levels were significantly higher in control 
cells at day 3 (Figure 5.13 C).  
Finally, colony C data showed that only BCRP was significantly upregulated after 3 days in 
PT compared to both controls. MRP4, OATP4C1 and CUBN were also upregulated in both 
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medium conditions after 3 days compared to day 0. Instead, P-gp and AQP1 expression was 
significantly upregulated in day 3 control cells (Figure 5.14 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter Five 
 
187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
Figure 5.12 Differentiation of colony A towards a PT state. 
UPCs from colony A at passage 6 were cultured for 3 days in a medium that induces 
differentiation towards a PT state. Pictures were taken at (A) day 3 in control medium and 
(B) day 3 in PT differentiation medium using a 4x objective. Scale bar is 100 μm. (C) qPCR 
analysis of the relative expression of PT genes at day 0, day 3 in control medium and day 
3 in PT differentiation medium compared to a tubular fraction (P2). Statistical significance 
was determined by Mann-Whitney test, *p<0.05. 
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A B Day 3 Ctrl Day 3 PT Diff 
C 
Figure 5.13 Differentiation of colony B towards a PT state. 
UPCs from colony B at passage 6 were cultured for 3 days in a medium that induces 
differentiation towards a PT state. Pictures were taken at (A) day 3 in control medium and 
(B) day 3 in PT differentiation medium using a 4x objective. Scale bar is 100 μm. (C) qPCR 
analysis of the relative expression of PT genes at day 0, day 3 in control medium and day 
3 in PT differentiation medium compared to a tubular fraction (P2). Statistical significance 
was determined by Mann-Whitney test, *p<0.05. 
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Colony C 
A B Day 3 Ctrl Day 3 PT Diff 
C 
Figure 5.14 Differentiation of colony C towards a PT state. 
UPCs from colony C at passage 6 were cultured for 3 days in a medium that induces 
differentiation towards a PT state. Pictures were taken at (A) day 3 in control medium and 
(B) day 3 in PT differentiation medium using a 4x objective. Scale bar is 100 μm. (C) qPCR 
analysis of the relative expression of PT genes at day 0, day 3 in control medium and day 
3 in PT differentiation medium compared to a tubular fraction (P2). Statistical significance 
was determined by Mann-Whitney test, *p<0.05. 
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5.3.7 Analysis of PT transporters activity 
Using the same CMFDA assay developed for the ciPTECs in Chapter 2, we assessed whether 
or not isolated UPCs exhibited any functionality for MRP2, MRP4 and P-gp transporters 
after 3 days in their growth medium and after 3 days in PT differentiation medium.  
All 3 isolated colonies generated a significant increase in CMFDA accumulation after the 
addition of both inhibitors in control and PT differentiated cells, which confirmed the 
presence and functionality of MRP2/4 and P-gp in these cell lines (Figure 5.15 – 5.17). 
Whereas the levels of fluorescence were low and did not surpass 2-fold in any case, the P-
gp results were very similar to the ones observed for ciPTECs in Chapter 2 (Figure 2.14). 
Furthermore, although the control vs differentiated fluorescence was similar in all graphs, 
colony A differentiated cells demonstrated a slightly greater functionality levels of MRP2/4 
at 1.56 μM and 3.13 μM of MK571 (Figure 5.15 A) and colony B differentiated cells 
displayed a higher function for P-gp at 1.48 μM, 4.44 μM and 13.33 μM of PSC833 (Figure 
5.16 B). At the highest concentration of MK571, an unexpected decrease in fluorescence 
could be detected in all 3 UPCs, but not for PSC833 inhibitor. Overall, the differentiated 
cells did not exhibit greater levels of PT transporters functionality compared to their 
control. 
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Figure 5.15 Study of MRP2, MRP4 and P-gp function in colony A. 
One set of colony A cells were cultured in their own medium for 3 days and another set in 
PT differentiation medium also for 3 days. Then they were both incubated in CMFDA 
solution (1.25 μM) with (A) increasing concentrations of MK571 (MRP inhibitor) or (B) 
increasing concentrations of PSC833 (P-gp inhibitor). Data are represented in fold change 
and compared to the control (0 μM). Data are mean ± SEM (n = 3). Statistical significance 
was determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.16 Study of MRP2, MRP4 and P-gp function in colony B. 
One set of colony B cells were cultured in their own medium for 3 days and another set in 
PT differentiation medium also for 3 days. Then they were both incubated in CMFDA 
solution (1.25 μM) with (A) increasing concentrations of MK571 (MRP inhibitor) or (B) 
increasing concentrations of PSC833 (P-gp inhibitor). Data are represented in fold change 
and compared to the control (0 μM). Data are mean ± SEM (n = 3). Statistical significance 
was determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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Figure 5.17 Study of MRP2, MRP4 and P-gp function in colony C. 
One set of colony C cells were cultured in their own medium for 3 days and another set in 
PT differentiation medium also for 3 days. Then they were both incubated in CMFDA 
solution (1.25 μM) with (A) increasing concentrations of MK571 (MRP inhibitor) or (B) 
increasing concentrations of PSC833 (P-gp inhibitor). Data are represented in fold change 
and compared to the control (0 μM). Data are mean ± SEM (n = 3). Statistical significance 
was determined by One Way ANOVA test, *p<0.05, **p<0.01, ***p<0.001. 
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5.3.8 Spontaneous podocyte differentiation or pre-established fate? 
As previously mentioned, not all the isolated colonies displayed progenitor characteristics. 
In fact, most of the cells stopped dividing before passage 5 and exhibited an enlarged 
cytoplasm that mirrored a podocyte morphology (Shankland et al. 2007). From colony D to 
H, we could observe flat cells with interdigitating processes and different sizes of arborized 
cytoplasms (Figure 5.18 – 5.22). Some cells reached nearly 400 µm in diamater (it has been 
shown that they can reach 500 µm diameter in vivo (Saleem et al. 2002)). Moreover, some 
of the cells were multinucleated, (marked by arrows in Figure 5.19 and Figure 5.20). It is 
important to note that no specific medium treatment was performed; cells suddenly 
slowed down division and stopped proliferating once they adopted a podocyte phenotype. 
This development occurred at different points during tissue culture. For instance, colony G 
cells started the podocyte differentiation at passage 4 (Figure 5.21), while cells from colony 
H started differentiation towards podocytes as soon as passage 1 (Figure 5.22).  
 
Colony D  
 
 
 
 
 
 
 
 
 
 
A B 
Figure 5.18 Colony D revealed podocyte-like features at passage 3. 
The colony stopped division at passage 3 and changed its morphology resembling 
podocyte-like cells. Images were taken using (A) 4x and (B) 10x objectives. Scale bar is 
100 μm. 
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Colony E 
 
 
 
 
 
 
 
 
 
 
 
Colony F  
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
 
Figure 5.19  Colony E revealed podocyte-like features at passage 4. 
The colony stopped division at passage 4 and changed its morphology resembling 
podocyte-like cells. Picture B is an amplified image of the delineated square in A. The 
arrow marks a binucleated cell. Images were taken using (A) 4x (scale bar is 100 μm) and 
(B) 20x objectives (scale bar is 50 μm). 
A B 
Figure 5.20  Colony F revealed podocyte-like features at passage 4. 
The colony stopped division at passage 4 and changed its morphology resembling 
podocyte-like cells. The arrows mark cells with more than 1 nucleus. Images were taken 
using a 20x objective. Scale bar is 50 μm. 
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Colony G  
 
 
 
 
 
 
 
 
 
 
Colony H 
 
 
 
 
 
 
 
 
 
 
We pursued some further characterisation of colonies D and E to assess if the podocyte 
morphology was also supported by the expression of podocyte markers. We performed IF 
for podocin and synaptopodin as well as qPCR to analyse the mRNA expression of some 
podocyte genes. 
Figure 5.21  Colony G revealed podocyte-like features at passage 4. 
The colony stopped division at passage 4 and changed its morphology resembling 
podocyte-like cells. Images were taken using (A) 4x and (B) 10x objective. Scale bar is 
100 μm. 
A B 
Figure 5.22  Colony H revealed podocyte-like features at passage 1. 
The colony stopped division at passage 1 and changed its morphology resembling 
podocyte-like cells. Images were taken using (A) 10x (scale bar is 100 μm) and (B) 20x 
objective (scale bar is 50 μm). 
 
A B 
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The IF images revealed the presence of podocyte markers in the two colonies that we 
assessed. Colony D was only stained with podocin, whereas colony E was stained for 
podocin and synaptopodin. Podocin plays a key role in the glomerular slit diaphragm 
(Mollet et al. 2009) while synaptopodin is an actin-associated protein found in 
differentiated podocytes and specifically localised in the cytoskeleton of foot processes 
(Mundel et al. 1997a, Garovic et al. 2007). Podocin was detected in all the podocyte-like 
cells from colony D at passage 3, even the ones with a less expanded cytoplasm (Figure 
5.23). Although slightly more irregular, a similar pattern for podocin expression was 
identified in colony E at passage 4. Furthermore, these urine cells also had good expression 
levels of synaptopodin, with bigger cells displaying higher fluorescence for this marker 
(Figure 5.24). Binucleated cells could also be detected in both colonies throughout the 
population. 
 
Colony D 
 
 
 
 
 
 
 
 
 
 
 
 
Podocin 
 
Merged 
Figure 5.23 Podocin IF staining in colony D at passage 3.  
Cells were stained for podocin (green) and the DNA was stained using Hoechst 
33342 (blue). Images were taken using a 40x objective and they were 
representative of the whole cell population. Scale bar is 20 μm. 
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Colony E 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Podocin Synaptopodin Merged A 
B 
Figure 5.24 Podocin IF staining in colony E at passage 4.  
Cells were stained for podocin (green) and synaptopodin (red). The DNA was stained using 
Hoechst 33342 (blue). Images were taken using (A) 20x objective (scale bar is 50 μm) and 
(B) 40x objective (scale bar is 20 μm) and they were representative of the whole cell 
population.  
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qPCR results for colony D were compared to the gene expression from a human kidney. No 
mRNA levels of NPHS1, NPHS2 or WT1 were identified (see Appendix 2 for further details). 
This observation contrasts with the IF data, where the NPHS2 encoded protein, podocin, 
was clearly detected. SYNPO expression was present in colony D, a lower relative 
expression compared to human kidney and no difference was observed between passage 2 
and passage 3 (Figure 5.25).  
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Figure 5.25 Relative expression of podocyte markers plus WT1 in colony D 
throughout passages. 
The relative expression of podocyte genes as well as WT1 in colony D was analysed 
by qPCR at passage 2 (P2) and passage 3 (P3). Gene names are displayed above each 
set of bars. Data was normalised against human kidney tissue. Data are mean ± SEM 
(n = 3). Statistical significance was determined by Mann-Whitney test, *p<0.05. 
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The gene expression data of cells derived from colony E was compared to the mRNA 
expression of human kidney tissue (Figure 5.26 A) as well as to the expression of a 
conditionally immortalised podocyte (ciPodocyte) cell line after 10 days at 37°C (Figure 5.26 
B). As previously seen in colony D, no expression of NPHS2 was detected in colony E cells. 
However, this cell line had detectable levels of SYNPO, NPHS1 and WT1 mRNA (Figure 5.26 
A). Furthermore, it was interesting to see how SYNPO expression significantly increased 
with each passage. WT1 expression in passage 3 was also significantly higher compared to 
passage 2 but no statistical difference was detected in passage 4. NPHS1 expression could 
not be found at passage 2, however the mRNA levels became detectable at passage 3 with 
an increasing trend in expression. Compared to human kidney, the mRNA levels of the 
assessed genes were lower. Nevertheless, when compared to an already established 
podocyte cell line such as ciPodocytes (Saleem et al. 2002), SYNPO expression at passage 4 
was not statistically different (Figure 5.26 B). Moreover, ciPodocytes did not express 
NPHS1, the gene encoding nephrin, which was detected in our podocyte-like colony E. 
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Figure 5.26 Relative expression of podocyte markers plus WT1 in colony E 
throughout passages. 
The relative expression of podocyte genes as well as WT1 in colony D was 
analysed by qPCR at passage 2 (P2), passage 3 (P3) and passage 4 (P4). Gene 
names are displayed above each set of bars. Data was normalised against (A) 
human kidney tissue and (B) a ciPodocyte cell line after 10 days at 37°C. Data are 
mean ± SEM (n = 3). Statistical significance was by Mann-Whitney test, *p<0.05. 
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5.4 DISCUSSION 
 
The first aim of this chapter was to detect colony formations of UPCs in urine cultures, 
isolate them and perform a simple characterisation. Considering that  kidney tubule cells 
isolated from human tissue can only divide in vitro for up to 6 passages (Baer et al. 1997) 
and that from a single cell we obtained a population able to reach passage 10 at a steady 
growth rate, based on the findings of Zhang et al. we defined our isolated cell lines as UPCs. 
Additionally, the doubling times observed by Zhang et al. were very similar to the ones 
obtained from colonies A, B and C. The urothelial origin of the cells was ruled out by the 
lack of expression of UPK1A (Wu et al. 2009) which was in agreement with other published 
observations (Bharadwaj et al. 2013). Furthermore, clonogenicity values detected during 
the exponential growth phase were similar to the ones obtained for cancer cell lines using 
the same clonogenic method (Fedr et al. 2013). Hence, indicating that the division capacity 
of the isolated urine-derived cells was consistent with progenitor characteristics.  
Within this chapter, the expression of the recognised kidney progenitor markers CD133 and 
CD24 (Lindgren et al. 2011) was assessed, although a screening for general progenitor 
surface markers such as c-Kit (a stem cell factor receptor) (Matsui et al. 2004) was not 
performed. The differential expression of both markers in the isolated colonies of UPCs 
might be an indication that while these two markers are reliable to select kidney 
progenitors in vivo (Romagnani and Remuzzi 2014), in vitro culture conditions might trigger  
aberrant regulation of their expression. As a result, they should not be considered 
progenitor-specific after in vitro culture. If a more in depth characterisation was to be 
performed, it would be interesting to analyse the expression of other kidney progenitor 
markers such as NCAM1 (neural cell adhesion molecule 1), which has been linked to 
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clonogenic potential (Buzhor et al. 2013), or Six2, an early nephron progenitor marker like 
WT1 (Kobayashi et al. 2008).  
Before assessing the expression of kidney markers, and particularly PT markers, prior to and 
after culture in differentiation-promoting medium, we also analysed the variation in 
expression of these markers throughout passages. We theorised that if the isolated cells 
were progenitors and therefore committed to a renal fate, some markers would show an 
increasing/decreasing trend in mRNA levels with time. An increasing/decreasing trend in 
markers expression would also be detected if they were dedifferentiated cells instead. 
Although no general trend was detected amongst donors, the general expression of PT 
genes was similar to the expression obtained in ciPTECs (Chapter 2). Therefore, these data 
support the conclusion that the isolated colonies were either PT progenitors or 
dedifferentiated PT cells (Berger et al. 2014). This observation also supports the recently 
published concept of nephron segment-restricted progenitors (Bussolati and Camussi 2015) 
.   
In light of the above conclusions and in order to address the second aim, the differentiation 
protocol (Narayanan et al. 2013) was adapted to 3 days as it was considered that the 
starting point consisted of cells that still preserved renal characteristics. Moreover, longer 
incubations than 3 days needed a lower number of cells at the start, which resulted in an 
imbalance between both conditions (control cells would become over-confluent while 
treated cells would not reach confluence). The differentiation towards a PT state was not 
highly successful and the fact that the medium did not trigger the same response in each 
colony was probably due to specific characteristics of the different colonies. Although some 
PT features were acquired, a different and more specific medium for UPCs as well as other 
resources such as biomaterials should be investigated as a more effective method to direct 
PT differentiation (Chen et al. 2014, Hoppensack et al. 2014). Functional data were also 
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obtained after presumed PT differentiation and revealed very few differences between 
control and PT differentiated cells. However, all three isolated colonies displayed functional 
levels of important renal drug efflux transporters, supporting once more the existence of 
renal progenitor colonies rather than stem cells.  
Through the process of obtaining UPCs, we encountered other colonies, mainly of type II 
that early differentiated into podocytes. These conclusions were initially confirmed by the 
observation of morphological features of mature podocytes such as large, branched, 
arborized and frequently binucleated cells (Mundel et al. 1997b, Krtil et al. 2007). 
Subsequently, qPCR analysis revealed increasing levels of SYNPO expression throughout 
passages. In vivo, SYNPO expression is specific to postmitotic mature podocytes (Shankland 
et al. 2007), hence, its detection confirmed a differentiated podocyte phenotype. IF results 
supported the qPCR data and also showed podocin expression, another specific podocyte 
marker (Shankland et al. 2007). 
To investigate the possibility of spontaneous podocyte differentiation compared with pre-
established fate, we reasoned that if the medium used was the cause of the spontaneous 
podocyte differentiation, then our UPCs should have eventually adopted a podocyte 
phenotype. However, although they became bigger at the latest passage due to a 
slowdown in division rate, only colony B displayed podocyte morphology despite expressing 
important PT markers. Generally, cells from the other two colonies did not become 
arborized, big and multinucleated. Therefore, although IF for podocyte markers should be 
performed to confirm final podocyte differentiation, it could be reasoned that results 
supported pre-established fate over medium-driven differentiation. However, contradictive 
data for colony B had been previously obtained. While qPCR results would classify colony B 
as PT progenitor, final morphology suggested a podocyte origin. Functional experiments did 
not add further evidence to elucidate this matter as P-gp and MRPs are expressed in both 
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PT cells and podocytes (Zennaro et al. 2014). It is also worth highlighting that colony B was 
the only colony that maintained expression of WT1. As well as being a renal progenitor 
marker (Kreidberg 2010), in the adult kidney it is also expressed in podocytes (Mundlos et 
al. 1993). Consequently, following the theory that colony B might have originated from a 
progenitor/dedifferentiated podocyte, a differentiation towards this cell type using VRAD  
(Vitamin D3, retinoic-acid-supplemented DMEM) medium (Ronconi et al. 2009) might have 
been more effective than the PT differentiation applied and warrants further investigation.  
In summary, we were able to isolate UPCs that demonstrated functional levels of some 
important drug efflux transporters. However, further studies are required to achieve the 
goal of establishing a patient-specific nephrotoxicity model. Therefore, further 
characterisation and better selection methods could be used to obtain better UPC lines and 
develop a deeper understanding of isolated urine-derived colonies. To improve the 
selection methods and avoid aberrant regulation of renal progenitor markers due to in vitro 
conditions, colonies co-expressing CD133+ and CD24+ surface markers should be selected at 
passage 0 (Lazzeri et al. 2015). Furthermore, detection of additional surface cell markers 
described to be linked to segment specific renal progenitors should be considered in order 
to bring some insight into the origin of the renal progenitors (Bussolati and Camussi 2015) 
and to select the best differentiation route. For instance, UPCs expressing the initial CD133 
and CD24 combination, plus CD106, would most likely proceed from glomerular outgrowths  
and therefore they would probably respond better on a podocyte differentiation treatment 
(Angelotti et al. 2012). Other medium compositions used in other published investigations 
to isolate and culture progenitor cells from kidney tissue could also be explored, which 
might favour the growth of UPC colonies and delay differentiation (Lazzeri et al. 2015).    
In conclusion, we have shown that it is possible to isolate UPCs of kidney origin from urine 
of healthy subjects that express some PT characteristics. Therefore, the initial stages have 
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been established to further explore the possibility of a urine-derived PT nephrotoxicity 
model. In addition to novel models for predictive and mechanistic toxicity, isolated UPCs 
have potential to be applied as an autologous non-invasive source to pursue regenerative 
and personalised medicine (Romagnani et al. 2013, Oliveira Arcolino et al. 2015). This has 
recently been demonstrated for a podocyte model derived from UPCs for the investigation 
of different genetic glomerular pathologies (Lazzeri et al. 2015). 
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6.1  INTRODUCTION 
Drug-induced mitochondrial dysfunction has lately attracted attention from industry as it 
has become apparent that it is a key feature to increase the success rate of new 
compounds under development. This interest originated after it was proven that 
mitochondrial liabilities are linked to late-stage drug attrition and organ toxicity 
(Nadanaciva and Will 2011, Dykens et al. 2007, Chan et al. 2005). So far, in vitro assays to 
predict mitotoxicity have only been developed in a bone marrow cell line (K562 cells) (Swiss 
et al. 2013) and in a liver cell line (HepG2 cells) (Kamalian et al. 2015). However, even 
though a broad range of nephrotoxins target the mitochondria, there is no equivalent 
model in a kidney cell line. Therefore, the re-characterised ciPTECs in Chapter 2 were used 
to establish an in vitro model that could better assess drugs that specifically induce renal 
mitochondrial toxicity. 
To facilitate our aims, the medium change approach developed by Marroquin et al. and 
later modified by Kamalian, L. et al. was first implemented to ciPTECs as it has been 
previously done in other cell lines (Aguer et al. 2011, Kamalian et al. 2015). ciPTECs were 
the renal line of choice since they are a newly developed PT cell line that expresses multiple 
endogenous organic ion transporters, mimicking renal excretion and reabsorption in the PT  
(Wilmer et al. 2010). Despite having perfectly healthy mitochondria, it was conceivable that 
ciPTECs had fallen into the Crabtree effect, which would translate into a high glycolytic 
activity and a partial inhibition of cellular OXPHOS  (Rodriguez-Enriquez et al. 2001). This 
would therefore diminish ciPTECs susceptibility to mitotoxic compounds. Hence, the 
implementation of Marroquin et al. approach by replacing glucose for galactose in the 
culture medium resulted in a good strategy to drive cells to a higher OXPHOS state, 
increasing at the same time their mitotoxic susceptibility.  
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In parallel with the ciPTECs mitochondrial toxicity model, in Chapter 5 we projected to 
develop a new renal in vitro model from urine. As a non-invasive method, the acquirement 
of human progenitor cells from urine avoids significant ethical concerns and presents a 
wide array of possibilities (Zhang et al. 2014, Zhang et al. 2008). Nowadays, in vitro 
nephrotoxicity assessment during drug development, as well as the study of underlying 
mechanisms of renal toxicity, is limited to the metabolic and genetic characteristics of a 
specific cell line. To investigate this problem, we proposed that if UPCs could be efficiently 
differentiated into mature PT cells and podocytes, it would offer the opportunity to 
perform patient-specific pharmacological and toxicological studies. Specifically, the use of 
UPCs from different sources could increase the accuracy of the results by carrying 
interesting donor variability, which would be useful to analyse different individual drug 
kinetics and metabolism for mechanistic studies (Turner et al. 2015).  
 
6.2  POTENTIAL OF THE NEWLY DEVELOPED PT MITOTOXICITY MODEL IN DRUG 
DEVELOPMENT  
The media replacement strategy performed on ciPTECs in Chapter 3 delivered two 
significantly distinctive energetic configurations, achieving a higher aerobic metabolic state 
in galactose conditions. In contrast to other cell lines such as HepG2 cells (Kamalian et al. 
2015) or skeletal muslcle cells (Dott et al. 2014), our newly developed renal mitotoxicity 
model showed higher sensitivity and quicker adaptation, respectively. Therefore, this would 
translate into a quicker applicability and a much accurate responsiveness for the 
pharmacological industry in higher throughput screenings. Moreover, since the two 
distinctive energetic configurations can serve as a predictive tool to detect mitochondrial 
toxicity, the potential to discover drugs that can interfere with mitochondrial dynamics 
offered by this model overcomes by far the possibilities of any other renal model. This was 
demonstrated in this thesis by the classification of adefovir as a mitotoxic compound for 
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the first time in vitro. Therefore, further experiments using a varied panel of renal mitotoxic 
and non-mitotoxic drugs could provide valuable information about drug-related 
mitochondrial liabilities and their underlying toxicity mechanisms. Furthermore, as 
previously mentioned, industry could highly benefit from this PT mitotoxic model, 
specifically to yield safer drugs in the future. In fact, if this model was to be incorporated in 
early stages of drug development, it could feedback crucial information about the potential 
of a particular compound to induce renal mitochondrial dysfunction. Nevertheless, the 
implementation of a program to screen for mitochondrial toxicity should not be applied to 
completely discriminate and stop new drugs from being developed, but to gain a deeper 
understanding of the nephrotoxicity process and help improve safety measures. The 
mitotoxic results should be backed up with further assessment of the cytotoxic potential to 
stop a compound from reaching the market.  
 
6.3  ADEFOVIR TOXICITY MECHANSIM AND IMPACT OF NOVEL ASSAYS  
Publications have previously described polymerase- as a possible adefovir target, causing 
mtDNA depletion and therefore specific mitochondrial toxicity (Tanji et al. 2001). But 
recently, Crean et al. have demonstrated that adefovir triggers a downregulation of the 
expression of genes involved in mitochondrial biogenesis (Crean et al. 2015). However, the 
mechanism is still unclear and it has been shown that other nucleotide reverse 
transcriptase inhibitors (NtRTIs), such as TFV, do not cause any mtDNA depletion (de Baar 
et al. 2007). The mechanistic studies performed in Chapter 4, which had the objective to 
undercover the molecular mechanisms triggering adefovir nephrotoxicity, revealed that this 
compound is most likely inducing a mitochondrial multifactorial toxicity (Figure 6.1). If 
adefovir was capable of targeting polymerase-, it would only produce an impact on 
mitochondrial encoded proteins at long term (de Baar et al. 2007). This would not explain 
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the observed toxicity after 24 h of treatment. However, if adefovir was targeting the 
mitochondrial redox carriers through another pathway, that could be recapitulated by a 
quantitative depletion of these proteins. Both hypotheses have been previously linked to 
adefovir toxicity (Tanji et al. 2001, de Baar et al. 2007, Zhang et al. 2015), however, the fact 
that we could observe a protein depletion after only 24 h of exposure suggests that 
adefovir was mainly targeting protein synthesis at that concentration range. Additionally, 
an increase in ROS was detected. It is worth noting that mitochondria are not only a major 
source for ROS but also a major target, which includes mtDNA as it is less protected from 
radical damage than nDNA due to a lack of histones (Duchen 2004). As a consequence, it 
could be postulated that at high concentrations of adefovir, ROS and depleted 
mitochondrial encoded proteins drive nephrotoxicity, whereas at lower concentrations and 
Figure 6.1 Representation of potential toxicity targets of adefovir mitotoxicity 
mechanism in the PT. 
Adefovir enters the PT cell through OAT1 and OAT3 transporters from the basolateral 
membrane and is excreted via MRP2 and MRP4 to the urine. Once inside, results have 
shown to induce mitochondrial encoded protein depletion as well as an increase in ROS, 
which can also target the mitochondria. In addition, other reports have suggested 
mtDNA as a target. Therefore, the research carried out points towards a multifactorial 
toxicity.  
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longer treatments mtDNA depletion combined with persistent levels of slightly upregulated 
ROS could be responsible for a much milder PT dysfunction. Interestingly, this hypothesis 
seems to correlate with the situation observed clinically, where adefovir can only be 
administered at controlled low concentrations due to dose-limiting nephrotoxicity (Jia et al. 
2015).  
More refined assays and assessment techniques/instruments are being developed and 
becoming available, which may help to develop safer drugs and treatments. In this thesis, 
Seahorse technology and the ciPTEC mitotoxicity model have helped to undercover insights 
into the mechanisms of adefovir-induced mitochondrial toxicity. When the compound was 
discovered no such data could have been obtainable. Hence, if adefovir was currently 
pending to go to the market, its unveiled molecular toxicity mechanisms could reduce the 
nephrotoxicity risk and improve risk/benefit profiles by using controlled doses from the 
very start. However, better assessment techniques could have also hampered the market 
approval of the drug. Such implications would be detrimental since adefovir is still an 
effective treatment for chronic hepatitis B patients (Menendez-Arias et al. 2014). 
Therefore, new data has to be interpreted very carefully because there is a risk to lose on 
beneficial compounds from being approved. 
 
6.4  NOVEL CELL MODELS TO PREDICT ANTIVIRAL-INDUCED RENAL TOXICITY 
In drug discovery, it still remains a challenge to translate the in vitro findings to in vivo and 
clinical outcomes. Undeniable progress has been achieved in developing more relevant cell 
models and better understanding the properties of drugs (McKim 2010). However, there is 
still room for improvement in safety prediction during early drug development.  
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The choice of an appropriate in vitro model is essential to obtain translatable cytotoxicity 
data. In general, cell models have altered expression of metabolic enzymes and 
transporters, which are usually downregulated. This can influence the cytotoxic response 
particularly in drugs that are substrates for specific transporters such as adefovir and TFV. 
To counterbalance this, new toxicity cell models are being developed by transfecting 
already established cell lines with transporters such as OAT1 and OAT3 (Mandikova et al. 
2013, Zhang et al. 2015, Nieskens et al. 2016). However, while cell models with 
downregulated expression of some transporters might underestimate cytotoxicity, cell lines 
overexpressing specific transporters run the risk of over-estimating drug-induced cytotoxic 
potential.  Additionally, overexpressing OAT uptake transporters could also cause excessive 
intracellular accumulation of the drug, triggering a toxicity mechanism that does not reflect 
the in vivo toxicity pathway. An example is the transfected HEK-OAT1 cell line (Zhang et al. 
2015), where adefovir and TFV showed very low IC50 values and an intracellular drug 
concentration 10x higher than the initial dose. The applicability of a cell model with these 
characteristics to score the nephrotoxicity of a compound is highly debatable. For example, 
the HEK-OAT1 cell line is derived from HEK 293 cells, which are a non-polarised expression 
system with poor overall predictive power, possibly due to low PT similarity. Furthermore, 
even though OAT1 has been overexpressed, important efflux transporters remain low or 
lacking in expression also favouring drug accumulation. Consequently, the predictive value 
of antiviral toxicity studies in similar overexpressing OAT1 or OAT3 cell lines should be 
considered low. In contrast, the PT cell model developed during the course of the 
investigations presented in this thesis to assess drug-induced mitochondrial nephrotoxicity 
represents a more powerful tool to predict clinical antiviral toxicity. This affirmation is 
based on the fact that ciPTECs confidently mimic drug absorption and excretion with 
adefovir EC50 values (EC50GLU = 4.18 μg/ml and EC50GAL = 0.68 μg/ml) below the Cmax in 
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human plasma (Cmax = 4.61 μg/ml) directly after administration of adefovir, which is 
completely unbound in plasma or serum (Cundy et al. 1995). 
Although no mRNA levels of OAT1 and OAT3 transporters were detected, the clear 
cytotoxic response of ciPTECs to adefovir exposure and the radioactive TFV uptake assay 
proved that these transporters are present and functional in this PT cell line. Conversely, it 
was originally thought that ciPTECs lacked these two xenobiotic transporters and a recent 
publication has revealed the creation of overexpressing ciPTEC-OAT1 and ciPTEC-OAT3 cell 
lines (Nieskens et al. 2016). Although the conclusions of these reports claim to have 
developed promising predictive platforms for drug screening, our parental ciPTEC line has 
shown to be much more sensitive to adefovir toxicity. Furthermore, ciPTEC-OAT1 cell line is 
surprisingly more sensitive to TFV than to adefovir, suggesting that the spontaneous 
incorporation into the genome might have perturbed the expression of other transporters 
as well. In summary, ciPTECs in glucose vs. galactose conditions are a highly reliable tool to 
extrapolate in vitro data to clinical outcomes with the added value to screen for specific 
mitochondrial liabilities. 
  
6.5  PT DIFFERENTIATED UPCS AS A STRATEGY TO STUDY AND CIRCUMVENT 
RENAL TOXICITY   
Worldwide, chronic kidney disease (CKD) is considered a main health problem and affects 
more than 10% of the population (Eckardt et al. 2013). Therefore, different strategies using 
renal progenitors to ameliorate and even repair tubule damage have already been put in 
place (Angelotti et al. 2012, Bussolati et al. 2005). In Chapter 5, the first steps have been 
attained to obtain a population of UPCs-derived PT cells that can be applied in 
nephrotoxicity studies, disease modelling and regenerative therapy. All these strategies 
could help improve renal toxicity and CKD through different routes. However, further 
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characterisation and better isolation and differentiation protocols are required to optimise 
the generation of these UPCs-derived PT cells. 
A patient specific urine-derived PT nephrotoxicity model could bring valuable information 
about the impact of a drug on a specific patient, particularly those that are already under 
medication known to perturb kidney dynamics and function. Specifically, the response of 
the urine-derived PT nephrotoxicity model could be a useful tool to adjust the dosing 
treatment and avoid renal toxicity. Moreover, unexpected drug-induced toxicities due to 
polymorphisms in drug efflux and uptake transporters could also be investigated (Knops et 
al. 2015, Sprowl et al. 2012). For instance, while an overexpression of MRP2/4 or stronger 
receptor affinity could enhance adefovir efflux and hence a decrease in drug efficacy, an 
under-expression or low affinity could lead to drug accumulation and therefore toxicity 
(Vigano et al. 2011).  
Another strategy to model the impact of CKD on drug toxicity could be to establish PT 
models of genetic disorders such as cystinosis or Dent’s disease (Bokenkamp and Ludwig 
2011) from differentiated UPCs (Lazzeri et al. 2015). Some genetic PT disorders have 
already been studied by immortalising urine PT cells (Wilmer et al. 2011, Peeters et al. 
2011). However, by isolating progenitors from urine the immortalisation process could be 
avoided, and so the risk of modifying gene expression due to random insertion of vectors 
into the DNA. The functional analysis of glomerular pathogenic mutations has already been 
achieved using UPCs differentiated podocytes as a new research and diagnostic tool (Lazzeri 
et al. 2015).   
Finally, UPCs could promote renal repair in patients suffering from kidney injury (Zhang et 
al. 2014). Cell therapy studies using CD133+ CD24+ UPCs and other adult renal progenitor 
cells have demonstrated to improve renal function in preclinical models of AKI and CKD 
(Lazzeri et al. 2015, Ronconi et al. 2009, Angelotti et al. 2012, Harari-Steinberg et al. 2013). 
Chapter Six 
216 
 
Furthermore, both PT differentiated and non-differentiated UPCs could have the potential 
to contribute to tissue repair via paracrine stimulation and/or tissue engraftment (Bussolati 
and Camussi 2015).  
 
6.6  CONCLUDING REMARKS 
In summary, the results presented in this thesis show that: 
 The implementation of the glucose vs. galactose strategy in ciPTECs delivered the 
first renal in vitro model capable of specifically identifying mitotoxic compounds. 
 In accordance with clinical data, our in vitro PT mitotoxicity model was able to 
classify adefovir as a mitochondrial toxicant, which had not been demonstrated 
before in preclinical studies. 
 The interrogation of bioenergetics and additional mechanistic studies revealed that 
adefovir nephrotoxicity is multifactorial. In particular, mitochondrial protein 
depletion and high levels of ROS were identified to drive mitotoxicity at high 
concentrations of the drug. 
 UPCs of kidney origin can be isolated from healthy subjects and, although PT 
differentiation conditions need to be optimised, they hold the potential to be used 
as a nephrotoxicity model in personalised medicine and also to pursue regenerative 
studies. 
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Appendix 1 
Table showing the list of genes and their TaqMan® Gene Expression Assay used for qPCR: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Primer ID 
MRP4 Hs00988717_m1 
MRP2 Hs00166123_m1 
P-gp Hs00184500_m1 
BCRP Hs01053790_m1 
AQP1 Hs01028916_m1 
OATP4C1 Hs00698884_m1 
LRP2 Hs00189742_m1 
CUBN Hs00153607_m1 
OAT1 Hs00537914_m1 
OAT3 Hs00188599_m1 
PEPT 1 Hs00953898_m1 
SYNPO Hs00702468_s1 
AQP3 Hs01105469_g1 
NCCT Hs01027568_m1 
WT1 Hs01103751_m1 
UPK1A Hs00199638_m1 
GAPDH Hs02758991_g1 
18S Hs03003631_g1 
RPLP0 Hs99999902_m1 
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Appendix 2 
Table listing the genes studied in PCR and qPCR experiments and their protein names. 
Gene name(s) 
Encoded 
protein 
Site of expression 
in the urinary 
system 
Function 
MRP2 ; ABCC2 MRP2 PT 
Efflux pump located in the 
apical membrane 
MRP4 ; ABCC4 MRP4 PT 
Efflux pump located in the 
apical membrane 
P-gp ; MDR1; 
ABCB1 
P-
glycoprotein; 
P-gp 
PT 
Efflux pump located in the 
apical membrane 
BCRP ; ABCG2 BCRP PT 
Efflux pump located in the 
apical membrane 
OAT1 ; 
SLC22A6 
OAT1 PT 
Involved in the uptake of 
organic anions from blood 
OAT3 ; 
SLC22A8 
OAT3 PT 
Involved in the uptake of 
organic anions from blood 
OATP4C1 ; 
SLCO4C1 
OATP4C1 PT 
Involved in the uptake of 
organic anions 
LRP2 Megalin Podocytes and PT 
Cubilin endocytic co-
transporter that plays a role 
in lipoprotein uptake 
CUBN Cubilin Podocytes and PT 
Megalin endocytic co-
transporter that plays a role 
in lipoprotein uptake 
AQP1 
Aquaporin 1 ; 
AQP1 
PT Water channel protein 
PEPT1 ; 
SLC15A1 
Peptide 
transporter 1 ; 
PEPT1 
PT  
Proton-dependant 
oligopeptide transporter  
SYNPO Synaptopodin Podocytes 
Shape and motility 
modulator of podocyte foot 
processes 
NPHS1 Nephrin Podocytes 
Regulates glomerular 
vascular permeability 
NPHS2 Podocin Podocytes 
Regulates of glomerular 
permeability 
NCCT ; NCC ; 
SLC12A3 
Na-Cl co-
transporter 
Distal tubules 
Key mediator of sodium and 
chloride reabsorption 
AQP3 
Aquaporin 3 ; 
AQP3 
Collecting duct Water channel protein 
WT1 
Wilms tumor 
protein 
Podocytes, 
developing 
nephron 
Transcription factor involved 
in cellular development and 
survival 
UPK1A 
Uroplakin-1a ; 
UPKa 
Urothelial cells 
Component of the 
asymmetric unit membrane  
* Source: UniProtKB website / References: (International Transporter et al. 2010, 
Obermuller et al. 1995, Hall et al. 2005) 
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Appendix 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing the depletion of squamous cells over consecutive medium changes. 
(a) After seeding the cells from urine in a 24-well plate, 99% of the cells were fully 
differentiated epithelial cells (called squamous cells) that did not adhere to the well 
surface. (b) After the second change in medium, the population of squamous cells was 
reduced significantly. Images were taken using a 10x objective. Scale bar is 200 μm. 
a b 
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Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type I colonies 
a b 
c d 
e f 
g h 
Appendix 
222 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure showing examples of type I colonies isolated from urine. 
Type I colonies show well-defined edges, compact and cobblestone-like cells. 
Pictures (a-b) were taken using a 4x objective (scale bar is 100 μm), (c-g) were 
taken using a 10x objective (scale bar is 100 μm) and (h-i) were taken using a 
20x objective (scale bar is 50 μm). 
Continued Appendix 4 
i 
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Appendix 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type II colonies 
b c 
d e 
a 
Figure showing examples of type II colonies isolated from urine. 
Type II colonies show more scattered arrangement with cells adopting rice 
grain morphology. Pictures (a-c) were taken using a 4x objective (scale bar is 
100 μm) and (d-e) were taken using a 10x objective (scale bar is 100 μm). 
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Appendix 6 
Colony A 
Table listing Ct values of the renal markers analysed by qPCR 
Data are mean ± SEM (n = 3) 
 
Colony B 
Table listing Ct values of the renal markers analysed by qPCR 
Data are mean ± SEM (n = 3) 
 
Colony C 
Table listing Ct values of the renal markers analysed by qPCR 
Data are mean ± SEM (n = 3) 
 
Ct value 
± SEM 
MPR4 MRP2 P-gp BCRP AQP1 OATP4C1 CUBN SYNPO AQP3 NCCT 
P1 
30.20 ± 
0.04 
-- 
34.9 
±0.04 
32.8 
± 0.2 
38.2 
± 0.7 
36.54 ± 
0.23 
34.21 
±0.54 
31.59 
± 0.08 
31.39 
± 0.2 
-- 
P3 
28.87 ± 
0.14 
38.94 
±0.51 
33.6 
± 0.3 
31.39 
±0.09 
35.16 
± 0.3 
35.3 ± 
0.38 
32.58 
±0.26 
30.07 
± 0.13 
31.3 
± 0.2 
-- 
P5 
28.21 ± 
0.12 
37.12 
±0.03 
31.89 
± 0.4 
30.6 
± 0.2 
33.8 
±0.66 
35.1 ± 
0.5 
31.69 
±0.08  
28.32 
± 0.46 
30.5 
±0.48 
-- 
P7 
28.39 ± 
0.06 
37.35 
±0.61  
31.51 
±0.04 
30.87 
±0.11 
32.35 
±0.04 
35.17 ± 
0.7 
32.64 
±0.22 
27.77 
± 0.08 
32.24 
±0.04 
35.42 
±0.03 
Ct 
value 
± SEM 
MPR4 MRP2 P-gp BCRP AQP1 OATP4C1 CUBN SYNPO AQP3 WT1 
P3 
28.21
± 0.03 
36.70± 
0.09 
28.04
±0.07 
35.8 ± 
0.3 
33.9 
±0.14 
33.46 
±0.19 
31.49 
±0.06 
26.08 ± 
0.09 
31.22 
±0.11 
27.6 
±0.08 
P5 
28.54
± 0.01 
38.14± 
0.19 
28.92
±0.04 
35.05± 
0.34 
36.7 
±0.35 
31.41 
±0.12 
34.81 
±0.42 
28.78 ± 
0.03 
33.46 
±0.11 
30.22 
± 0.1 
P7 
28.51
± 0.05 
37.26± 
0.5 
28.98
±0.08 
35.2 
±0.04 
36.09 
±0.13 
31.09 ± 
0.05 
33.03 
±0.24 
27.92 ± 
0.03 
34.31 
±0.09 
31.44 
±0.14 
P9 
28.73
± 0.06 
36.57± 
0.4 
28.9 
±0.01 
35.88 
±0.34 
34.24
± 0.2 
29.97 ± 
0.15 
32.27 
±0.4 
27.46 ± 
0.07 
36.94 
±0.43 
33.05 
±0.13 
Ct 
value 
± SEM 
MPR4 MRP2 P-gp BCRP AQP1 OATP4C1 CUBN SYNPO AQP3 WT1 
P3 
30.89
±0.46  
36.34 
±0.44 
32.84 
±0.14 
36.99 
±0.73 
36.68 
±0.54 
30.91±
0.46 
36.01 
±0.13 
34.4 
±0.22 
37.64 
± 0.3 
25.62 
±0.85  
P5 
30.79 
±0.29 
35.76 
±0.15 
33.50 
±0.26 
36.75 
±0.62 
34.27
±0.27 
30.95 
±0.25 
36.56 
±0.42 
31.96 
±0.07 
36.87  
±0.19 
-- 
P7 
28.54 
±0.06 
36.03 
±0.58 
31.87 
±0.19 
36.51 
±0.24 
32.55 
±0.08 
29.7 
±0.15 
34.06 
±0.32 
28.8 
±0.07 
34.43
±0.05 
-- 
P9 
28.25 
±0.04 
37.37 
± 0.03 
30.1 
±0.02 
36.29 
±0.57 
35.2 
± 0.2 
30.18 ± 
0.09 
32.91 
±0.13 
28.88 
±0.06 
33.75 
±0.18 
-- 
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